University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln

Papers in Plant Pathology

Plant Pathology Department

11-21-2006

NUCLEC ACDS ENCODING PSEUDOMONAS HOP PROTEINS AND USE THEREOF

Alan Collmer Ithaca, NY

James R. Alfano *Lincoln, NE*

Xiaoyan Tang *Manhattan, KS*

C. Robin Buell Olney, MD

Gregory B. Martin *Ithaca, NY*

Follow this and additional works at: https://digitalcommons.unl.edu/plantpathpapers

Part of the Other Plant Sciences Commons, Plant Biology Commons, and the Plant Pathology Commons

Collmer, Alan; Alfano, James R.; Tang, Xiaoyan; Buell, C. Robin; and Martin, Gregory B., "NUCLEC ACDS ENCODING PSEUDOMONAS HOP PROTEINS AND USE THEREOF" (2006). *Papers in Plant Pathology*. 624. https://digitalcommons.unl.edu/plantpathpapers/624

This Article is brought to you for free and open access by the Plant Pathology Department at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Papers in Plant Pathology by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.



US007138569B2

(12) United States Patent

Collmer et al.

(54) NUCLEIC ACIDS ENCODING PSEUDOMONAS HOP PROTEINS AND USE THEREOF

- Inventors: Alan Collmer, Ithaca, NY (US); James R. Alfano, Lincoln, NE (US); Xiaoyan Tang, Manhattan, KS (US); C. Robin Buell, Olney, MD (US); Gregory B. Martin, Ithaca, NY (US)
- (73) Assignees: Cornell Research Foundation, Inc., Ithaca, NY (US); Kansas State University Research Foundation, Manhattan, KS (US); Boyce Thompson Institute for Plant Research, Inc., Ithaca, NY (US); The Institute for Genomic Research, Rockville, MD (US); The Board of Regents of the University of Nebraska, Lincoln, NE (US)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 226 days.
- (21) Appl. No.: 10/114,828
- (22) Filed: Apr. 2, 2002

(65) **Prior Publication Data**

US 2003/0182681 A1 Sep. 25, 2003

Related U.S. Application Data

- (60) Provisional application No. 60/280,918, filed on Apr. 2, 2001, provisional application No. 60/356,408, filed on Feb. 12, 2002.
- (51) Int. Cl.

C12N 15/82	(2006.01)
C12N 15/31	(2006.01)
C12N 15/63	(2006.01)

(10) Patent No.: US 7,138,569 B2

(45) **Date of Patent:** Nov. 21, 2006

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,342,654 B1 1/2002 Li et al.

OTHER PUBLICATIONS

Lazar et al, 1988, Mol. Cell. Biol. 8:1247-1252.* Hill et al, 1998, Biochem. Biophys. Res. Comm. 244:573-577.* Keller et al, 1999, Plant Cell 11:223-235.* Bauer et al. 1999, Acta Hort. 489:301-304.* Espinosa et al, 2003, Molec. Microlbiol. 49:377-387.*

Collmer et al., "Pseudomonas syringae Hrp Type III Secretion System and Effector Proteins," PNAS 97(16):8770-8777 (2000). Alfano et al., "The Pseudomonas syringae Hrp Pathogenicity Island has a Tripartite Mosaic Structure Composed of a Cluster of Type III Secretion Genes Bounded by Exchangeable Effector and Conserved Effector Loci That Contribute to Parasitic Fitness and Pathogenicity in Plants," PNAS 97(9):4856-4861 (2000).

Fouts et al., "Genomewide Identification of *Pseudomonas syringae* pv. Tomato DC3000 Promoters Controlled by the HrpL Alternative Sigma Factor," *PNAS* 99(4):2275-2280 (2002), with supplemental material available online at www.pnas.org.

Petnicki-Ocwieja et al., "Genomewide Identification of Proteins Secreted by the Hrp Type III Protein Secretion System of *Pseudomonas syringae* pv. Tomato DC3000," *PNAS* 99(11):7652-7657 (2002), with supplemental material available online at www. pnas.org.

* cited by examiner

Primary Examiner—Anne Kubelik

(74) Attorney, Agent, or Firm-Nixon Peabody LLP

(57) **ABSTRACT**

The present invention relates to isolated nucleic acid molecules encoding a type III—secreted bacterial protein capable of modifying a cell death pathway in a plant cell. One aspect of the present invention involves an isolated nucleic acid molecule having a nucleotide sequence that encodes the HopPtoD2 protein of *Pseudomonas syringae* pv. *syringae* DC 3000. Expression vectors, host cells, and transgenic plants which include the DNA molecules of the present invention are also disclosed. The nucleic acid molecules of the present invention can be used to impart disease resistance to a plant and to make a plant hypersusceptible to colonization by nonpathogenic bacteria.

12 Claims, 1 Drawing Sheet



FIĞ. 1



FIG. 2A



FIG. 2B

NUCLEIC ACIDS ENCODING PSEUDOMONAS HOP PROTEINS AND USE THEREOF

This application claims benefit of U.S. Provisional Patent 5 Application Ser. Nos. 60/280,918, filed Apr. 2, 2001, and 60/356,408, filed Feb. 12, 2002, each of which is hereby incorporated by reference in its entirety.

This work was supported by National Science Foundation Grant Nos. DBI-0077622 and MCB-9982646 and National 10 Research Initiative Competitive Grants Program, U.S. Department of Agriculture, Grant Nos. 97-35303-4488 and 01-35319-10019. The U.S. Government may have certain rights in this invention.

FIELD OF THE INVENTION

The present invention relates to isolated DNA molecules corresponding to the open reading frames of Pseudomonas syringae pv. tomato DC3000, the isolated avirulence effector 20 proteins and hrp-dependent outer proteins encoded thereby, as well as their various uses.

BACKGROUND OF THE INVENTION

The plant pathogenic bacterium Pseudomonas syringae is noted for its diverse and host-specific interactions with plants. A specific strain may be assigned to one of at least 40 pathovars based on its host range among different plant species and then further assigned to a race based on differ- 30 ential interactions among cultivars of the host. In host plants the bacteria typically grow to high population levels in leaf intercellular spaces and then produce necrotic lesions. In nonhost plants or in host plants with race-specific resistance, the bacteria elicit the hypersensitive response (HR), a rapid, 35 defense-associated programmed death of plant cells in contact with the pathogen (Alfano & Collmer, J. Bacteriol. 179:5655-5662 (1997)). The ability to produce either of these reactions in plants appears to be directed by hrp (HR and pathogenicity) and hrc (HR and conserved) genes that 40 encode a type III protein secretion pathway and by avr (avirulence) and hop (Hrp-dependent outer protein) genes that encode effector proteins injected into plant cells by the pathway (Alfano & Collmer, J. Bacteriol. 179:5655-5662 (1997)). These effectors may also betray the parasite to the 45 HR-triggering R-gene surveillance system of potential hosts (hence the avr designation), and plant breeding for resistance based on such gene-for-gene (avr-R) interactions may produce complex combinations of races and differential cultivars (Keen, Annu. Rev. Genet. 24:447-463 (1990)). hrp/hrc 50 genes are probably universal among necrosis-causing gramnegative plant pathogens, and they have been sequenced in P. syringae pv. syringae (Psy) 61, Erwinia amylovora Ea321, Xanthomonas campestris pv. vesicatoria (Xcv) 85-10, and Ralstonia solanacearum GMI1000 (Alfano & 55 polypeptides from plant pathogens. Collmer, J. Bacteriol. 179:5655-5662 (1997)). Based on their distinct gene arrangements and regulatory components, the hrp/hrc gene clusters of these four bacteria can be divided into two groups: I (Pseudomonas and Erwinia) and II (Xanthomonas and Ralstonia). The discrepancy between 60 nucleic acid molecules having a nucleotide sequence which the distribution of these groups and the phylogeny of the bacteria provides some evidence that hrp/hrc gene clusters have been horizontally acquired and, therefore, may represent pathogenicity islands (Pais) (Alfano & Collmer, J. Bacteriol. 179:5655-5662 (1997)). 65

Virulence effector proteins delivered to or into host cells by type III secretion systems are key factors in the patho2

genicity of many bacteria, including animal pathogens in the genera Salmonella, Yersinia, Shigella, and Escherichia, and plant pathogens in the genera Pseudomonas, Erwinia, Xanthomonas, Ralstonia, and Pantoea (Galán & Collmer, Science 284:1322-1328 (1999)). In plant pathogens, the type III secretion machinery is referred to as the hypersensitive response and pathogenicity (Hrp) system because secretion mutants typically lose their ability to elicit the defenseassociated hypersensitive response in nonhost plants and to grow parasitically or be pathogenic in host plants (Alfano & Collmer, J. Bacteriol. 179:5655-5662 (1997)). These phenotypes demonstrate the importance of the Hrp system in bacterium-plant interactions, and global identification of effectors will be important for understanding the pathogen-15 esis of bacteria that use type III secretion systems. Unfortunately, several factors have hindered searches for type III effector genes. These factors include: (i) effectors are often redundant with mutants having only subtle phenotypes; (ii) with few exceptions (see e.g., Miao & Miller, Proc. Natl. Acad. Sci. USA 97:7539-7544 (2000)) motifs that can identify proteins as substrates for type III secretion have not been recognized (Lloyd et al., Mol. Microbiol. 39:520-532) (2001); (iii) many effectors show no similarity to known proteins; and (iv) some pathogens have multiple type III secretion systems which deliver different sets of effectors (Cornelis & Van Gijsegem, Annu. Rev. Microbiol. 54:735–774 (2000)). Thus, a complete inventory of type III effector genes is lacking for any pathogen, although it seems that pathogens such as Salmonella may have many such genes (Worley et al., Mol. Microbiol. 36:749-761 (2000)).

Plant pathogen type III effector proteins are mostly designated Avr or Hop, depending on whether their primary phenotype involves plant reaction or secretion behavior. Many effectors were initially discovered through their ability to betray the pathogen to the host R (resistance) gene surveillance system, thereby rendering the pathogen avirulent on a test plant (Keen, Annu. Rev. Genet. 24:447-463 (1990)). Over 25 effector genes have been identified by Avr or Hop phenotypes in various P. syringae pathovars and races (Vivian & Arnold, J. Plant Pathol. 82:163-178 (2000); Alfano et al., Proc. Natl. Acad. Sci. USA 97:4856-4861 (2000)). The encoded effectors seem to determine both basic pathogenicity and host range, but the number of such proteins produced by any single strain has not been systematically investigated. P. s. tomato DC3000 is known to carry at least three avr genes, avrPto (Ronald et al., J. Bacteriol. 174:1604–1611 (1992)), avrPtoB, and avrE (Lorang & Keen, Mol. Plant-Microbe Interact. 8:49-57 (1995)), with the latter being in the Hrp pathogenicity island along with five other candidate effector genes (Alfano et al., Proc. Natl. Acad. Sci. USA 97:4856-486 (2000); Lorang & Keen, Mol. Plant-Microbe Interact. 8:49-57 (1995)).

The present invention is a further advance in the effort to identify, clone, and sequence Avr and Hop proteins or

SUMMARY OF THE INVENTION

One aspect of the present invention relates to isolated (i) encodes a protein or polypeptide including SEQ ID No: 2, SEQ ID No: 4, SEQ ID No: 6, SEQ ID No: 8, SEQ ID No: 10, SEQ ID No: 12, SEQ ID No: 14, SEQ ID No: 16, SEQ ID No: 18, SEQ ID No: 20, SEQ ID No: 22, or SEQ ID No: 24; or (ii) hybridizes, under stringency conditions including a hybridization medium which includes 0.9×SSC at a temperature of 42° C., to a DNA molecule complementary to SEQ ID No: 1, SEQ ID No: 3, SEQ ID No: 5, SEQ ID No: 7, SEQ ID No: 9, SEQ ID No: 11, SEQ ID No: 13, SEQ ID No: 15, SEQ ID No: 17, SEQ ID No: 19, SEQ ID No: 21, or SEQ ID No: 23; or (iii) includes a nucleotide sequence which is complementary to the nucleic acid molecules of (i) 5 and (ii). Expression vectors, host cells, and transgenic plants which include the DNA molecules of the present invention are also disclosed. Methods of making such host cells and transgenic plant are disclosed.

A further aspect of the present invention relates to isolated 10 effector proteins or polypeptides encoded by the nucleic acid molecules of the present invention. Compositions which contain the proteins or polypeptides are also disclosed.

Yet another aspect of the present invention relates to methods of imparting disease resistance to a plant. Accord-15 ing to one approach, this method is carried out by transforming a plant cell with a heterologous DNA molecule of the present invention and regenerating a transgenic plant from the transformed plant cell, wherein the transgenic plant expresses the heterologous DNA molecule under conditions 20 effective to impart disease resistance. According to one approach, this method is carried out by treating a plant with a protein or polypeptide of the present invention under conditions effective to impart disease resistance to the treated plant. 25

A further aspect of the present invention relates to a method of causing eukaryotic cell death which includes: introducing into a eukaryotic cell a cytotoxic *Pseudomonas* protein of the present invention, said introducing being performed under conditions effective to cause cell death.

A still further aspect of the present invention relates to a method of treating a cancerous condition which includes introducing a cytotoxic *Pseudomonas* protein of the present invention into cancer cells of a patient under conditions effective to cause death of cancer cells, thereby treating the 35 cancerous condition.

Yet another aspect of the present invention relates to a method of modifying a metabolic pathway in a cell which includes: introducing into a cell a protein or polypeptide of the present invention which interacts with a native cellular 40 protein involved in a metabolic pathway, wherein the protein or polypeptide modifies the metabolic pathway through its interaction with the native cellular protein.

It is believed that bacteria have evolved effector proteins to make exquisite alterations in host metabolism. While 45 plant resistance and cancer cell toxicity are important uses, as mentioned above, it is believed that these effector proteins can be used to modify or effect metabolic targets in eukaryotes, including both yeasts and higher order species, such as plants and animals. It is noteworthy that several of the 50 effector proteins being claimed in this application have homologs in other phytopathogenic bacteria. Thus, these proteins appear to represent a set of effectors that are 4

conserved among *Pseudomonas, Erwinia, Xanthomonas,* and *Ralstonia* spp. By disrupting the function of these effectors through, for example, transgenic expression thereof in a host plant, it is believed that use of these effectors may lead to widely applicable means for controlling diseases of plants.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is an RNA blot analysis of HrpL-dependent expression of representative virulence-implicated genes. Each well was loaded with 25 µg of total RNA isolated from CUCPB5114 cultures carrying either vector control pCPP5031 or P_{nptII} -hrpL plasmid pCPP5032 (lanes 2 and 3, respectively). PCR-amplified internal fragments were used as probes; lane 1 in each case contains PCR product of the corresponding probe. AvrPpiB1_{Pto} and AvrPpiB2_{Pto} are 100% identical, therefore their signals cannot be distinguished.

FIGS. 2A-B illustrate assays for Hrp system-dependent secretion in culture or translocation in plants of various Avr and Hop proteins. In FIG. 2A, DC3000 or a DC3000 hrcC mutant (Yuan & He, J. Bacteriol. 178:6399-6402 (1996), which is hereby incorporated by reference in its entirety) carrying test ORFs (i.e., candidate effectors) fused to either the FLAG (F) or hemagglutinin (HA) epitopes were grown in Hrp-inducing media, and cultures were separated into cell (lanes 1-3) and supernatant (lanes 4-5) fractions and analyzed by SDS-PAGE and immunobloting. Lanes: 1 and 4, wild type DC3000; 2 and 5, wild type DC3000(pTestORF); 3 and 6, DC3000 hrcC mutant(pTestORF). As an additional control against leakage, pCPP2318 (which encodes the mature form of β -lactamase, β -lac) was included in all strains. The presence of an epitope-tagged protein in the supernatant fraction of the wild type (lane 5), but absence in the hrcC secretion mutant (lane 6), indicated that the test ORF encoded a secreted product. In FIG. 2B, AvrRpt2 translocation assays were performed with a DC3000 Avr-Rps4 homolog (now designated HopPtoK). Constructs that contained ORFs fused to AvrRpt2 lacking translocation signals were electroporated into P. s. phaseolicola 3121. Test strains were infiltrated into A. thaliana Col-0 (RPS2). Plant responses were scored 18 hr after inoculation for hypersensitive collapse (HR) or no visible response (N).

DETAILED DESCRIPTION OF THE INVENTION

One aspect of the present invention relates to *Pseudomo-nas syringae* pv. *syringae* DC 3000 nucleic acid molecules which encode Avr or Hop effector proteins.

A first nucleic acid molecule is a homolog of avrPphE of *Pseudomonas syringae* pv. *phaseolicola* and has a nucleotide sequence according to SEQ ID No: 1 as follows:

atgaaaatac ataacgetgg eetaaceeea eetttgeegg geatttegaa tggaaaegtt 60 ggaaaggegg egeaateate aataaeteaa eegeaggee ageaaggete ttatggettg 120 eeaeeagaaa getetgagae tegeeetga agggegegg egaaetatee atatteatea 180 gtaeaaaeae ggttgeegee egttgegtet getgggaaae egetgeetga taeaeeate 240 tetttgeeeg getaettaet gttgegaagg etggaeeate geeetgga teaggaaggt 300 aeceaaaagte tgateeegge agaeaagget gtggetgaag egegeegtge attgeeett 360 ggaagaggea atattgatgt ggatgegeaa ettteeaate tggaaagtg ageeegeace 420

-continued

cttgcagcaaggtgcttgagaaaagatgccgaggccgccggtcatgagcctatgcctgc480aatgagccgatgaactggcatgttcttgttgcgatgtcaggccaggtgttcggcgggg540aactgtggcgaacatgctcgtatagcgagcttcgcctatggagctttggcccaggaaaac600ggacgatctgaatatgaaaacatctactggctgcatcgactggggaga600gctgaaaccgacgaatcccagtctggcacctcaacgattgtcatggatcc910ggttcagccatattgcggaggacgatgggttgcgaaaaactggatgg900caagtctcgccatcaaaagtggtcgcattgcgcagga960tttgtccgcagagtgagcgacaagttgacctcccctgatttgcggcgtca1020gatattgaagcggtcggagtcgcaatgtcgctcgcaccaaggcgcgtcaggacgttgc1140agacgagatgtctgatgagcttgagtgaggggtagaggc1145agacgagatgtctgatgagcttgatgagaggc1155

The encoded protein, designated AvrPphE_{*Pto*}, has an amino 25 acid sequence according to SEQ ID No: 2 as follows:

Met Lys Ile His Asn Ala Gly Leu Thr Pro Pro Leu Pro Gly Ile Ser -5 Asn Gly Asn Val Gly Lys Ala Ala Gln Ser Ser Ile Thr Gln Pro Gln Ser Gln Gln Gly Ser Tyr Gly Leu Pro Pro Glu Ser Ser Glu Thr Arg Pro Asp Arg Ala Arg Ala Asn Tyr Pro Tyr Ser Ser Val Gln Thr Arg Leu Pro Pro Val Ala Ser Ala Gly Lys Pro Leu Pro Asp Thr Pro Ser Ser Leu Pro Gly Tyr Leu Leu Leu Arg Arg Leu Asp His Arg Pro Val Asp Gln Glu Gly Thr Lys Ser Leu Ile Pro Ala Asp Lys Ala Val Ala Glu Ala Arg Arg Ala Leu Pro Phe Gly Arg Gly Asn Ile Asp Val Asp Ala Gln Leu Ser Asn Leu Glu Ser Gly Ala Arg Thr Leu Ala Ala Arg Cys Leu Arg Lys Asp Ala Glu Ala Ala Gly His Glu Pro Met Pro Ala Asn Glu Pro Met Asn Trp His Val Leu Val Ala Met Ser Gly Gln Val Phe Gly Ala Gly Asn Cys Gly Glu His Ala Arg Ile Ala Ser Phe Ala Tyr Gly Ala Leu Ala Gln Glu Asn Gly Arg Ser Glu Tyr Glu Asn Ile Tyr Leu Ala Ala Ser Thr Glu Glu Asp His Val Trp Ala Glu Thr Asp Glu Ser Gln Ser Gly Thr Ser Thr Ile Val Met Asp Pro Trp Ser Asn

						-	con	tinı	ued						
Gly	Ser	Ala	Ile	Phe 245	Ala	Glu	Asp	Ser	Arg 250	Phe	Ala	Lys	Asn	Arg 255	Asn
Ala	Val	Glu	Arg 260	Thr	Asp	Thr	Phe	Asn 265	Leu	Ser	Thr	Ala	Ala 270	Glu	Ala
Gly	Lys	Ile 275	Thr	Arg	Glu	Thr	Ala 280	Glu	Lys	Ala	Leu	Thr 285	Gln	Val	Thr
Thr	Arg 290	Leu	Gln	Lys	Arp	Leu 295	Ala	Asp	Gln	Gln	Glu 300	Gln	Val	Ser	Pro
Ile 305	Lys	Ser	Gly	Arp	Ty r 310	Arg	Pro	Glu	Lys	Ser 315	Val	Leu	Asp	Asp	Ala 320
Phe	Val	Arg	Arg	Val 325	Ser	Asp	Lys	Leu	Thr 330	Ser	Pro	Asp	Leu	Arg 335	Arg
Ala	Leu	Gln	Val 340	Asp	Ile	Glu	Ala	Val 345	Gly	Val	Ala	Met	Ser 350	Leu	Gly
Thr	Lys	Gly 355	Val	Lys	Asp	Ala	Thr 360	Arg	Gln	Ala	Arg	Pro 365	Leu	Val	Glu
Leu	Ala 370	Val	Lys	Val	Ala	Ser 375	Pro	Gln	Gly	Leu	Ala 380	Arg	Arg	Asp	Val

AvrPphE_{Pto} has been shown to be expressed by DC3000. It ²⁵ has been demonstrated that AvrPphE of *Pseudomonas syrin*gae pv. phaseolicola is recognized within plant cells and that this protein alone is required for hypersensitive response induction (Stevens et al., "Sequence variations in alleles of the avirulence gene avrPphE: R2 from *Pseudomonas syrin-*³⁰ gae pv. phaseolicola lead to loss of recognition of the AvrPphE protein within bean cells and a gain in cultivar-specific virulence," *Mol. Microbiol.* 29(1):165–177 (1998); Mansfield et al., "Characterization of avrPphE, a gene for cultivar-specific avirulence from *Pseudomonas syringae* pv.

phaseolicola which is physically linked to hrpY, new hrp gene identified in the halo-blight bacterium," *Mol. Plant Microbe Interact.* 7(6):726–739 (1994), each of which is hereby incorporated by reference in its entirety). AvrPphE has been shown to be secreted by a type III secretion system and translocated into plants. AvrPphE matches the R2 resistance gene of *Phaseolus*.

A second nucleic acid molecule is a homolog of avrRps4 of *Pseudomonas syringae* pv. *pisi* and has a nucleotide sequence according to SEQ ID No: 3 as follows:

atgaatcgca tttcaaccag ctcagtaaat tccagcttca attacacggc ccctacggag 60 gaagegeaaa accepttege steagegees gacaattees steagttgt caccacaaca 120 tctatcgccc aagcgtcgga agggctacaa aggccggggg caacgctaag catgcaggcc 180 cagcgactgc gccaattgat ggggagcccg tctgagcagt gccggaggga cacaatgtta 240 gctaaagctt ttgatgctca acgcctaaac attaacactc aagcaggctc ttccaacagc 300 ccacacttga acgeteteaa caegeteeaa caaegaeaet teaaaeetge ggetggtggg 360 ctagaaatcc cagttacatc caactcctta ttgggcggtg gcaggcaagt ctatcaaatt 420 ggctcatcgt cacgcgagct aagccaccga ccggtcaatg atcaggaccg cgcgcccttc 480 agggcgcttg agcggctgca cgccgagttg tttagaggtg ggccgattga gtttgtgcct 540 agaggcagca acgtgttggc ctcaaacgtg agggatgtcg acatggacga gttcgatgtc 600 atcaactcta aagacggctg ccaaggcatt ggcaccactg gcctgggacc ctgcattgca 660 gtgtgtgcaa gaggcatgga tagagaaggg cttccggtgc tgggtgtcta tcaccacagt 720 ggtatcggct caccagagga taccatggct actcttgatc aagcgatgcg cgataaaggt 780 gctttgcaaa tcaaatactc cctggtaggc ggcatgatca tgcctaaaga ggaagaggct 840 ggcagctatg acgacgagca aagctttttg gcattgaaag gcagttattc aatcgaaggg 900 gcgcgcttgc atgtatccga aggcgaagag gacgtgcata ccggcgagga caacagtgtc 960 aatgttctgc tgatgcctga ccgcgttctg tacggtcgcg acacgctcta ctgctga 1017 The encoded protein, originally designated AvrRps_{*Pto*} and now renamed HopPtoK, has an amino acid sequence according to SEQ ID No: 4 as follows:

Met 1	Asn	Arg	Ile	Her 5	Thr	Ser	Ser	Val	Asn 10	Ser	Ser	Phe	Asn	Tyr 15	Thr
Ala	Pro	Thr	Glu 20	Glu	Ala	Gln	Asn	Arg 25	Phe	Ala	Ser	Ala	Pro 30	Asp	Asn
Ser	Pro	Leu 35	Val	Val	Thr	Thr	Thr 40	Ser	Ile	Ala	Gln	Ala 45	Ser	Glu	Gly
Leu	Gln 50	Arg	Pro	Gly	Ala	Thr 55	Leu	Ser	Met	Gln	Ala 60	Gln	Arg	Leu	Arg
Gln 65	Leu	Met	Gly	Ser	Pro 70	Ser	Glu	Gln	Сув	Arg 75	Arg	Asp	Thr	Met	Leu 80
Ala	Lys	Ala	Phe	Asp 85	Ala	Gln	Arg	Leu	Asn 90	Ile	Asn	Thr	Gln	Ala 95	Gly
Ser	Ser	Asn	Ser 100	Pro	His	Leu	Asn	Ala 105	Leu	Asn	Thr	Leu	Gln 110	Gln	Arg
His	Phe	L y s 115	Pro	Ala	Ala	Gly	Gl y 120	Leu	Glu	Ile	Pro	Val 125	Thr	Ser	Asn
Ser	Leu 130	Leu	Gly	Gly	Gly	Arg 135	Gln	Val	Tyr	Gln	Ile 140	Gly	Ser	Per	Ser
Arg 145	Glu	Leu	Ser	His	Arg 150	Pro	Val	Asn	Asp	Gln 155	Asp	Arg	Ala	Pro	Phe 160
Arg	Ala	Leu	Glu	Arg 165	Leu	His	Ala	Glu	Leu 170	Phe	Arg	Gly	Gly	Pro 175	Ile
Glu	Phe	Val	Pro 180	Arg	Gly	Ser	Asn	Val 185	Leu	Ala	Ser	Asn	Val 190	Arg	Asp
Val	Asp	Met 195	Asp	Glu	Phe	Asp	Val 200	Ile	Asn	Ser	Lys	Asp 205	Gly	Cys	Gln
Gly	Ile 210	Gly	Thr	Thr	Gly	Leu 215	Gly	Pro	Сув	Ile	Ala 220	Val	Сув	Ala	Arg
Gly 225	Met	Asp	Arg	Glu	Gly 230	Leu	Pro	Val	Leu	Gly 235	Val	Tyr	His	His	Ser 240
Gly	Ile	Gly	Ser	Pro 245	Glu	Asp	Thr	Met	Ala 250	Thr	Leu	Asp	Gln	Ala 255	Met
Arg	Asp	Lys	Gl y 260	Ala	Leu	Gln	Ile	L y s 265	Tyr	Ser	Leu	Val	Gl y 270	Gly	Met
Ile	Met	Pro 275	Lys	Glu	Glu	Glu	Ala 280	Gly	Per	Tyr	Asp	Asp 285	Glu	Gln	Ser
Phe	Leu 290	Ala	Leu	Lys	Gly	Ser 295	Tyr	Ser	Ile	Glu	Gly 300	Ala	Arg	Leu	His
Val 305	Ser	Glu	Gly	Glu	Glu 310	Asp	Val	His	Thr	Gl y 315	Glu	Asp	Asn	Ser	Val 320
Asn	Val	Leu	Leu	Met 325	Pro	Asp	Arg	Val	Leu 330	Tyr	Gly	Arp	Asp	Thr 335	Leu

HopPtoK has been shown to be a secreted protein that is expressed by DC3000. The *Pseudomonas syringae* pv. *pisi* AvrRps4 effector matches the disease locus RPS4. It has previously been demonstrated that *Pseudomonas syringae* strains carrying avrRps4 induces a hypersensitive response 5 on specific accessions of both Arabidopsis and soybean (Hinsch et al., "Identification of a new Arabidopsis disease resistance locus, RPs4, and cloning of the corresponding avirulence gene, avrRps4, from *Pseudomonas syringae* pv. *pisi,* "*Mol. Plant Microbe Interact.* 9(1):55–61 (1996), which is hereby incorporated by reference in its entirety).

A third nucleic acid molecule is a homolog of avrPphF orf1 of *Pseudomonas syringae* pv. *phaseolicola* and has a nucleotide sequence according to SEQ ID No: 5 as follows:

ttgcctgaca agaaacatat cgatgaagtc tattgctttg agtttcaaag tggtatgaac	120 180
	180
gtaaaagtat accaagacga atttcgctgg gtatatttca ccgctgacgt tgggacattt 🔅	
caagatagca gtattgacac attaaactac gegeteeage tgaacaactt tageettaga 💈	240
aaacctttcc tgaccttcgg aatgacgaag gagaaaaatg gtgtattgca tacacgcacc	300
cccttgattg aggtagacaa cgtgcaaatg cgcaggatat ttgaggagct tataggcgtg	360
gcaggtgaaa tcagaaaaac actaaaactc aaatag	396

The encoded protein has an amino acid sequence according to SEQ ID No: 6 as follows:

Met
1LysAsnAlaPhe
5AspLeuValGlu
10GluGluLusAlaLysAspTyrAsnMetProLeuProAspLysLysLysHisIleAspGluValTyrCysAsnMetProProLeuProAspLysLysHisIleAspGluValTyrCysPheGluPheGlnSerGlyMetAsnValLysValTyrGlnAspGluPhoArpTrySoTyrPheThrAlsAspValGlyFurPhoGluAspSerSerArpTryValTyrPhoFurAspAspValGlyFurPhoGluAspSerSerArpTryLusAspTyrAlaLeuGluLusAspAspAspAspAspAspSerSerArpTryLusTryAlaLusGluLusAspAspGluLysAspSerSerSerArpTryLusTryGluMetTryLusAspAspSerSerSerSerSerArpTryLusTryGluKitSerTryLusAspAspSerSerSerSerSerSer<td

This protein is believed to be a chaperone protein for the ⁵⁰ protein of SEQ ID NO: 8 described below.

A fourth nucleic acid molecule is also homolog of avrPphF orf2 of *Pseudomonas syringae* pv. *phaseolicola* and has a nucleotide sequence according to SEQ ID No: 7 as follows:

gtgtatagcc catcccatac acaacgaata acttcagctc cctctacatc cactcatgtt 60 ggtggagata cactgacatc cattcatcag ctttcgcata gtcagagaga gcagtttctg 120 aacatgcatg atccaatgag agtaatggga cttgaccatg ataccgagct tttcagaacg 180 acggatagtc gctatataaa aaacgataaa ctcgcgggca atccacaatc catggcgagt 240 atccttatgc atgaagaact gcgccccaat cgttttgcca gccatacagg tgcccaacca 300 cacgaagcaa gggcgtacgt tccgaaaaga ataaaagcca ccgatctagg agttccatca 360

-continued

ctgaacgtaa	tgactggctc	gctagcgcga	gacggaatta	gagcttatga	tcacatgagt	420
gataatcagg	tctctgtcaa	aatgcgactg	ggagattttc	tcgaaagggg	tggcaaggtc	480
tatgccgacg	cttcgtctgt	agctgacgat	ggggaaacat	cacaagctct	gattgtcaca	540
ttgcccaaag	gacagaaagt	gccggtcgaa	agggtctga			579

The encoded protein, designated AvrPphF_{Pto}, has an amino acid sequence according to SEQ ID No: 8 as follows:

Val 1	Tyr	Ser	Pro	Ser 5	His	Thr	Gln	Arg	Ile 10	Thr	Ser	Ala	Pro	Ser 15	Thr
Ser	Thr	His	Val 20	Gly	Gly	Asp	Thr	Lou 25	Thr	Ser	Ile	His	Gln 30	Leu	Ser
His	Ser	Gln 35	Arg	Glu	Gln	Phe	Leu 40	Asn	Met	His	Asp	Pro 45	Met	Arg	Val
Met	Gly 50	Leu	Asp	His	Asp	Thr 55	Glu	Leu	Phe	Arg	Thr 60	Thr	Asp	Ser	Arg
Tyr 65	Ile	Lys	Asn	Asp	Lys 70	Leu	Ala	Gly	Asn	Pro 75	Gln	Ser	Met	Ala	Ser 80
Ile	Leu	Met	His	Glu 85	Glu	Leu	Arg	Pro	Asn 90	Arg	Phe	Ala	Ser	His 95	Thr
Gly	Ala	Gln	Pro 100	His	Glu	Ala	Arg	Ala 105	Tyr	Val	Pro	Lys	Arg 110	Ile	Lys
Ala	Thr	Asp 115	Leu	Gly	Val	Pro	Ser 120	Leu	Asn	Val	Met	Thr 125	Gly	Ser	Leu
Ala	Arg 130	Asp	Gly	Ile	Arg	Ala 135	Tyr	Asp	His	Met	Ser 140	Asp	Asn	Gln	Val
Ser 145	Val	Lys	Met	Arg	Leu 150	Gly	Asp	Phe	Leu	Glu 155	Arg	Gly	Gly	Lys	Val 160
Tyr	Ala	Asp	Ala	Ser 165	Ser	Val	Ala	Asp	Asp 170	Gly	Glu	Thr	Ser	Gln 175	Ala
Leu	Ile	Val	Thr 180	Leu	Pro	Lys	Gly	Gln 185	Lys	Val	Pro	Val	Glu 190	Arg	Val

AvrPphF_{Pto} has been shown to be expressed by DC3000. 45 play a role in both development of the hypersensitive Fusion of both the homolog of AvrPphF orf1 and AvrPph- F_{Pto} with the AvrRpt2 reporter (AvrRpt2 Δ 40) caused a hypersensitive response in Arabidopsis Col-0, suggesting that AvrPphF_{Pto} is secreted. Neither Orf1-AvrRpt2 Δ 40 (Avr-PphF_{Pto}) nor Orf2-AvrRpt2 Δ 40 alone causes the hypersen- 50 sitive response in Arabidopsis Col-0, although mutants of the homolog of AvrPphF orf1 have shown reduced disease symptoms on tomato. The Pseudomonas syringae pv. phaseolicola AvrPphF effector protein has been shown to

response and virulence in several plants (Tsiamis et al., "Cultivar-specific avirulence and virulence functions assigned to avrPphF in Pseudomonas syringae pv. phaseolicola, the cause of bean halo-blight disease," EMBO J. 19(13):3204-3214 (2000), which is hereby incorporated by reference in its entirety).

A fifth nucleic acid molecule is a homolog of avrPphD of Pseudomonas syringae pv. phaseolicola and has a nucleotide sequence according to SEQ ID No: 9 as follows:

atgaatcctc tacgatctat tcaacacaac attgcaactc ccccaatcag tggcggtcag 60 ccattagacg cggtgggccc tcaggcccag caatcccatc ctaaaaggat ttcaccttct 120 caattgagcc aaagcgctca ccaggctcta gaacgccttt cagctaatgc cgaacaccaa 180 cgccttgcat cactggtacg caacgctctg caggatggca catttcaatt tcaatccagt 240 aaccacacgc aagtaaccta taaagcgtca atctgtctgc cagctgacac cgataccgtg 300 agaaccgacc acttgattaa taacgagctg acggttcagg cccgattaaa tgatcaatcg 360

-continued gagtacgaca tcgtcagcgc acatttgcat ggctcttcga aagccatatc cttcgacgta 420 cccagccccc cgcccgcaca tggttcagca tcttctgtct tgagtgaacg gacccatcta 480 ggtatgagtc gcgttctctc acaagatgca gtagacagca gtagcctgga aactccgtta 540 ctgagctcgc cagaccattc tcgtccgcca tcacagccaa agcccgtgca tatcgggtcg 600 gtccgcaggg actctggtag ccttgtttcc gataacccgg tagtgcaggc cctgctatcg 660 tttgcgcagg ccgaccaggc atttccacca caggccgcga gcattgccgg ggtccagctg 720 gaaatgcggc cacgtcggga tattgagaaa gcacttgagg aattcaaagg cgccttcacg 780 gtggtgaagg cgcaactgat gtccggtgcc aactcgtcgg agcgtgtaga tgaggatgtc 840 aacgcagaca tccatatccc cttattgctc aaggccatcg agcggggggc tgcggcattt 900 ggtccaaacg catcaatcgg ccagaatagc gcgaaagcgt ttctcgcctc atgtgctccc 960 aagatcacgt ccaatgacga tgtcctctcc gagttcatca accagaaact caaggggggac 1020 gacgatette aggttegeet gggegeacag gaattgttge atgtageeae caagaaggaa 1080 ttccagctcg gcggtctagc cggcagcatc ggggtcagca gcatactcgg ctcggcatgg 1140 gagettggeg ettetgaget gttgaaaaat geeatetteg geaaaaattt etcaeegage 1200 caatatgccc tgcaattggc tggaatcgat tcagtgcctc ctttgattat cgagtccatg 1260 gacaccatgt gcgtacttgc catcatcaag ggcatgaagg gtgaggagtg gtccatgagc 1320 gatctacttc ccaaggcgtt gaaggccggt gctatttcct cggtggtgtc attccccaat 1380 aatgttttgc agtatgcagg tttcaaatcc agagtcggcg atcttgcggc aaactcagtg 1440 acaactgaag cggccatctt tggcgccgcc tccggtattc cacccgaggt caaggaaagt 1500 gaagagctga tgcgtgctgg cttattccag agcatgaagg acggcgtgat ggctcattca 1560 ggcgaggggg tggacaccaa aaaaacgatt gagcggatga cgcgccatgc gctggatatc 1620 gctccgggcg aaagcaccgc tgtcaagtcc atggggctgg catcgattgt cgggatgatt 1680 ccactgattg ccagcaacaa ggcaaccggg ctgctgtcgg aacaggtact gcgtattttc 1740 cggagegeeg tetteaatee aategaagee ategetetga acgegttgge gettggeggg 1800 cgtgtcaacg ttcccgggct atttgattcc gacaatgcca agcatgcacg cgtggtacaa 1860 accatecttg egegggeeag ceageacatg gaagetggag acegtgaeat tteegeagag 1920 gagetacate aaatgetgge teeecgage gagtteetge gecatgtggg atetgegatt 1980 gtcaacggca tgaatgccag ctttgaggca attcccgccc tggttcggaa gcttggatat 2040 ggtgaggctc cattggccga acgtattccg tatcaagacc tggctgtgcc cgacacgtcg 2100 cggcagcccg caccctga 2118

The encoded protein, originally designated AvrPphD1_{*Pto*} and now renamed HopPtoD1, has an amino acid sequence according to SEQ ID No: 10 as follows:

Met Asn Pro Leu Arg Her Ile Gln His Asn Ile Ala Thr Pro Pro Ile 1 5 10 15 Ser Gly Gly Gln Pro Leu Asp Ala Val Gly Pro Gln Ala Gln Gln Her 25 20 30 His Pro Lys Arg Ile Ser Pro Ser Gln Leu Ser Gln Ser Ala His Gln 35 40 45 Ala Leu Glu Arg Leu Ser Ala Asn Ala Glu His Gln Ary Leu Ala Ser 50 55 60

-continued Leu Val Arg Asn Ala Leu Gln Asp Gly Thr Phe Gln Phe Gln Ser Ser Asn His Thr Gln Val Thr Tyr Lys Ala Ser Ile Cys Leu Pro Ala Asp 85 90 95 Thr Asp Thr Val Arg Thr Asp His Leu Ile Asn Asn Glu Leu Thr Val Gln Ala Arg Leu Asn Asp Gln Ser Glu Tyr Asp Ile Val Ser Ala His Leu His Gly Ser Ser Lys Ala Ile Ser Phe Asp Val Pro Ser Pro Pro 130 135 140 Pro Ala His Gly Ser Ala Ser Ser Val Leu Ser Glu Arg Thr His Leu Gly Met Ser Arg Val Leu Ser Gln Asp Ala Val Asp Ser Ser Ser Leu Glu Thr Pro Leu Leu Ser Ser Pro Asp His Ser Arg Pro Pro Ser Gln Pro Lys Pro Val His Ile Gly Ser Val Arg Arg Asp Ser Gly Ser Leu 195 200 205 Val Ser Asp Asn Pro Val Val Gln Ala Leu Leu Ser Phe Ala Gln Ala Asp Gln Ala Phe Pro Pro Gln Ala Ala Ser Ile Ala Gly Val Gln Leu Glu Met Arg Pro Arg Arg Asp Ile Glu Lys Ala Leu Glu Glu Phe Lys 245 250 255 Gly Ala Phe Thr Val Val Lys Ala Gln Leu Met Ser Gly Ala Asn Ser 260 265 270 Ser Glu Arg Val Asp Glu Asp Val Asn Ala Asp Ile His Ile Pro Leu 275 280 285 Leu Leu Lys Ala Ile Glu Arg Gly Ala Ala Ala Phe Gly Pro Asn Ala 290 295 300 Ser Ile Gly Gln Asn Ser Ala Lys Ala Phe Leu Ala Ser Cys Ala Pro Lys Ile Thr Ser Asn Asp Asp Val Leu Ser Glu Phe Ile Asn Gln Lys Leu Lys Gly Asp Asp Asp Leu Gln Val Arg Leu Gly Ala Gln Glu Leu 340 345 350 Leu His Val Ala Thr Lys Lys Glu Phe Gln Leu Gly Gly Leu Ala Gly Ser Ile Gly Val Ser Ser Ile Leu Gly Ser Ala Trp Glu Leu Gly Ala Ser Glu Leu Lys Asn Ala Ile Phe Gly Lys Asn Phe Ser Pro Ser Gln Tyr Ala Leu Gln Leu Ala Gly Ile Asp Ser Val Pro Pro Leu Ile Ile Glu Ser Met Asp Thr Met Cys Val Leu Ala Ile Ile Lys Gly Met Lys Gly Glu Glu Trp Ser Met Ser Asp Leu Leu Pro Lys Ala Leu Lys Ala Gly Ala Ile Ser Ser Val Val Ser Phe Pro Asn Asn Val Leu Gln Tyr Ala Gly Phe Lys Ser Arg Val Gly Asp Leu Ala Ala Asn Ser Val Thr Thr Glu Ala Ala Ile Phe Gly Ala Ala Ser Gly Ile Pro Pro Glu 485 490 495

-continued

Val	Lys	Glu	Ser 500	Glu	Glu	Leu	Met	Arg 505	Ala	Gly	Leu	Phe	Gln 510	Ser	Met
Lys	Asp	Gly 515	Val	Met	Ala	His	Ser 520	Gly	Glu	Gly	Val	Asp 525	Thr	Lys	Lys
Thr	Ile 530	Glu	Arg	Met	Thr	Arg 535	His	Ala	Leu	Asp	Ile 540	Ala	Pro	Gly	Glu
Ser 545	Thr	Ala	Val	Lys	Ser 550	Met	Gly	Leu	Ala	Ser 555	Ile	Val	Gly	Met	Ile 560
Pro	Leu	Ile	Ala	Ser 565	Asn	Lys	Ala	Thr	Gly 570	Leu	Leu	Ser	Glu	Gln 575	Val
Leu	Arg	Ile	Phe 580	Arg	Ser	Ala	Val	Phe 585	Asn	Pro	Ile	Glu	Ala 590	Ile	Ala
Leu	Asn	Ala 595	Leu	Ala	Leu	Gly	Gly 600	Arg	Val	Asn	Val	Pro 605	Gly	Leu	Phe
Asp	Ser 610	Asp	Asn	Ala	Lys	His 615	Ala	Arg	Val	Val	Gln 620	Thr	Ile	Leu	Ala
Arg 625	Ala	Ser	Gln	His	Met 630	Glu	Ala	Gly	Asp	Arg 635	Asp	Ile	Ser	Ala	Glu 640
Glu	Leu	His	Gln	Met 645	Leu	Ala	Pro	Arg	Ser 650	Glu	Phe	Leu	Arg	His 655	Val
Gly	Ser	Ala	Ile 660	Val	Asn	Gly	Met	Asn 665	Ala	Ser	Phe	Glu	Ala 670	Ile	Pro
Ala	Leu	Val 675	Arg	Lys	Leu	Gly	Ty r 680	Gly	Glu	Ala	Pro	Leu 685	Ala	Glu	Arg
Ile	Pro 690	Tyr	Gln	Asp	Leu	Ala 695	Val	Pro	Asp	Thr	Ser 700	Arg	Gln	Pro	Ala
Pro															

⁷⁰⁵

HopPtoD1 has been shown to be a secreted protein that is expressed by DC3000.

A sixth nucleic acid molecule is another homolog of ⁴⁰ avrPphD of *Pseudomonas syringae* pv. *phaseolicola* and has a nucleotide sequence according to SEQ ID No: 11 as follows:

atgaatcccc tgcaacctat tcagcacagc attacaaatt cccaaatgag tggtggtcag 60 caattagagg cggagggctc tcaggcccac aattcctatt cccatcctga caggattcg 120 ctttcccaat tgagccaaag cgctcaccta gctctagatc acctttcaac tcagcctaat 180 accgatcacc aacgcgttgc atcactggta cgcaacgctg tgcaggacgg taagttccaa 240 cttcaatcca gtaacgacac gcaagtaacc tataaaactt cagtctgtcc gccagctaac 300 gccgacacca tgggggccgc ccacttaatt aataacgagc tgacggttca ggcccgatta 360 aatgatcaac ttgagtacga catcgtcagc gctcattgt atggcccttc ggaagccat 420 tccatcgatg catccagtcc tccctcggcc aacgatctag cgtcctctgg cttgagggaa 480 cgtacgcacc taggtatga tcgtgtcctc ttacgctacg cggtgcccc tcgggaaacc 540 gaagaccaat gtgttatggt gatcgacaa atgcccccc ccaaacacgg caaaatgtct 600 ttcttccgta ccactaatga cttgagcaaa ctgccttgg gaatggagac gggcgggttg 660 tccgacctga aattggctgg ttgtgaacgt attcttccg tcgagcaga atctcatgcg 720

The encoded protein, originally designated AvrPphD2_{*Pto*} and now renamed HopPtoD2, has an amino acid sequence according to SEQ ID No: 12 as follows:

Met Asn Pro Leu Gln Pro Ile Gln His Ser Ile Thr Asn Ser Gln Met Ser Gly Gly Gln Gln Leu Glu Ala Glu Gly Ser Gln Ala His Asn Ser Tyr Her His Pro Asp Arg Ile Ser Leu Ser Gln Leu Ser Gln Ser Ala His Leu Ala Leu Asp His Leu Her Thr Gln Pro Asn Thr Asp His Gln Arg Val Ala Ser Leu Val Arg Asn Ala Val Gln Asp Gly Lys Phe Gln Leu Gln Ser Ser Asn Asp Thr Gln Val Thr Tyr Lys Thr Ser Val Cys Pro Pro Ala Asn Ala Asp Thr Met Gly Ala Ala His Leu Ile Asn Asn Glu Leu Thr Val Gln Ala Arg Leu Asn Asp Gln Leu Glu Tyr Asp Ile Val Ser Ala His Leu Tyr Gly Pro Ser Glu Ala Ile Ser Ile Asp Ala Ser Ser Pro Pro Ser Ala Asn Asp Leu Ala Ser Ser Gly Len Ser Glu Arg Thr His Leu Gly Met Asn Arg Val Leu Leu Arg Tyr Ala Val Pro Pro Arg Glu Thr Glu Asp Gln Cys Val Met Val Ile Asp Lys Met Pro Pro Pro Lys His Gly Lys Met Ser Phe Phe Arg Thr Thr Asn Asp Leu Ser Lys Leu Pro Leu Gly Met Glu Thr Gly Gly Leu Ser Asp Leu Lys Leu Ala Gly Cys Glu Arg Ile Ser Ser Val Glu Gln Val Lys Ser Ile Arg Ala Ala Leu Gly Gly Gly Pro Leu Thr Val Leu Asp Leu Arg Glu

						-	cont	tinu	ıed						
Glu	Ser	His	Ala 260	Ile	Val	Asn	Gly	Leu 265	Pro	Ile	Thr	Leu	Arg 270	Gly	Pro
Met	Asp	T rp 275	Ala	Asn	Ala	Gly	Leu 280	Ser	Gln	Val	Asp	Gl y 285	Ala	Ala	Arg
Glu	Ser 290	Ala	Met	Ile	Thr	Glu 295	Leu	Lys	Arg	Thr	L y s 300	Ser	Leu	Thr	Leu
Val 305	Asp	Ala	Asn	Tyr	Val 310	Lys	Gly	Lys	Lys	Ser 315	Asn	Pro	Gln	Thr	Thr 320
Glu	Leu	Lys	Asn	Leu 325	Asn	Val	Arg	Ser	Glu 330	Arg	Glu	Val	Val	Thr 335	Glu
Ala	Gly	Ala	Thr 340	Tyr	Arg	Arg	Val	Ala 345	Ile	Thr	Asp	His	Asn 350	Arg	Pro
Ser	Pro	Glu 355	Ala	Thr	Asp	Glu	Leu 360	Val	Asp	Ile	Met	Arg 365	His	Сув	Leu
Gln	Ala 370	Asn	Glu	Ser	Leu	Val 375	Val	His	Cys	Asn	Gly 380	Gly	Arg	Gly	Arg
Thr 385	Thr	Thr	Ala	Met	Ile 390	Met	Val	Asp	Met	Leu 395	Lys	Asn	Ala	Arg	Asn 400
His	Ser	Ala	Glu	Thr 405	Leu	Ile	Thr	Arg	Met 410	Ala	Lys	Leu	Ser	Ty r 415	Asp
Tyr	Asn	Met	Thr 420	Asp	Leu	Gly	Ser	Ile 425	Ser	Ala	Leu	Lys	Arg 430	Pro	Phe
Leu	Glu	Asp 435	Arg	Leu	Lys	Phe	Leu 440	Gln	Ala	Phe	His	Asp 445	Tyr	Ala	Arg
Asn	Asn 450	Pro	Ser	Gly	Leu	Ser 455	Leu	Asn	Trp	Thr	Gln 460	Trp	Arg	Ala	Lys
Ile 465	Ala	Leu	Glu												

HopPtoD2 has been shown to be a secreted protein that is expressed by DC3000.

A seventh nucleic acid molecule is a homolog of avrPpiC2 of *Pseudomonas syringae* pv. *pisi* and has a nucleotide ⁴⁰ sequence according to SEQ ID No: 13 as follows:

atgacaatcg tgtctggaca catcggaaaa cacccaagcc taaccactgt tcaagctggg60tcttcggctt cggtcgagaa tcaaatgcct gatcctgcac agttcagtga tggacggtgg120aaaaagcttc cgacccaatt gtcgtcaatt acattggcga gattcgatca ggatatttgc180acqaataatc atggcatcag tcagcgtgca atgtgcttg gcctttcatt gagctggatt240aacatgattc atgccgggaa agatcatgtt acgccctatg catcggcaga aagaatgagg300tttctgggtt cctttgaagg ggtggtgcat gctcgtactg ttcataactt ctatcggact360gagcacaaat ttctgatgga gcaagcttcc gcaaaccccg gagtatcaag tggcgcgatg420gctggcacag aagttatt gcaagctgct gagttgaagg ggttaaagct tcaacctgtt480ctagagggca cagatgaagc tgcgctaccc ttcctaattg cgtgtaagca gtcagggcgg540caggtgggca cagatgaagc tgcgctaagc tccttatgtg atgcaattgt agaaaataag600agaaggggtaa tggtgatata cagccaaga attgcccacg ctttgggctt ttctgtatca660tcagatggca aaagagcgac cttattgat cccaatctcg gagagttca taccacctcg720aaagcgttgg ctgatactat cgaaacata tcatcggcag atggccgc tttaatcgcc780gttcaagtat tcgcttcaaa aatacactga810

The encoded protein, originally designated AvrPpiC2_{*Pto*} and now renamed HopPtoC, has an amino acid sequence according to SEQ ID No: 14 as follows:

Met 1	Thr	Ile	Val	Ser 5	Gly	His	Ile	Gly	Lys 10	His	Pro	Ser	Leu	Thr 15	Thr
Val	Gln	Ala	Gly 20	Ser	Ser	Ala	Ser	Val 25	Glu	Asn	Gln	Met	Pro 30	Asp	Pro
Ala	Gln	Phe 35	Ser	Asp	Gly	Arg	Trp 40	Lys	Lys	Leu	Pro	Thr 45	Gln	Leu	Ser
Ser	Ile 50	Thr	Leu	Ala	Arg	Phe 55	Asp	Gln	Asp	Ile	Cys 60	Thr	Asn	Asn	His
Gly 65	Ile	Ser	Gln	Arg	Ala 70	Met	Cys	Phe	Gly	Leu 75	Ser	Leu	Ser	Trp	Ile 80
Asn	Met	Ile	His	Ala 85	Gly	Lys	Asp	His	Val 90	Thr	Pro	Tyr	Ala	Ser 95	Ala
Glu	Arg	Met	Arg 100	Phe	Leu	Gly	Ser	Phe 105	Glu	Gly	Val	Val	His 110	Ala	Arg
Thr	Val	His 115	Asn	Phe	Tyr	Arg	Thr 120	Glu	His	Lys	Phe	Leu 125	Met	Glu	Gln
Ala	Ser 130	Ala	Asn	Pro	Gly	Val 135	Ser	Ser	Gly	Ala	Met 140	Ala	Gly	Thr	Glu
Ser 145	Leu	Leu	Gln	Ala	Ala 150	Glu	Leu	Lys	Gly	Leu 155	Lys	Leu	Gln	Pro	Val 160
Leu	Glu	Asp	Lys	Ser 165	Asn	Ser	Gly	Leu	Pro 170	Phe	Leu	Ile	Ala	Сув 175	Lys
Gln	Ser	Gly	Arg 180	Gln	Val	Ser	Thr	A sp 185	Glu	Ala	Ala	Leu	Ser 190	Ser	Leu
Cys	Asp	Ala 195	Ile	Val	Glu	Asn	Lys 200	Arg	Gly	Val	Met	Val 205	Ile	Tyr	Ser
Gln	Glu 210	Ile	Ala	His	Ala	Leu 215	Gly	Phe	Ser	Val	Ser 220	Ser	Asp	Gly	Lys
Arg 225	Ala	Thr	Leu	Phe	Asp 230	Pro	Asn	Leu	Gly	Glu 235	Phe	His	Thr	His	Ser 240
Lys	Ala	Leu	Ala	Asp 245	Thr	Ile	Glu	Asn	Ile 250	Ser	Ser	Ala	Asp	Gly 255	Leu
Pro	Leu	Ile	Gly 260	Val	Gln	Val	Phe	Ala 265	Ser	Lys	Ile	His			

HopPtoC has been shown to be a secreted protein that is expressed by DC3000.

An eighth nucleic acid molecule is a homolog of avrP- 50 piB1 of *Pseudomonas syringae* pv. *pisi* and has a nucleotide sequence according to SEQ ID No: 15 as follows:

atgcacgcaa atcctttaag ctctttcaac agagctcaac atggcaatct gactaatgta 60 gaggccagcc aagttaaatc ggcaggaacc tcttccacca ctaatataga cagtaaaaac 120 attgaagaac atgttqcaga cagactcagt gattaggca gacctgatgg tggatggttt 180 ttcgagaagt cacttggcac cttgaaaaat ttaaatcttg agcagttagc cggaatccat 240 gatgtactaa aattaacaga tggcgtaaag aacattgtct cttttggagc tcgggaagga 300 ggcttcgagt tggcaatgca gttcgtcat gattataca gatctcaaca tccggatgaa 360 aactcgccgc acgatgccgc aactcattat cttgatgcaa tcagcctgca atcaaacaaa 420

-continued
attacaaaac tigaaaaact acaacatgta gatgtattaaaatgcaaa cccgtttteg480gatgtoggg acaaaaacg aattgogcac gcaaaaaaa tiggcattet cataacgca540gagtggetgg gttetgatt etgtaaacag gaattecagt ggettagega aacaaaaaa600aaagacataa aatetgeat tigtgatett aaagatgtag acttaaaaag caaaaatag620acaagtatet teaatttige agaettecat aaateageg teatgage aageacae720cccgaategg gattgaataa tigtaaaaat ggaaatage tigaeette taagegaeta attee780taataacg accgtgagte atgggaacta aatattee tagggaeta a831

The encoded protein, designated AvrPpiB1_{*Pto*}, has an amino acid sequence according to SEQ ID No: 16 as follows:

Met 1	His	Ala	Asn	Pro 5	Leu	Ser	Ser	Phe	Asn 10	Arg	Ala	Gln	His	Gly 15	Asn
Leu	Thr	Asn	Val 20	Glu	Ala	Ser	Gln	Val 25	Lys	Ser	Ala	Gly	Thr 30	Ser	Ser
Thr	Thr	Asn 35	Ile	Asp	Ser	Lys	Asn 40	Ile	Glu	Glu	His	Val 45	Ala	Asp	Arg
Leu	Ser 50	Asp	Leu	Gly	Arg	Pro 55	Asp	Gly	Gly	Trp	Phe 60	Phe	Glu	Lys	Ser
Leu 65	Gly	Thr	Leu	Lys	Asn 70	Leu	Asn	Leu	Glu	Gln 75	Leu	Ala	Gly	Ile	His 80
Asp	Val	Leu	Lys	Leu 85	Thr	Asp	Gly	Val	Lys 90	Asn	Ile	Val	Ser	Phe 95	Gly
Ala	Arg	Glu	Gl y 100	Gly	Phe	Glu	Leu	Ala 105	Met	Gln	Phe	Arg	His 110	Asp	Leu
Tyr	Arg	Ser 115	Gln	His	Pro	Asp	Glu 120	Asn	Ser	Pro	His	Asp 125	Ala	Ala	Thr
His	Ty r 130	Leu	Asp	Ala	Ile	Ser 135	Leu	Gln	Ser	Asn	L y s 140	Phe	Thr	Lys	Leiu
Glu 145	Lys	Leu	Gln	His	Val 150	Asp	Val	Phe	Lys	Met 155	Gln	Asn	Pro	Phe	Trp 160
Asp	Val	Gly	Tyr	L y s 165	Asn	Gly	Ile	Ala	His 170	Ala	Lys	Lys	Met	Ala 175	Phe
Phe	Ile	Thr	Pro 180	Glu	Trp	Leu	Gly	Ser 185	Asp	Phe	Cys	Lys	Gln 190	Glu	Phe
Gln	Trp	Leu 195	Ser	Glu	Thr	Lys	Asn 200	Lys	Asp	Ile	Lys	Ser 205	Ala	Phe	Val
Ile	Phe 210	Lys	Asp	Val	Asp	Leu 215	Lys	Ser	Lys	Asn	Met 220	Thr	Ser	Ile	Phe
Asn 225	Phe	Ala	Asp	Phe	His 230	Lys	Ser	Arg	Val	Met 235	Met	Ala	Ser	Thr	Pro 240
Pro	Glu	Ser	Gly	Leu 245	Asn	Asn	Val	Lys	Ile 250	Glu	Asn	Ser	Val	Asp 255	Leu
Asn	Phe	Lys	Arg 260	Leu	Leu	Thr	Asp	Arg 265	Glu	Ser	Trp	Glu	Leu 270	Asn	Asn
Phe	T.em	Glv	Asn												

Phe Leu Gly Asp 275 AvrPpiB1_{*Pto*} has been shown to be expressed by DC3000. A second copy of AvrPpiB1_{*Pto*} is present in the genome of DC3000. This second copy is identical and has been designated AvrPpiB2_{*Pto*}. The *Pseudomonas syringae* pv. *pisi* AvrPpiB effector protein was demonstrated to effect the 5 expression of a resistance mechanism governed by the R3 resistance locus of pea (Cournoyer et al., "Molecular characterization of the *Pseudomonas syringae* pv. *pisi* plasmid-

30

borne avirulence gene avrPpiB which matches the R3 resistance locus in pea," *Mol. Plant Microbe Interact.* 8(5): 700–708 (1995), which is hereby incorporated by reference in its entirety).

A ninth nucleic acid molecule is a homolog of avrXv3 of *Xanthomonas campestris* pv. *vesicatoria* and has a nucleotide sequence according to SEQ ID No: 17 as follows:

atggggctat gtatttcaaa acactctggt agcagttaca gctacagtga tagcgaccgc 60 tggcaagtgc ctgcatgccc tccaaacgcc aggtctgtat ccagtcatca aacagcatct 120 gcgagtgaca tcgcatcagg cgatgtggat gaacgtcctg caacgttttc tcattttcaa 180 cttgcgcggt gcggtggaga gtacacgctt agcatggttt ctgcagcggc ttatcaagca 240 gaaagacggc atcgcggtaa tttaataaaa gatcgtagtc aatccatact cccatgggtc 300 caggtatatc attctaaaaa aggtttggat tacagcttcc agatcgacag aactacgact 360 gttaaagtgg ctggattcaa ctgctctatc cccaataaca gagggactcg gcatttatac 420 agcgctggta cgagtcagac aaacatgcct gtcatcgcag acaacatgag cgcatgcatt 480 gctgtcgcgt gtgcggcgga aaacgtggat gctggcacgg gtgaacgtag gccggggggcg 540 aaagttcgcg tattccatct actccctttt cgacgcgaag accttgtgcc agaagaagtt 600 ttagcttctg tgcgcgatta tctgcgaacg accaaagaac aggggctaac aatgcgcgta 660 gctatgcatg gagggaatac agagggtgat ttctcagtca gcactgcgca ggcattgaaa 720 ggcctgtttg ctaatgaagg gatcccgctt gaatttgacg agacctgtgc aaaccgaacg 780 tctgaaacac tgcttggtgc cgttatctta gatgacaact cgactcattt cataaaacat 840 ctggtcgcac aataa 855

35

The encoded protein, originally designated AvrXv3_{*Pto*} and now renamed HopPtoJ, has an amino acid sequence according to SEQ ID No: 18 as follows:

Met 1	Gly	Leu	Cys	Ile 5	Ser	Lys	His	Ser	Gly 10	Ser	Ser	Tyr	Ser	Tyr 15	Ser
Asp	Ser	Asp	Arg 20	Trp	Gln	Val	Pro	Ala 25	Сув	Pro	Pro	Asn	Ala 30	Arg	Ser
Val	Ser	Ser 35	His	Gln	Thr	Ala	Ser 40	Ala	Ser	Asp	Ile	Ala 45	Ser	Gly	Asp
Val	Asp 50	Glu	Arg	Pro	Ala	Thr 55	Phe	Ser	His	Phe	Gln 60	Leu	Ala	Arg	Cys
Gly 65	Gly	Glu	Tyr	Thr	Leu 70	Ser	Met	Val	Ser	Ala 75	Ala	Ala	Tyr	Gln	Ala 80
Glu	Arg	Arg	His	Arg 85	Gly	Asn	Leu	Ile	Lys 90	Asp	Arg	Ser	Gln	Ser 95	Ile
Leu	Pro	Trp	Val 100	Gln	Val	Tyr	His	Ser 105	Lys	Lys	Gly	Leu	Asp 110	Tyr	Ser
Phe	Gln	Ile 115	Asp	Arg	Thr	Thr	Thr 120	Val	Lys	Val	Ala	Gl y 125	Phe	Asn	Cys
Ser	Ile 130	Pro	Asn	Asn	Arg	Gly 135	Thr	Arg	His	Leu	Tyr 140	Ser	Ala	Gly	Thr
Ser 145	Gln	Thr	Asn	Met	Pro 150	Val	Ile	Ala	Asp	Asn 155	Met	Ser	Ala	Сув	Ile 160

						-	con	tin	ued						
Ala	Val	Ala	Cys	Ala 165	Ala	Glu	Asn	Val	Asp 170	Ala	Gly	Thr	Gly	Glu 175	Arg
Arg	Pro	Gly	Ala 180	Lys	Val	Arg	Val	Phe 185	His	Leu	Leu	Pro	Phe 190	Arg	Arg
Glu	Asp	Leu 195	Val	Pro	Glu	Glu	Val 200	Leu	Ala	Ser	Val	Arg 205	Asp	Tyr	Leu
Arg	Thr 210	Thr	Lys	Glu	Gln	Gly 215	Leu	Thr	Met	Arg	Val 220	Ala	Met	His	Gly
Gl y 225	Asn	Thr	Glu	Gly	Asp 230	Phe	Ser	Val	Ser	Thr 235	Ala	Gln	Ala	Leu	Lys 240
Gly	Leu	Phe	Ala	Asn 245	Glu	Gly	Ile	Pro	Leu 250	Glu	Phe	Asp	Glu	Thr 255	Сув
Ala	Asn	Arg	Thr 260	Ser	Glu	Thr	Leu	Leu 265	Gly	Ala	Val	Ile	Leu 270	Asp	Asp
Asn	Ser	Thr 275	His	Phe	Ile	Lys	His 280	Leu	Val	Ala	Gln				

HopPtoJ has been shown to be a secreted protein that is expressed by DC3000. As reported in Astua-Monge et al. ("Resistance of tomato and pepper to T3 strains of *Xanth-*²⁵ *omonas campestris* pv. *vesicatoria* is specified by a plantinducible avirulence gene," *Mol. Plant Microbe Interact.* 13:911–921 (2000), which is hereby incorporated by reference in its entirety), it has been demonstrated that the *Xanthomonas campestris* AvrXv3 effector protein elicits a ³⁰ hypersensitive response in tomato NIL 216 and certain pepper genotypes, which suggests that AvrXv3 is like other

effectors in functioning inside plant cells. A uidA fusion enabled demonstration that the avrXv3 gene is part of the Hrp regulon. A domain in the C terminus of AvrXv3 is possibly responsible for transcriptional activation activity in yeast. For these reasons, it is also believed that HopPtoJ possesses similar characteristics and properties.

A tenth nucleic acid molecule is a homolog of hrmB of *Pseudomonas syringae* pv. *syringae* and has a nucleotide sequence according to SEQ ID No: 19 as follows:

atgatcatcg	acaatacgtt	cgcgctgaca	ctgtcatgcg	attacgcgcg	tgagcgcctg	60
ctgttgatcg	gcttgcttga	gccgcacaag	gacatacctc	agcagtgcct	tttggctggc	120
gctctcaatc	cgctcctcaa	tgcaggccca	ggccttggcc	tggatgagaa	aagcggcctg	180
tatcacgcgt	atcaaagcat	ccctcgagaa	aaactcagcg	tgccgacgct	caaacgcgaa	240
atggcaggtc	tgctggagtg	gatgaggggc	tggcgcgaag	caagccaata	g	291

The encoded protein, believed to be a chaperone for the ⁴⁵ protein of SEQ ID No: 22, has an amino acid sequence according to SEQ ID No: 20 as follows:

Met 1	Ile	Ile	Asp	Asn 5	Thr	Phe	Ala	Leu	Thr 10	Leu	Ser	Cys	Asp	Tyr 15	Ala
1				5					10					15	
Arg	Glu	Arg	Leu	Leu	Leu	Ile	Gly	Leu	Leu	Glu	Pro	His	Lys	Asp	Ile
			20					25					30		
Pro	Gln	Gln	Cys	Leu	Leu	Ala	Gly	Ala	Leu	Asn	Pro	Leu	Leu	Asn	Ala
		35					40					45			
Gly	Pro	Gly	Leu	Gly	Leu	Asp	Glu	Lys	Her	Gly	Leu	Tyr	His	Ala	Tyr
	50					55					60				
Gln	Ser	TIP	Pro	Ara	Glu	Lvs	Len	Ser	Val	Pro	Thr	Len	Lvs	Ara	Glu
65	001	110	110	9	70	275	204	201	vur	75		204	275	9	80
Met	Ala	Gly	Leu	Leu	Glu	Trp	Met	Arg	Gly	Trp	Arg	Glu	Ala	Ser	Gln
				90					90					90	

An eleventh nucleic acid molecule is a homolog of hrmA (also known as hopPsyA) of *Pseudomonas syringae* pv. *syringae* and has a nucleotide sequence according to SEQ ID No: 21 as follows:

atgaacccca ttcagtcacg cttctccagt gtgcaagagc tcagacgatc caacgttgat 60 attccggcgc tcaaagccaa tggccaactg gaggtcgacg gcaagaggta cgagattcgt 120 gcagccgatg acggaacaat ttcggtcctt cgaccggagc aacaatccaa agcgaaaagt 180 tttttcaagg gcgcttccca gttgataggt ggcagcagcc agcgcgcgca gattgcccag 240 gcgctcaacg agaaggtcgc atcggcacgc actgtcttgc accagagcgc tatgacgggc 300 ggacgettgg acaecettga geggggegaa ageageteag ceaeaacage cateaaacee 360 actgccaaac aggctgcgca aagtactttt aacagctttc atgagtgggc caaacaggca 420 gaggcgatgc gaaacccgtc tcgaatggat atctacaaga tctataaaca agatgcacct 480 cactcacacc ccatgagcga cgagcagcaa gaagagttcc tgcacacgct aaaggcattg 540 aatggcaaaa acggcattga ggtgcgcact caggaccacg acagcgtcag aaataaaaaa 600 gaccgcaacc tggacaagta catcgcagag agcccggatg caaagaggtt tttctatcga 660 attatcccca aacatgagcg ccgagaagat aagaatcaag ggcgattgac cattggcgtg 720 caaccccaat atgcaacaca gttgacccgc gccatggcaa ccctgatagg gaaggaaagt 780 gcaatcacgc atggcaaagt aataggcccc gcctgccacg gccaaatgac cgattcggca 840 gttttgtata tcaacggtga tgttgcaaag gcagaaaagc tgggcgagaa actgaaacag 900 atgagcggca ttcctctgga tgcgttcgtt gagcacaccc ctttgagcat gcaatccctg 960 agtaaaggtc tgtcctatgc agaaagcatc ctgggcgaca ccagaggcca tgggatgtcg 1020 cgagcggaag tgatcagcga tgccttgagg atggacggga tgccatttct ggccagattg 1080 aagctatcac tgtctgccaa tggctatgac ccggacaacc cggcccttcg aaacacgaaa 1140 tga 1143

The encoded protein, designated HopPsyA_{*Pto*}, has an amino 40 acid sequence according to SEQ ID No: 22 as follows:

Met Asn Pro Ile Gln Ser Arg Phe Ser Ser Val Gln Glu Leu Arg Arg 5 10 Ser Asn Val Asp Ile Pro Ala Leu Lys Ala Asn Gly Gln Leu Glu Val 25 Asp Gly Lys Arg Tyr Glu Ile Arg Ala Ala Asp Asp Gly Thr Ile Ser 35 40 45 Val Leu Arg Pro Glu Gln Gln Ser Lys Ala Lys Ser Phe Phe Lys Gly 50 55 60 Ala Ser Gln Leu Ile Gly Gly Ser Ser Gln Arg Ala Gln Ile Ala Gln 65 75 70 80 Ala Leu Asn Glu Lys Val Ala Ser Ala Arg Thr Val Leu His Gln Ser 90 Ala Met Thr Gly Gly Arg Leu Asp Thr Leu Glu Arg Gly Glu Ser Ser 100 105 110 Ser Ala Thr Thr Ala Ile Lys Pro Thr Ala Lys Gln Ala Ala Gln Ser 120 125 115 Thr Phe Asn Ser Phe His Glu Trp Ala Lys Gln Ala Glu Ala Met Arg 135 140 130

						_	con	tinu	led						
Asn 145	Pro	Ser	Arg	Met	Asp 150	Ile	Tyr	Lys	Ile	Ty r 155	Lys	Gln	Asp	Ala	Pro 160
His	Ser	His	Pro	Met 165	Ser	Asp	Glu	Gln	Gln 170	Glu	Glu	Phe	Leu	His 175	Thr
Leu	Lys	Ala	Leu 180	Asn	Gly	Lys	Asn	Gl y 185	Ile	Glu	Val	Arg	Thr 190	Gln	Asp
His	Asp	Ser 195	Val	Arg	Asn	Lys	Lys 200	Asp	Arg	Asn	Leu	Asp 205	Lys	Tyr	Ile
Ala	Glu 210	Ser	Pro	Asp	Ala	L y s 215	Arg	Phe	Phe	Tyr	Arg 220	Ile	Ile	Pro	Lys
His 225	Glu	Arg	Arg	Glu	Asp 230	Lys	Asn	Gln	Gly	Arg 235	Leu	Thr	Ile	Gly	Val 240
Gln	Pro	Gln	Tyr	Ala 245	Thr	Gln	Leu	Thr	Arg 250	Ala	Met	Ala	Thr	Leu 255	Ile
Gly	Lys	Glu	Ser 260	Ala	Ile	Thr	His	Gl y 265	Lys	Val	Ile	Gly	Pro 270	Ala	Сув
His	Gly	Gln 275	Met	Thr	Asp	Ser	Ala 280	Val	Leu	Tyr	Ile	Asn 285	Gly	Asp	Val
Ala	Lys 290	Ala	Glu	Lys	Leu	Gly 295	Glu	Lys	Leu	Lys	Gln 300	Met	Ser	Gly	Ile
Pro 305	Leu	Asp	Ala	Phe	Val 310	Glu	His	Thr	Pro	Leu 315	Ser	Met	Gln	Ser	Leu 320
Ser	Lys	Gly	Leu	Ser 325	Tyr	Ala	Glu	Ser	Ile 330	Leu	Gly	Asp	Thr	Arg 335	Gly
His	Gly	Met	Ser 340	Arg	Ala	Glu	Val	Ile 345	Ser	Asp	Ala	Leu	Arg 350	Met	Asp
Gly	Met	Pro 355	Phe	Leu	Ala	Arg	Leu 360	Lys	Leu	Ser	Leu	Ser 365	Ala	Asn	Gly
Tyr	Asp 370	Pro	Asp	Asn	Pro	Ala 375	Leu	Arg	Asn	Thr	Lys 380				

HopPsyA_{Pto} has been shown to be a secreted protein that is $_{40}$ viral pathogens upon recombinant expression thereof in expressed by DC3000. It has been shown that HopPsyA is characterized by cytotoxicity when expressed recombinantly in eukaryotes (i.e., in plants and yeast), and further that HopPsyA is capable of altering metabolic (e.g., Mad2) pathways in targeted cells (see PCT Application Publication 45 No. WO 01/75066 to Collmer et al., published Oct. 11, 2001, which is hereby incorporated by reference in its entirety). Moreover, it has been shown that HopPsyA (HrmA) can be used to effect enhanced resistance to bacterial, fungal, and

plants (U.S. Pat. No. 6,342,654 to Li et al., which is hereby incorporated by reference in its entirety). Based on its shared amino acid identity of about 52% when compared to HopPsyA, it is believed that HopPsyA_{Pto} possesses these same characteristics.

A twelfth nucleic acid molecule is hopPtoB2, a homolog of hopB of Pseudomonas syringae pv. syringae DC3000, and has a nucleotide sequence according to SEQ ID No: 23 as follows:

gtgccgcgta tcgtcgccgg ccatgcagaa ggcgtgtgcg tggtcaacgg ccggcactat 60 gtcgagctgt ccggtagaac ctttcaagtc cattacgaca cacatctgcg cggctggcag 120 attgtcgatc cagaaaaccc gttcgccttt tttggccagc agccggtgcg cctagatgaa 180 cagggggcaat ggcagcttgt cgcccgtcga cgtctgcgtg gcggtggcgt aggtgactcc 240 agccatgccc acctgcccga agaaacaccg ggctccagca caggctcgat tccgagcgac 300 tacgaaatgc cggccgccat gcaggcaggc cttgatgtcg tgttgagcaa caagccctac 360 gacccgaccg ggattggcat ggagtcttac tttgagagct atttcgtgga tctgcgtcag 420 agttttgtgg cgcgcaggga aaagctttat gaggatgccc ggacattttt cgccggtttt 480 tctccgccgc caaagccgca attgcctccg ctggcgccac ctgttgccat cgacaccctg 540

-continued attgaacacg tottogogca gggtaacggo otggttttga gtgaagcaco gaagtoggto 600 gccagcaaac ggctgctgtt actcaacatg ccgctgctgg ccgaacagcg tgtcaagatt 660 ctgtatatcg agcacctgct gaccgacaag cacctgtcta aactggccag gtatcgtcaa 720 ctgggcaaaa agagccgctc aggctcgcac gaactcaagc attacctgca cgatctcaac 780 cgcgggacgc tgaacaattc cagcaccgac tacgactatt accacctcat caaggcagcg 840 catcgctatg gtatcgaggt gcgaccgttc agctcgtcga tcagctaccc gtttctggac 900 catccggtat tgagcgcagc caacgacacg actgcagtac aaaaaatgag caattttttc 960 ggccatacgc tcatcagcag cgatgtcgca tccgcgccga caaaacgctg ggttgccttg 1020 ctcgaccaga agctggccac gacccacgac ggggtattag gcattgccga aatgcagggc 1080 gtggtcagtg tgcatgtccg cgacatcccg gcaggccggc cgacgcgcat cactaaaggc 1140 acaggegaac tgccaegega gggeaegeag geeegetgeg actteaegat tgegttttee 1200 gatecgaege tgattgtgce ceaggegeet caecegeaeg gtaceaaact ggaegaeatg 1260 ctgctcagag aactgagggg ccaatctgcc ggtgccgggg gcgaacgctg ggccggccag 1320 tacggattca tccgtgacga ggacggtgcc tggcggtgga tcgcgcctga ggactggccc 1380 gcagacagee cgatgaegge aateeageaa teeetgaeeg accetgteta tgagatgeea 1440 ctggacactc gaacaacgct tcatacgctg gcgaacttcg aaagaagggg gctcgacatg 1500 gagtatttct ttgaagaaag ccagtacgaa actgttcgca acgtattcgc cctgcaccgc 1560 aaaaagctgc aacaggatgc ggccttgatc agcgctgtac agttgccgcc tcgtccgacg 1620 atgccggccg tcaaccctcg gacgaccacg gcgcagctgt ttgaaacgct gtaccagcac 1680 accgatggca tcgtgatcgg cgagtcgcat ttttcggtcg ccagcaagaa aatgatcatc 1740 gacaacctgc cgttgctgtc gcagcaaaac gtacgaacgc tgtacatgga gcacttgctc 1800 accgacttgc atcaggcgga tctggatcgc tttttcgaaa cagggcaaat gagcaaaacc 1860 ctgcttcacg acctgaaagt gctggatcgg ggccatcgca ccgacccgga caaggtttac 1920 acctttgagc aactggtcat caaggcgcag cagcacggca tggaagtccg cgccatcgac 1980 tgcgcagcca gctaccacct tagtggcctt gacaacgatg gttcaatcac ccgtcagcaa 2040 atgatgaact actttgcgtc gcgcaccctg cgcaggcatc aggacgtcat gggctcacac 2100 aagtggatcg cgctggtcgg caacagccat tccaatgtct atcaaggcgt cgtgcctggt 2160 atcgccgagc tggaaggcgg catcggcctg cgggttatcg acgtggcacc ggggcagtcg 2220 aagggtgtca tgcacgacct ggggggggctg gtctcggcag acatctcgag aaccaaagta 2280 cacatcaaaag gcgattatcg agtggagata gaaataccgc gtgcgaagga tgccattcgg 2340 ccaccccagc ctgttaccct cgaacagcga ctggccagac cgggattgtt tctggtggaa 2400 gagagtgagg gcaatctgct gaccattgtc caccgcgctc gcgacacctg gattcaccgc 2460 acgccggtgc tggtcaatgc cgagggcaag ctgtacctgg agcgcgtgcg ctggccgcgc 2520 atccacctca aaccctttga tgacatggac gcgctggtag cggcgctgga ggagatgaac 2580 2598

ctgacgcggg taggctga

The encoded HopPtoB2 protein has an amino acid sequence according to SEQ ID No: 24 as follows:

Val Pro Arg Ile Val Ala Gly His Ala Glu Gly Val Cys Val Val Asn Gly Arg His Tyr Val Glu Leu Ser Gly Arg Thr Phe Gln Val His Tyr Asp Thr His Leu Arg Gly Trp Gln Ile Val Asp Pro Glu Asn Pro Phe Ala Phe Phe Gly Gln Gln Pro Val Arg Leu Asp Glu Gln Gly Gln Trp 50 55 60 Gln Leu Val Ala Arg Arg Arg Leu Arg Gly Gly Gly Val Gly Asp Ser 65 70 75 80 Ser His Ala His Leu Pro Glu Glu Thr Pro Gly Ser Ser Thr Gly Ser Ile Pro Ser Asp Tyr Glu Met Pro Ala Ala Met Gln Ala Gly Leu Asp 100 105 110 Val Val Leu Ser Asn Lys Pro Tyr Asp Pro Thr Gly Ile Gly Met Glu 115 120 125 Ser Tyr Phe Glu Ser Tyr Phe Val Asp Leu Arg Gln Ser Phe Val Ala Arg Arg Glu Lys Leu Tyr Glu Asp Ala Arg Thr Phe Phe Ala Gly Phe Ser Pro Pro Pro Lys Pro Gln Leu Pro Pro Leu Ala Pro Pro Val Ala Ile Asp Thr Leu Ile Glu His Val Phe Ala Gln Gly Asn Gly Leu Val Leu Ser Glu Ala Pro Lys Ser Val Ala Ser Lys Arg Leu Leu Leu Asn Met Pro Leu Leu Ala Glu Gln Arg Val Lys Ile Leu Tyr Ile Glu His Leu Leu Thr Asp Lys His Leu Ser Lys Leu Ala Arg Tyr Arg Gln Leu Gly Lys Lys Ser Arg Ser Gly Ser His Glu Leu Lys His Tyr Leu His Asp Leu Asn Arg Gly Thr Leu Asn Asn Ser Ser Thr Asp Tyr Asp Tyr Tyr His Leu Ile Lys Ala Ala His Arg Tyr Gly Ile Glu Val Arg Pro Phe Ser Ser Ser Ile Ser Tyr Pro Phe Leu Asp His Pro Val Leu Ser Ala Ala Asn Asp Thr Thr Ala Val Gln Lys Met Ser Asn Phe Phe Gly His Thr Leu Ile Ser Ser Asp Val Ala Ser Ala Pro Thr Lys Arp Trp Val Ala Leu Leu Asp Gln Lys Leu Ala Thr Thr His Asp Gly Val Leu Gly Ile Ala Glu Met Gln Gly Val Val Ser Val His Val Arg Asp Ile Pro Ala Gly Arg Pro Thr Arg Ile Thr Lys Gly Thr Gly Glu Leu Pro Arp Glu Gly Thr Gln Ala Arg Cys Asp Phe Thr Ile Ala Phe Ser

-continued Asp Pro Thr Leu Ile Val Pro Gln Ala Pro His Pro His Gly Thr Lys 405 410 415 Leu Asp Asp Met Leu Leu Arg Glu Leu Arg Gly Gln Ser Ala Gly Ala Gly Gly Glu Arg Trp Ala Gly Gln Tyr Gly Phe Ile Arg Asp Glu Asp Gly Ala Trp Arg Trp Ile Ala Pro Glu Asp Trp Pro Ala Asp Ser Pro
 Met Thr Ala Ile Gln Gln Ser Leu Thr Asp Pro Val Tyr Glu Met Pro

 465
 470
 475
 480
 Leu Asp Thr Arg Thr Thr Leu His Thr Leu Ala Asn Phe Glu Arg Arg Gly Leu Asp Met Glu Tyr Phe Phe Glu Glu Ser Gln Tyr Glu Thr Val Arg Asn Val Phe Ala Leu His Arg Lys Lys Leu Gln Gln Asp Ala Ala Leu Ile Ser Ala Val Gln Leu Pro Pro Arg Pro Thr Met Pro Ala Val Asn Pro Arg Thr Thr Thr Ala Gln Leu Phe Glu Thr Leu Tyr Gln His Thr Asp Gly Ile Val Ile Gly Glu Ser His Phe Ser Val Ala Ser Lys Lys Met Ile Ile Asp Asn Leu Pro Leu Leu Ser Gln Gln Asn Val Arg Thr Leu Tyr Met Glu His Leu Leu Thr Asp Leu His Gln Ala Asp Leu 595 600 605 Asp Arg Phe Phe Glu Thr Gly Gln Met Ser Lys Thr Leu Leu His Asp 610 615 620 Leu Lys Val Leu Asp Arg Gly His Arg Thr Asp Pro Asp Lys Val Tyr Thr Phe Glu Gln Leu Val Ile Lys Ala Gln Gln His Gly Met Glu Val Arg Ala Ile Asp Cys Ala Ala Ser Tyr His Leu Ser Gly Leu Asp Asn Asp Gly Ser Ile Thr Arg Gln Gln Met Met Asn Tyr Phe Ala Ser Arg Thr Leu Arg Arg His Gln Asp Val Met Gly Ser His Lys Trp Ile Ala Leu Val Gly Asn Ser His Ser Asn Val Tyr Gln Gly Val Val Pro Gly Ile Ala Glu Leu Glu Gly Gly Ile Gly Leu Arg Val Ile Asp Val Ala Pro Gly Gln Ser Lys Gly Val Met His Asp Leu Gly Glu Leu Val Ser Ala Asp Ile Ser Arg Thr Lys Val His Ile Lys Gly Asp Tyr Arg Val Glu Ile Glu Ile Pro Arg Ala Lys Asp Ala Ile Arg Pro Pro Gln Pro Val Thr Leu Glu Gln Arg Leu Ala Arg Pro Gly Leu Phe Leu Val Glu Glu Ser Glu Gly Asn Leu Leu Thr Ile Val His Arg Ala Arg Asp Thr 805 810 815 Trp Ile His Arg Thr Pro Val Leu Val Asn Ala Glu Gly Lys Leu Tyr 820 825 830

-continued

Met Asp Ala Leu Val Ala Ala Leu Glu Glu Met Asn Leu Thr Arg Val 855 850 860

Gly

865

HopPtoB2 has been shown to be a secreted protein that is expressed by DC3000.

Fragments of the above-identified proteins or polypeptides as well as fragments of full length proteins can also be 15 used according to the present invention.

Suitable fragments can be produced by several means. Subclones of the gene encoding a known protein can be produced using conventional molecular genetic manipulation for subcloning gene fragments, such as described by 20 Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Springs Laboratory, Cold Springs Harbor, N.Y. (1989), and Ausubel et al. (ed.), Current Protocols in Molecular Biology, John Wiley & Sons (New York, N.Y.) (1999 and preceding editions), each of which is hereby incorporated by 25 reference in its entirety. The subclones then are expressed in vitro or in vivo in bacterial cells to yield a smaller protein or polypeptide that can be tested for activity, e.g., as a product required for pathogen virulence.

In another approach, based on knowledge of the primary 30 structure of the protein, fragments of the protein-coding gene may be synthesized using the PCR technique together with specific sets of primers chosen to represent particular portions of the protein. Erlich, H. A., et al., "Recent Advances in the Polymerase Chain Reaction," Science 252: 35 1643-51 (1991), which is hereby incorporated by reference. These can then be cloned into an appropriate vector for expression of a truncated protein or polypeptide from bacterial cells as described above.

As an alternative, fragments of a protein can be produced $_{40}$ by digestion of a full-length protein with proteolytic enzymes like chymotrypsin or Staphylococcus proteinase A, or trypsin. Different proteolytic enzymes are likely to cleave different proteins at different sites based on the amino acid sequence of the particular protein. Some of the fragments 45 that result from proteolysis may be active virulence proteins or polypeptides.

Chemical synthesis can also be used to make suitable fragments. Such a synthesis is carried out using known amino acid sequences for the polyppetide being produced. 50 Alternatively, subjecting a full length protein to high temperatures and pressures will produce fragments. These fragments can then be separated by conventional procedures (e.g., chromatography, SDS-PAGE).

Variants may also (or alternatively) be modified by, for 55 example, the deletion or addition of amino acids that have minimal influence on the properties, secondary structure and hydropathic nature of the polypeptide. For example, a polypeptide may be conjugated to a signal (or leader) sequence at the N-terminal end of the protein which co- 60 translationally or post-translationally directs transfer of the protein. The polypeptide may also be conjugated to a linker or other sequence for ease of synthesis, purification, or identification of the polypeptide.

The proteins or polypeptides used in accordance with the 65 present invention are preferably produced in purified form (preferably at least about 80%, more preferably 90%, pure)

by conventional techniques. Typically, the protein or polypeptide of the present invention is secreted into the growth medium of recombinant host cells (discussed infra). Alternatively, the protein or polypeptide of the present invention is produced but not secreted into growth medium. In such cases, to isolate the protein, the host cell (e.g., E. *coli*) carrying a recombinant plasmid is propagated, lysed by sonication, heat, or chemical treatment, and the homogenate is centrifuged to remove bacterial debris. The supernatant is then subjected to sequential ammonium sulfate precipitation. The fraction containing the protein or polypeptide of interest is subjected to gel filtration in an appropriately sized dextran or polyacrylamide column to separate the proteins. If necessary, the protein fraction may be further purified by HPLC.

Other DNA molecules encoding other effector proteins or polypeptides can also be identified by determining whether such DNA molecules hybridize under stringent conditions to a nucleic acid molecule as identified above. An example of suitable stringency conditions is when hybridization is carried out at a temperature of about 37° C. using a hybridization medium that includes 0.9× sodium citrate ("SSC") buffer, followed by washing with 0.2×SSC buffer at 37° C. Higher stringency can readily be attained by increasing the temperature for either hybridization or washing conditions or increasing the sodium concentration of the hybridization or wash medium. Nonspecific binding may also be controlled using any one of a number of known techniques such as, for example, blocking the membrane with protein-containing solutions, addition of heterologous RNA, DNA, and SDS to the hybridization buffer, and treatment with RNase. Wash conditions are typically performed at or below stringency. Exemplary high stringency conditions include carrying out hybridization at a temperature of about 42° C. up to and including about 65° C. for up to about 20 hours in a hybridization medium containing 1M NaCl, 50 mM Tris-HCl, pH 7.4, 10 mM EDTA, 0.1% sodium dodecyl sulfate (SDS), 0.2% ficoll, 0.2% polyvinylpyrrolidone, 0.2% bovine serum albumin, and 50 µg/ml E. coli DNA, followed by washing carried out at between about 42° C. to about 65° C. in a 0.2×SSC buffer.

The delivery of effector proteins or polypeptides can be achieved in several ways: (1) as a stable transgene; (2) transiently expressed via Agrobacterium or viral vectors; (3) delivered by the type III secretion systems of disarmed pathogens or recombinant nonpathogenic bacteria which express a functional, heterologous type III secretion system; or (4) delivered via topical application followed by TAT protein transduction domain-mediated spontaneous uptake into cells. Each of these is discussed infra.

The DNA molecule encoding the protein or polypeptide can be incorporated in cells using conventional recombinant DNA technology. Generally, this involves inserting the DNA molecule into an expression system to which the DNA molecule is heterologous (i.e. not normally present). The heterologous DNA molecule is inserted into the expression

system or vector in proper sense orientation and correct reading frame. The vector contains the necessary elements for the transcription and translation of the inserted proteincoding sequences.

U.S. Pat. No. 4,237,224 to Cohen and Boyer, which is 5 hereby incorporated by reference in its entirety, describes the production of expression systems in the form of recombinant plasmids using restriction enzyme cleavage and ligation with DNA ligase. These recombinant plasmids are then introduced by means of transformation and replicated in 10 unicellular cultures including prokaryotic organisms and eukaryotic cells grown in tissue culture.

Recombinant genes may also be introduced into viruses, such as vaccina virus. Recombinant viruses can be generated by transfection of plasmids into cells infected with virus.

Suitable vectors include, but are not limited to, the following viral vectors such as lambda vector system gt11, gt WES.tB, Charon 4, and plasmid vectors such as pBR322, pBR325, pACYC177, pACYC1084, pUC8, pUC9, pUC18, pUC19, pLG339, pR290, pKC37, pKC101, SV 40, pBlue- 20 script II SK +/- or KS +/- (see "Stratagene Cloning Systems" Catalog (1993) from Stratagene, La Jolla, Calif., which is hereby incorporated by reference), pQE, pIH821, pGEX, pET series (see F. W. Studier et. al., "Use of T7 RNA Polymerase to Direct Expression of Cloned Genes," Gene 25 Expression Technology vol. 185 (1990), which is hereby incorporated by reference in its entirety), and any derivatives thereof Recombinant molecules can be introduced into cells via transformation, particularly transduction, conjugation, mobilization, or electroporation. The DNA sequences are 30 cloned into the vector using standard cloning procedures in the art, as described by Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Springs Laboratory, Cold Springs Harbor, N.Y. (1989), which is hereby incorporated by reference in its entirety. 35

A variety of host-vector systems may be utilized to express the protein-encoding sequence(s). Primarily, the vector system must be compatible with the host cell used. Host-vector systems include but are not limited to the following: bacteria transformed with bacteriophage DNA, 40 plasmid DNA, or cosmid DNA; microorganisms such as yeast containing yeast vectors; mammalian cell systems infected with virus (e.g., vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (e.g., baculovirus); and plant cells infected by bacteria. The expression elements 45 of these vectors vary in their strength and specificities. Depending upon the host-vector system utilized, any one of a number of suitable transcription and translation elements can be used.

Different genetic signals and processing events control 50 many levels of gene expression (e.g., DNA transcription and messenger RNA (mRNA) translation).

Transcription of DNA is dependent upon the presence of a promoter which is a DNA sequence that directs the binding of RNA polymerase and thereby promotes mRNA synthesis. 55 The DNA sequences of eukaryotic promoters differ from those of prokaryotic promoters. Furthermore, eukaryotic promoters and accompanying genetic signals may not be recognized in or may not function in a prokaryotic system, and, further, prokaryotic promoters are not recognized and 60 do not function in eukaryotic cells.

Similarly, translation of mRNA in prokaryotes depends upon the presence of the proper prokaryotic signals which differ from those of eukaryotes. Efficient translation of mRNA in prokaryotes requires a ribosome binding site 65 called the Shine-Dalgarno ("SD") sequence on the mRNA. This sequence is a short nucleotide sequence of mRNA that

is located before the start codon, usually AUG, which encodes the amino-terminal methionine of the protein. The SD sequences are complementary to the 3'-end of the 16S rRNA (ribosomal RNA) and probably promote binding of mRNA to ribosomes by duplexing with the rRNA to allow correct positioning of the ribosome. For a review on maximizing gene expression, see Roberts and Lauer, *Methods in Enzymology*, 68:473 (1979), which is hereby incorporated by reference in its entirety.

Promoters vary in their "strength" (i.e. their ability to promote transcription). For the purposes of expressing a cloned gene, it is desirable to use strong promoters in order to obtain a high level of transcription and, hence, expression of the gene. Depending upon the host cell system utilized, any one of a number of suitable promoters may be used. For instance, when cloning in E. coli, its bacteriophages, or plasmids, promoters such as the T7 phage promoter, lac promoter, trp promoter, recA promoter, ribosomal RNA promoter, the P_R and P_L promoters of coliphage lambda and others, including but not limited, to lacUV5, ompF, bla, lpp, and the like, may be used to direct high levels of transcription of adjacent DNA segments. Additionally, a hybrid trp-lacUV5 (tac) promoter or other E. coli promoters produced by recombinant DNA or other synthetic DNA techniques may be used to provide for transcription of the inserted gene.

Bacterial host cell strains and expression vectors may be chosen which inhibit the action of the promoter unless specifically induced. In certain operations, the addition of specific inducers is necessary for efficient transcription of the inserted DNA. For example, the lac operon is induced by the addition of lactose or IPTG (isopropylthio-beta-D-galactoside). A variety of other operons, such as trp, pro, etc., are under different controls.

Specific initiation signals are also required for efficient gene transcription and translation in prokaryotic cells. These transcription and translation initiation signals may vary in "strength" as measured by the quantity of gene specific messenger RNA and protein synthesized, respectively. The DNA expression vector, which contains a promoter, may also contain any combination of various "strong" transcription and/or translation initiation signals. For instance, efficient translation in E. coli requires an SD sequence about 7-9 bases 5' to the initiation codon ("ATG") to provide a ribosome binding site. Thus, any SD-ATG combination that can be utilized by host cell ribosomes may be employed. Such combinations include but are not limited to the SD-ATG combination from the cro gene or the N gene of coliphage lambda, or from the E. coli tryptophan E, D, C, B or A genes. Additionally, any SD-ATG combination produced by recombinant DNA or other techniques involving incorporation of synthetic nucleotides may be used.

Once the isolated DNA molecule encoding the polypeptide or protein has been cloned into an expression system, it is ready to be incorporated into a host cell. Such incorporation can be carried out by the various forms of transformation noted above, depending upon the vector/host cell system. Suitable host cells include, but are not limited to, bacteria, virus, yeast, mammalian cells, insect, plant, and the like.

Because it is desirable for recombinant host cells to secrete the encoded protein or polypeptide, it is preferable that the host cell also possess a functional type III secretion system. The type III secretion system can be heterologous to host cell (Ham et al., "A Cloned *Erwinia chrysanthemi* Hrp (Type III Protein Secretion) System Functions in *Escherichia coli* to Deliver *Pseudomonas syringae* Avr Signals to Plant Cells and Secrete Avr Proteins in Culture," *Microbiol.* 95:10206–10211 (1998), which is hereby incorporated by reference in its entirety) or the host cell can naturally possess a type III secretion system. Host cells which naturally contain a type III secretion system include many pathogenic 5 Gram-negative bacterium, such as numerous *Erwinia* species, *Pseudomonas* species, *Xanthomonas* species, etc. Other type III secretion systems are known and still others are continually being identified. Pathogenic bacteria that can be utilized to deliver effector proteins or polypeptides are 10 preferably disarmed according to known techniques, i.e., as described above. Alternatively, isolation of the effector protein or polypeptide from the host cell or growth medium can be carried out as described above.

Another aspect of the present invention relates to a 15 transgenic plant which express a protein or polypeptide of the present invention and methods of making the same.

In order to express the DNA molecule in isolated plant cells or tissue or whole plants, a plant expressible promoter is needed. Any plant-expressible promoter can be utilized 20 regardless of its origin, i.e., viral, bacterial, plant, etc. Without limitation, two suitable promoters include the nopaline synthase promoter (Fraley et al., *Proc. Natl. Acad. Sci. USA* 80:4803–4807 (1983), which is hereby incorporated by reference in its entirety) and the cauliflower mosaic virus 25 35S promoter (O'Dell et al., "Identification of DNA Sequences Required for Activity of the Cauliflower Mosaic Virus 35S Promoter," *Nature*, 313(6005):810–812 (1985), which is hereby incorporated by reference in its entirety). Both of these promoters yield constitutive expression of 30 coding sequences under their regulatory control.

While constitutive expression is generally suitable for expression of the DNA molecule, it should be apparent to those of skill in the art that temporally or tissue regulated expression may also be desirable, in which case any regulated promoter can be selected to achieve the desired expression. Typically, the temporally or tissue regulated promoters will be used in connection with the DNA molecule that are expressed at only certain stages of development or only in certain tissues. 40

In some plants, it may also be desirable to use promoters which are responsive to pathogen infiltration or stress. For example, it may be desirable to limit expression of the protein or polypeptide in response to infection by a particular pathogen of the plant. One example of a pathogen-45 inducible promoter is the gst1 promoter from potato, which is described in U.S. Pat. Nos. 5,750,874 and 5,723,760 to Strittmayer et al., each of which is hereby incorporated by reference in its entirety.

Expression of the DNA molecule in isolated plant cells or 50 tissue or whole plants also requires appropriate transcription termination and polyadenylation of mRNA. Any 3' regulatory region suitable for use in plant cells or tissue can be operably linked to the first and second DNA molecules. A number of 3' regulatory regions are known to be operable in 55 plants. Exemplary 3' regulatory regions include, without limitation, the nopaline synthase 3' regulatory region (Fraley, et al., "Expression of Bacterial Genes in Plant Cells," Proc. Nat'l. Acad. Sci. USA, 80:4803-4807 (1983), which is hereby incorporated by reference in its entirety) and the 60 cauliflower mosaic virus 3' regulatory region (Odell, et al., "Identification of DNA Sequences Required for Activity of the Cauliflower Mosaic Virus 35S Promoter," Nature, 313 (6005):810-812 (1985), which is hereby incorporated by reference in its entirety). 65

The promoter and a 3' regulatory region can readily be ligated to the DNA molecule using well known molecular cloning techniques described in Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Press, NY (1989), which is hereby incorporated by reference in its entirety.

One approach to transforming plant cells with a DNA molecule of the present invention is particle bombardment (also known as biolistic transformation) of the host cell. This can be accomplished in one of several ways. The first involves propelling inert or biologically active particles at cells. This technique is disclosed in U.S. Pat. Nos. 4,945, 050, 5,036,006, and 5,100,792, all to Sanford, et al., each of which is hereby incorporated by reference in its entirety. Generally, this procedure involves propelling inert or biologically active particles at the cells under conditions effective to penetrate the outer surface of the cell and to be incorporated within the interior thereof When inert particles are utilized, the vector can be introduced into the cell by coating the particles with the vector containing the heterologous DNA. Alternatively, the target cell can be surrounded by the vector so that the vector is carried into the cell by the wake of the particle. Biologically active particles (e.g., dried bacterial cells containing the vector and heterologous DNA) can also be propelled into plant cells. Other variations of particle bombardment, now known or hereafter developed, can also be used.

Another method of introducing the DNA molecule into plant cells is fusion of protoplasts with other entities, either minicells, cells, lysosomes, or other fusible lipid-surfaced bodies that contain the DNA molecule. Fraley, et al., *Proc. Natl. Acad. Sci. USA*, 79:1859–63 (1982), which is hereby incorporated by reference in its entirety.

The DNA molecule may also be introduced into the plant cells by electroporation. Fromm, et al., *Proc. Natl. Acad. Sci. USA*, 82:5824 (1985), which is hereby incorporated by reference in its entirety. In this technique, plant protoplasts are electroporated in the presence of plasmids containing the DNA molecule. Electrical impulses of high field strength reversibly permeabilize biomembranes allowing the introduction of the plasmids. Electroporated plant protoplasts reform the cell wall, divide, and regenerate.

Another method of introducing the DNA molecule into plant cells is to infect a plant cell with *Agrobacterium tumefaciens* or *Agrobacterium rhizogenes* previously transformed with the DNA molecule. Under appropriate conditions known in the art, the transformed plant cells are grown to form shoots or roots, and develop further into plants. Generally, this procedure involves inoculating the plant tissue with a suspension of bacteria and incubating the tissue for 48 to 72 hours on regeneration medium without antibiotics at 25–28° C.

Agrobacterium is a representative genus of the Gramnegative family Rhizobiaceae. Its species are responsible for crown gall (*A. tumefaciens*) and hairy root disease (*A. rhizogenes*). The plant cells in crown gall tumors and hairy roots are induced to produce amino acid derivatives known as opines, which are catabolized only by the bacteria. The bacterial genes responsible for expression of opines are a convenient source of control elements for chimeric expression cassettes. In addition, assaying for the presence of opines can be used to identify transformed tissue.

Heterologous genetic sequences such as a DNA molecule of the present invention can be introduced into appropriate plant cells by means of the Ti plasmid of *A. tumefaciens* or the Ri plasmid of *A. rhizogenes*. The Ti or Ri plasmid is transmitted to plant cells on infection by *Agrobacterium* and is stably integrated into the plant genome. Schell, J., *Science*, 237:1176–83 (1987), which is hereby incorporated by reference in its entirety.

Plant tissue suitable for transformation include leaf tissue, root tissue, meristems, zygotic and somatic embryos, and 5 anthers.

After transformation, the transformed plant cells can be selected and regenerated.

Preferably, transformed cells are first identified using, e.g., a selection marker simultaneously introduced into the 10 host cells along with the DNA molecule of the present invention. Suitable selection markers include, without limitation, markers coding for antibiotic resistance, such as kanamycin resistance (Fraley, et al., *Proc. Natl. Acad. Sci. USA*, 80:4803–4807 (1983), which is hereby incorporated 15 by reference in its entirety). A number of antibiotic-resistance markers are known in the art and other are continually being identified. Any known antibiotic-resistance marker can be used to transform and select transformed host cells in accordance with the present invention. Cells or tissues are 20 grown on a selection media containing an antibiotic, whereby generally only those transformants expressing the antibiotic resistance marker continue to grow.

Once a recombinant plant cell or tissue has been obtained, it is possible to regenerate a full-grown plant therefrom. 25 Thus, another aspect of the present invention relates to a transgenic plant that includes a DNA molecule of the present invention, wherein the promoter induces transcription of the first DNA molecule in response to infection of the plant by an oomycete. Preferably, the DNA molecule is stably 30 inserted into the genome of the transgenic plant of the present invention.

Plant regeneration from cultured protoplasts is described in Evans, et al., *Handbook of Plant Cell Cultures Vol.* 1: (MacMillan Publishing Co., New York, 1983); and Vasil I. 35 R. (ed.), *Cell Culture and Somatic Cell Genetics of Plants*, Acad. Press, Orlando, Vol. I, 1984, and Vol. III (1986), each of which is hereby incorporated by reference in their entirety.

It is known that practically all plants can be regenerated 40 from cultured cells or tissues, including but not limited to, all major species of rice, wheat, barley, rye, cotton, sunflower, peanut, corn, potato, sweet potato, bean, pea, chicory, lettuce, endive, cabbage, cauliflower, broccoli, turnip, radish, spinach, onion, garlic, eggplant, pepper, celery, carrot, 45 squash, pumpkin, zucchini, cucumber, apple, pear, melon, strawberry, grape, raspberry, pineapple, soybean, tobacco, tomato, sorghum, and sugarcane.

Means for regeneration vary from species to species of plants, but generally a suspension of transformed protoplasts 50 or a petri plate containing transformed explants is first provided. Callus tissue is formed and shoots may be induced from callus and subsequently rooted. Alternatively, embryo formation can be induced in the callus tissue. These embryos germinate as natural embryos to form plants. The culture 55 media will generally contain various amino acids and hormones, such as auxin and cytokinins. It is also advantageous to add glutamic acid and proline to the medium, especially for such species as corn and alfalfa. Efficient regeneration will depend on the medium, on the genotype, and on the 60 history of the culture. If these three variables are controlled, then regeneration is usually reproducible and repeatable.

After the DNA molecule is stably incorporated in transgenic plants, it can be transferred to other plants by sexual crossing or by preparing cultivars. With respect to sexual 65 crossing, any of a number of standard breeding techniques can be used depending upon the species to be crossed.

Cultivars can be propagated in accord with common agricultural procedures known to those in the field.

Diseases caused by the vast majority of bacterial pathogens result in limited lesions. That is, even when everything is working in the pathogen's favor (e.g., no triggering of the hypersensitive response because of R-gene detection of one of the effectors), the parasitic process still triggers defenses after a couple of days, which then stops the infection from spreading. Thus, the very same effectors that enable parasitism to proceed must also eventually trigger defenses. Therefore, premature expression of these effectors is believed to "turn on" plant defenses earlier (i.e., prior to infection) and make the plant resistant to either the specific bacteria from which the effector protein was obtained or many pathogens. An advantage of this approach is that it involves natural products and plants seem highly sensitive to pathogen effector proteins.

According to one embodiment, a transgenic plant is provided that contains a heterologous DNA molecule of the present invention. When the heterologous DNA molecule is expressed in the transgenic plant, plant defenses are activated, imparting disease resistance to the transgenic plant. The transgenic plant can also contain an R-gene whose product is activated by the protein or polypeptide product of the heterologous DNA molecule. The R gene can be naturally occurring in the plant or heterologously inserted therein. By disease resistance, it is believed that the effector proteins of the present invention can impart to plants resistance against bacterial, viral, and/or fungal diseases.

In addition to imparting disease resistance, it is believed that stimulation of plant defenses in transgenic plants of the present invention will also result in a simultaneous enhancement in growth and resistance to insects.

Alternative to transgenic expression is topical application of the effector proteins to plants. The embodiments of the present invention where the effector polypeptide or protein is applied to the plant can be carried out in a number of ways, including: 1) application of an isolated protein (or composition containing the same) or 2) application of bacteria which do not cause disease and are transformed with a gene encoding the effector protein of the present invention. In the latter embodiment, the effector protein can be applied to plants by applying bacteria containing the DNA molecule encoding the effector protein. Such bacteria are preferably capable of secreting or exporting the protein so that the protein can contact plant cells. In these embodiments, the protein is produced by the bacteria in planta.

Such topical application can be carried out using an effector-TAT protein, which will afford transduction domain-mediated spontaneous uptake of the effector protein into cells. Basically, this is carried out by fusing an 11-amino acid peptide (YGRKKRRQRRR, SEQ ID No: 25) by standard rDNA techniques to the N-terminus of the effector protein, and the resulting tagged protein is taken up into animal cells by a poorly understood process. This peptide is the protein transduction domain (PTD) of the human immunodeficiency virus (HIV) TAT protein (Schwarze et al., "Protein transduction: unrestricted delivery into all cells?" Trends Cell Biol. 10:290-295 (2000), which is hereby incorporated by reference in its entirety). Other PTDs are known and can be used for this purpose (Prochiantz, "Messenger proteins: homeoproteins, TAT and others," Curr. Opin. Cell Biol. 12:400–406 (2000), which is hereby incorporated by reference in its entirety). See PCT Application Publication No. WO 01/19393 to Collmer et al., which is hereby incorporated by reference in its entirety.

When the effector protein is topically applied to plants, it can be applied as a composition, which includes a carrier in the form, e.g., of water, aqueous solutions, slurries, or dry powders. In this embodiment, the composition contains greater than about 5 nM of the protein of the present 5 invention.

Although not required, this composition may contain additional additives including fertilizer, insecticide, fungicide, nematicide, and mixtures thereof Suitable fertilizers include $(NH_4)_2NO_3$. An example of a suitable insecticide is 10 Malathion. Useful fungicides include Captan.

Other suitable additives include buffering agents, wetting agents, coating agents, and, in some instances, abrading agents. These materials can be used to facilitate the process of the present invention.

According to one embodiment, a transgenic plant including a heterologous DNA molecule of the present invention expresses one or more effector proteins, wherein the transgenic plant is capable of supporting growth of compatible nonpathogenic bacteria. The compatible nonpathogenic bac- 20 teria can be naturally occurring or it can be recombinant. Preferably, the nonpathogenic bacteria is recombinant and expresses one or more useful products. Thus, the transgenic plant becomes a green factory for producing desirable products. Desirable products include, without limitation, 25 products that can enhance the nutritional quality of the plant or products that are desirable in isolated form If desired in isolated form, the product can be isolated from plant tissues. To prevent competition between the non-pathogenic bacteria which express the desired product and those that do not, it 30 is possible to tailor the needs of recombinant, non-pathogenic bacteria so that only they are capable if living in plant tissues expressing a particular effector protein or polypeptide of the present invention.

The effector proteins or polypeptides of the present inven- 35 tion are believed to alter the plant physiology by shifting metabolic pathways to benefit the parasite and by activating or suppressing cell death pathways. Thus, they may also provide useful tools for efficiently altering the nutrient content of plants and delaying or triggering senescence. 40 There are agricultural applications for all of these possible effects.

Thus, a further aspect of the present invention relates more generally to a method of modifying a metabolic pathway in a cell by introducing into the cell an effector 45 protein or polypeptide of the present invention which interacts with a native cellular protein involved in a metabolic pathway of the cell. As a result of introducing the protein or polypeptide into the cell, the protein or polypeptide modifies the metabolic pathway through its interaction with the native 50 cellular protein. By way of example, the HopPsyA_{*Pto*} protein (SEQ ID No: 22) is believed to interact with Mad2.

Yet another aspect of the present invention relates to a method of causing eukaryotic cell death which is carried out by introducing into a eukaryotic cell a *Pseudomonas* protein 55 which is cytotoxic and causes cell death. One preferred protein of the present invention is HopPsyA_{Pro} (SEQ ID No: 22), homolog of HopPsyA. The eukaryotic cell which is treated can be either in vitro or in vivo. When treating eukaryotic cells in vivo, a number of different protein- or 60 DNA-delivery systems can be employed to introduce the effector protein into the target eukaryotic cell.

The protein- or DNA-delivery systems can be provided in the form of pharmaceutical compositions which include the delivery system in a pharmaceutically acceptable carrier, 65 which may include suitable excipients or stabilizers. The dosage can be in solid or liquid form, such as powders,

solutions, suspensions, or emulsions. Typically, the composition will contain from about 0.01 to 99 percent, preferably from about 20 to 75 percent of active compound(s), together with the carrier, excipient, stabilizer, etc.

The compositions of the present invention are preferably administered in injectable or topically-applied dosages by solution or suspension of these materials in a physiologically acceptable diluent with a pharmaceutical carrier. Such carriers include sterile liquids, such as water and oils, with or without the addition of a surfactant and other pharmaceutically and physiologically acceptable carrier, including adjuvants, excipients or stabilizers. Illustrative oils are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, or mineral oil. In general, water, saline, aqueous dextrose and related sugar solution, and glycols, such as propylene glycol or polyethylene glycol, are preferred liquid carriers, particularly for injectable solutions.

Alternatively, the effector proteins can also be delivered via solution or suspension packaged in a pressurized aerosol container together with suitable propellants, for example, hydrocarbon propellants like propane, butane, or isobutane with conventional adjuvants. The materials of the present invention also may be administered in a non-pressurized form such as in a nebulizer or atomizer.

Depending upon the treatment being effected, the compounds of the present invention can be administered orally, topically, transdermally, parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, by intranasal instillation, by intracavitary or intravesical instillation, intraocularly, intraarterially, intralesionally, or by application to mucous membranes, such as, that of the nose, throat, and bronchial tubes.

Compositions within the scope of this invention include all compositions wherein the compound of the present invention is contained in an amount effective to achieve its intended purpose. While individual needs vary, determination of optimal ranges of effective amounts of each component is within the skill of the art.

One approach for delivering an effector protein into cells involves the use of liposomes. Basically, this involves providing a liposome which includes that effector protein to be delivered, and then contacting the target cell with the liposome under conditions effective for delivery of the effector protein into the cell.

Liposomes are vesicles comprised of one or more concentrically ordered lipid bilayers which encapsulate an aqueous phase. They are normally not leaky, but can become leaky if a hole or pore occurs in the membrane, if the membrane is dissolved or degrades, or if the membrane temperature is increased to the phase transition temperature. Current methods of drug delivery via liposomes require that the liposome carrier ultimately become permeable and release the encapsulated drug at the target site. This can be accomplished, for example, in a passive manner wherein the liposome bilayer degrades over time through the action of various agents in the body. Every liposome composition will have a characteristic half-life in the circulation or at other sites in the body and, thus, by controlling the half-life of the liposome composition, the rate at which the bilayer degrades call be somewhat regulated.

In contrast to passive drug release, active drug release involves using an agent to induce a permeability change in the liposome vesicle. Liposome membranes can be constructed so that they become destabilized when the environment becomes acidic near the liposome membrane (see, e.g., *Proc. Natl. Acad. Sci. USA* 84:7851 (1987); *Biochemistry* 28:908 (1989), each of which is hereby incorporated by reference in their entirety). When liposomes are endocy-tosed by a target cell, for example, they can be routed to acidic endosomes which will destabilize the liposome and result in drug release.

Alternatively, the liposome membrane can be chemically modified such that an enzyme is placed as a coating on the membrane which slowly destabilizes the liposome. Since control of drug release depends on the concentration of enzyme initially placed in the membrane, there is no real 10 effective way to modulate or alter drug release to achieve "on demand" drug delivery. The same problem exists for pH-sensitive liposomes in that as soon as the liposome vesicle comes into contact with a target cell, it will be engulfed and a drop in pH will lead to drug release. 15

This liposome delivery system can also be made to accumulate at a target organ, tissue, or cell via active targeting (e.g., by incorporating an antibody or hormone on the surface of the liposomal vehicle). This can be achieved according to known methods.

Different types of liposomes can be prepared according to Bangham et al., *J. Mol. Biol.* 13:238–252 (1965); U.S. Pat. No. 5,653,996 to Hsu et al.; U.S. Pat. No. 5,643,599 to Lee et al., U.S. Pat. No. 5,885,613 to Holland et al.; U.S. Pat. No. 5,631,237 to Dzau et al.; and U.S. Pat. No. 5,059,421 to 25 Loughrey et al., each of which is hereby incorporated by reference in their entirety.

An alternative approach for delivery of effector proteins involves the conjugation of the desired effector protein to a polymer that is stabilized to avoid enzymatic degradation of 30 the conjugated effector protein. Conjugated proteins or polypeptides of this type are described in U.S. Pat. No. 5,681,811 to Ekwuribe, which is hereby incorporated by reference in its entirety.

Yet another approach for delivery of proteins or polypep- 35 tides involves preparation of chimeric proteins according to U.S. Pat. No. 5,817,789 to Heartlein et al., which is hereby incorporated by reference in its entirety. The chimeric protein can include a ligand domain and, e.g., an effector protein of the present invention. The ligand domain is specific for 40 receptors located on a target cell. Thus, when the chimeric protein is delivered intravenously or otherwise introduced into blood or lymph, the chimeric protein will adsorb to the targeted cell, and the targeted cell will internalize the chimeric protein, which allows the effector protein to de-45 stabilize the cell checkpoint control mechanism, affording its cytotoxic effects.

When it is desirable to achieve heterologous expression of an effector protein of the present invention in a target cell, DNA molecules encoding the desired effector protein can be delivered into the cell. Basically, this includes providing a nucleic acid molecule encoding the effector protein and then introducing the nucleic acid molecule into the cell under conditions effective to express the effector protein in the cell. Preferably, this is achieved by inserting the nucleic acid 55 molecule into an expression vector before it is introduced into the cell.

When transforming mammalian cells for heterologous expression of an effector protein, an adenovirus vector can be employed. Adenovirus gene delivery vehicles can be 60 readily prepared and utilized given the disclosure provided in Berkner, *Biotechniques* 6:616–627 (1988) and Rosenfeld et al., *Science* 252:431–434 (1991), WO 93/07283, WO 93/06223, and WO 93/07282, each of which is hereby incorporated by reference in their entirety. Adeno-associated 65 viral gene delivery vehicles can be constructed and used to deliver a gene to cells. The use of adeno-associated viral

54

gene delivery vehicles in vitro is described in Chatterjee et al., Science 258:1485-1488 (1992); Walsh et al., Proc. Nat'l. Acad. Sci. 89:7257-7261 (1992); Walsh et al., J. Clin Invest. 94:1440-1448 (1994); Flotte et al., J. Biol. Chem. 268: 3781-3790 (1993); Ponnazhagan et al., J. Exp. Med. 179: 733-738 (1994); Miller et al., Proc. Nat'l Acad. Sci. 91:10183-10187 (1994); Einerhand et al., Gene Ther. 2:336-343 (1995); Luo et al., Exp. Hematol. 23:1261-1267 (1995); and Zhou et al., Gene Ther. 3:223-229 (1996), each of which is hereby incorporated by reference in their entirety. In vivo use of these vehicles is described in Flotte et al., Proc. Nat'l Acad. Sci. 90:10613-10617 (1993); and Kaplitt et al., Nature Genet. 8:148-153 (1994), each of which is hereby incorporated by reference in their entirety. Additional types of adenovirus vectors are described in U.S. Pat. No. 6,057,155 to Wickham et al.; U.S. Pat. No. 6,033, 908 to Bout et al.; U.S. Pat. No. 6,001,557 to Wilson et al.; U.S. Pat. No. 5,994,132 to Chamberlain et al.; U.S. Pat. No. 5,981,225 to Kochanek et al.; and U.S. Pat. No. 5,885,808 20 to Spooner et al.; and U.S. Pat. No. 5.871,727 to Curiel, each of which is hereby incorporated by reference in their entirety).

Retroviral vectors which have been modified to form infective transformation systems can also be used to deliver nucleic acid encoding a desired effector protein into a target cell. One such type of retroviral vector is disclosed in U.S. Pat. No. 5,849,586 to Kriegler et al., which is hereby incorporated by reference in its entirety.

Regardless of the type of infective transformation system employed, it should be targeted for delivery of the nucleic acid to a specific cell type. For example, for delivery of the nucleic acid into tumor cells, a high titer of the infective transformation system can be injected directly within the tumor site so as to enhance the likelihood of tumor cell infection. The infected cells will then express the desired effector protein, thereby causing cytotoxic effects.

Particularly preferred is use of the effector proteins of the present invention to treat a cancerous condition (i.e., the eukaryotic cell which is affected is a cancer cell). This can be carried out by introducing or administering to a patient, a cytotoxic *Pseudomonas* protein under conditions effective to inhibit cancer cell division, thereby treating the cancer condition.

By introducing, it is intended that the effector protein is administered to the patient, preferably in the form of a composition which will target delivery to the cancer cells. Alternatively, when using DNA-based therapies, it is intended that the introducing be carried out by administering a targeted DNA delivery system to the patient such that the cancer cells are targeted and the effector protein is expressed therein. A number of known targeted delivery systems are known in the art and can be employed herewith.

EXAMPLES

The following Examples are intended to be illustrative and in no way are intended to limit the scope of the present invention.

Example 1

Detection of Protein Expression by *Pseudomonas* syringae pv. tomato DC3000

ORF-specific DNA fragments were amplified by PCR from DC3000 genomic DNA and printed onto amine-coated slides from Cell Associates (Houston). Each DNA sample

was printed three times on each slide with a BioRobotics (Boston) Microgrid II Arrayer by using MicroSpot2500 split pins. Slides were blocked according to the recommended protocol from Cell Associates. Of total RNA, 50-100 µg was used to synthesize cDNA probes for microarray analysis. 5 RNA was mixed with 3 µg of random hexamers (Invitrogen) in a total volume of 15 µl and incubated at 65° C. for 10 min. Reactions were then placed on ice for 2 min, to which were added 3 µl of 1 mM FluoroLink Cy3- or Cy5-dUTP (Amersham Biosciences, Piscataway, N.J.), 3 µl of 0.1 M DTT, 6 10 µl of 5× first-strand buffer, 0.6 µl of 50×dNTPs mix (25 mM dATP, dCTP, dGTP/10 mM dTTP), and 2 µl of Superscript II (GIBCO/BRL). Reactions were incubated at room temperature for 10 min, followed by 42° C. for 110 min. RNA was hydrolyzed by adding 1.5 µl of 1 M NaOH at 65° C. for 15 10 min followed by neutralizing with 1.5 µl of 1 M HCl. cDNA probes were purified by using a PCR purification kit (Qiagen, Valencia, Calif.) and were resuspended in 20 µl of hybridization buffer (5×SSC, 0.1% SDS, and 25% formamide, where 1×SSC=0.15 M sodium chloride/0.015 M 20 sodium citrate, pH 7). Denatured probes (99° C., 2 min) were hybridized to slides at 60° C. overnight in hybridization cassettes (Coming), after which slides were washed twice with 2×SSC, 0.1% SDS (60° C., 5 min), once with 2×SSC (room temperature, 5 min), and once with 0.2×SSC 25 (room temperature, 5 min).

Microarray images were visualized by using a ScanArray 5000 (Packard), using laser and PMT settings of 100 and 90, respectively. Images were overlaid and quantified by using IMAGENE 4.1 software (BioDiscovery; Marina Del Rey, 30 Calif.). Ratio data were extracted by using GENESIGHT 2.1 software (BioDiscovery). For these analyses, local background for each spot was corrected, and signals lower than 50 were flagged and eliminated. After flooring low signals to the value of 100, ratios of the overlaid images were calcu-35 lated for individual spots. 16S rRNA was used and, to normalize the data, the 16S rRNA was expressed to similar levels in both tested strains based on RNA blots. Finally, all of the replicated data were combined, and mean ratio data and SDs were calculated for each ORF. 40

To corroborate the microarray results, RNA blotting was performed on 10 ORFs from similarly grown cultures. RNA blot analyses were performed as described (Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Lab. Press, Plainview, N.Y.(1989), which is hereby 45 incorporated by reference). Of each RNA sample, 25 µg was resolved on 1.2% formaldehyde-agarose gels and transferred to Nylon membranes (Hybond-N+) by capillary blotting using 20×SSC. transferred to Nylon membranes (Hybond-N+) by capillary blotting using 20×SSC. RNA was bound to 50 the membrane by UV cross-linking. Probes were generated by PCR amplification from genomic DNA, using ORFspecific primers, and labeled with ³²P-dATP by random priming with a DECAprime II kit (Ambion). Hybridization was performed in 5×SSC, 50% formamide, 0.1% sodium- 55 lauroylsarcosine, 0.02% SDS, and 2% blocking reagent (Roche Molecular Biochemicals) at 42° C. overnight. Membranes were then washed twice with 2×SSC/0.1% SDS for 15 min, twice with 1×SSC/0.1% SDS for 15 min, and once with 0.1×SSC/0.1% SDS for 15 min before exposure on a 60 phosphor screen. Signals were detected and evaluated by using a Storm system (Molecular Dynamics) (FIG. 1).

The microarray experiments were in qualitative agreement with the RNA blot. These data indicate that Hrp promoter candidates with E values smaller (more signifi-65 cant) than 1e–4 are expressed at levels detected by the microarray and RNA blotting. However, within this group

there was no apparent relationship between the magnitude of the E value and the level of expression. Furthermore, one of 16 examined ORFs (see Fouts et al. (*Proc. Natl. Acad. Sci USA* 99: 2275–2280 (2002), which is hereby incorporated by reference in its entirety) with an E value substantially lower than this threshold, AvrXv3 (4e–6), was expressed at a level that was detected only by RNA blot analysis (Table 1 below), indicating that significant E values do not always predict strong expression.

TABLE 1

Results of Microarray Analysis											
Des- ignation	GenBank accession number ¹	Amino acid % identity	BLASTP p value	HMM E-value	Microarray signal ratio ²						
HopPsyA _{Pto}	L14926	52	9e-93	1.0e-5	11 ± 9						
AvrPphE _{Pto}	U16817	67	1e-117	2.5e-4	5 ± 2						
AvrPphF _{Pto}	AF231452	51	3e-36	1.7e-6	3 ± 2						
AvrPphD1 _{Pto}	AJ277494	89	0	1.9e-6	30 ± 17						
AvrXv3 _{Pto}	AF190120	27	7e-12	3.4e-6	ND						
AvrPpiB1 _{Pto}	X84843	100	1e-152	7.8e-6	11 ± 9						
AvrPpiB2 _{Pto}	X84843	100	1e-150	7.8e-6	10 ± 6						
AvrPphD2 _{Pto}	AJ277494	53	2e-44	3.0e-5	27 ± 11						
HopPtoB2 ³	AF232004			2.6e-3	ND						
AvrRps4 _{Pto}	L43559	72	2e-44	2.5e-2	ND						
Reference gei	ies										
16S rRNA*					1						
23S rRNA**					1						

¹GenBank accession number AF232004 is for DC3000 sequences, all others are for homologs originally found in other bacteria.

²Microarray signal is the mean ratio and standard deviation from 3 replicates of 2 independent experiments, calculated as described in the Materials and Methods. AvrPpiBl_{Pto} and AvrPpiB2_{Pto} are 100% identical, so their signals cannot be distinguished. AvrPphD1_{Pto} and AvrPphD2_{Pto} are 62% identical. ND = not detected

identical. ND = not detected. ³HopPtoB1 is secreted in a Hrp-dependent manner; HopPtoB2 has duplicated regions of homology with HopPtoB1.

By using an iterative process involving computational and gene expression data, an initial inventory of P. s. tomato DC3000 candidate type III secretion effector proteins was obtained. These are the presumed prime agents of host metabolic subversion. These analyses have revealed that the Hrp regulon, the primary regulon known to be expressed during infection, seems to control at least 48 genes and a subsidiary regulon directing phytotoxin production. The terative process focused on Hrp promoters in DC3000 and featured microarray experiments that tested the activity of novel Hrp promoters and demonstrated the validity of this approach for genomewide transcriptional profiling in DC3000. These findings suggest that the *P. syringae* Hrp regulon is more complex than expected and encompasses more than type III secretion system genes and effector genes.

The global search for DC3000 ORFs that are similar to known Avr/Hop proteins yielded AvrXv3_{Pto}, AvrPtoB, and the AvrPphD families as the only candidate effectors shared with Xanthomonas spp. (Noel et al., Mol. Microbiol. 41:1271–1281 (2001), which is hereby incorporated by reference in its entirety). Notably missing were members of the AvrBs2 and AvrBs3 families, which are widespread in Xanthomonas spp., or any members of the AvrRxv/YopJ family, which are found in genera as diverse as Salmonella, Yersinia, Xanthomonas, Erwinia, and Rhizobium, and have also been reported in another strain of P. syringae (i.e., P. s. syringae B728a) (Galán & Collmer, Science 284:1322–1328 (1999); Alfano et al., Proc. Natl. Acad. Sci. USA 97:4856-4861 (2000), each of which is hereby incorporated by reference in its entirety). However, it is important to note that further searches after closure and annotation of the

DC3000 genome may yield additional homologs of known effectors. In addition, genomic projects with other pathogens will enlarge the set of candidate effector genes available for comparison.

The majority of *P. syringae* avr genes that have been 5 cloned on the basis of Avr phenotype have come from three pathovars that parasitize legumes *glycinea*, *phaseolicola*, and *pisi*. P. s. tomato has a different host range and diverges from these other pathovars in rRNA comparisons (Manceau & Horvais, *Appl. Environ. Microbiol.* 63:498–505 (1997), 10 which is hereby incorporated by reference in its entirety). Nevertheless, of the 15 avr gene families found in these legume-attacking pathovars, 6 are also found in DC3000. This finding suggests the existence of a core set of *P. syringae* effectors in addition to those in the Hrp pathoge- 15 nicity island CEL.

The analyses described above and reported in Fouts et al. (*Proc. Natl. Acad. Sci USA* 99: 2275–2280 (2002), which is hereby incorporated by reference in its entirety) revealed a striking apparent redundancy among the candidate effector 20 protein genes hopPtoA, hopPtoB, avrPphD_{*Pto*}, and avrPpiB1_{*Pto*}, as well as in three Hrp-related factors that may play a role in type III protein translocation across bacterial and plant cell walls.

All of the analyzed candidate effector genes seem to be 25 expressed in a HrpL-dependent manner except for avrRps4_{Pto}, hopPtoA2, and hopPtoB2 (avrXv3_{Pto} was HrpL-activated, but relatively poorly). avrRps4_{Pto} was cloned originally from Pseudomonas syringae pisi and renders recombinant DC3000 avirulent on most Arabidopsis 30 accessions (Hinsch & Staskawicz, Mol. Plant-Microbe Interact. 9:55-61 (1996), which is hereby incorporated by reference in its entirety), and avrXv3 is from an Xanthomonas campestris pv. vesicatoria race that is avirulent on tomato carrying the Xv3 R gene (Astua-Monge et al., Mol. 35 Plant-Microbe Interact. 13:911-921 (2000), which is hereby incorporated by reference in its entirety). There exists a possibility that poor expression of these two avr genes in DC3000 is a factor in the virulence of DC3000 on Arabidopsis and tomato carrying the cognate R genes.

Example 2

In vitro Secretion of Effector Proteins

Secretion assays were performed using P. s. tomato DC3000 strains carrying a pML123 derivative containing a PCR-cloned ORF (encoding a candidate Hrp-secreted protein) fused to nucleotide sequences that encoded either the HA or FLAG epitopes along with their native ribosome 50 binding sites and an engineered stop codon (Labes et al., *Gene* 89:37–46 (1990), which is hereby incorporated by reference in its entirety).

Four effector proteins were tested for their secretion from the above-identified strains. Primers and the constructs used 55 to prepare the transform the host strains are identified as follows:

For HopPtoC expression, the hopPtoC gene was cloned using forward primer (agtcggatccgaatagggcgctgaaaatatgacaatcgtgte, SEQ ID No: 26) containing a BamHI ₆₀ site and reverse primer (agtcctcgagtcacttgtcatcgtcgtccttgtagtcgtgtatttttgaagcgaa, SEQ ID No: 27) containing an XhoI site and FLAG epitope codons. The hopPtoC gene was cloned into plasmid vector pLN50.

For HopPtoD1 expression, the hopPtoD1 gene was cloned 65 using forward primer (ccacacattggatccgattacttcatccgggacagctgatagcgc, SEQ ID No: 28) containing a BamHI 58

site and reverse primer (attctcgagtcatttatcatcatcatcatttataatcgggtgcgggctgccgcgac, SEQ ID No: 29) containing an XhoI site and FLAG epitope codons. The hopPtoD1 gene was cloned into plasmid vector pLN167.

For HopPtoD2 expression, the hopPtoD2 gene was cloned using forward primer (atgcaagcttatccaatgcctttcgtca, SEQ ID No: 30) containing a HindIII site and reverse primer (atgcctcgagtcaagcgtaatctggaacatcgtatgggtattctaacgctattttgc, SEQ ID No: 31) containing an XhoI site and HA epitope codons. The hopPtoD2 gene was cloned into plasmid vector pLN130.

For HopPtoJ expression, the hopPtoJ gene was cloned using forward primer (agtaaagcttgagctgcacgcatgcgag, SEQ ID No: 32) containing a HindIII site and reverse primer (agtatctagatcacttgtcatcgtcgtccttgtagtcttgtgcgaccagatgttt,

SEQ ID No: 33) containing an XbaI site and FLAG epitope codons. The hopPtoJ gene was cloned into plasmid vector pLN164.

Constructs carrying different epitope-tagged ORFs were electroporated into DC3000 and a DC3000 hrcC mutant and grown in Hrp-inducing conditions (Yuan & He, J. Bacteriol. 178:6399-6402 (1996), which is hereby incorporated by reference in its entirety). Additionally, all of the DC3000 strains also carried pCPP2318, a construct that contains blaM lacking signal peptide sequences (Charkowski et al., J. Bacteriol. 179:3866-3874 (1997), which is hereby incorporated by reference in its entirety). DC3000 cultures were separated into cell-bound and supernatant fractions as described (van Dijk et al., J. Bacteriol. 181:4790-4797 (1999), which is hereby incorporated by reference in its entirety). Proteins were separated with SDS-PAGE by standard procedures (Sambrook et al., Molecular Cloning Second Ed. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.) (1989), which is hereby incorporated by reference in its entirety), transferred to polyvinylidene difluoride membranes, and immunoblotted using anti-FLAG (Sigma Chemical Co., St. Louis, Mo.), -HA (Roche Molecular Biochemicals, Indianapolis, Ind.), or $-\beta$ -lactamase (5 Prime→3 Prime Inc., Boulder, Colo.) as primary antibodies. 40 Primary antibodies were recognized by goat anti-rabbit immunoglobulin G-alkaline phosphatase conjugate (Sigma Chemical Co.), which were visualized by chemiluminescence using a Western-Light chemilumincescence detection system (Tropix, Bedford, Mass.) and X-Omat X-ray film.

Each of these DC3000 proteins were found to be secreted (FIG. 2A). Because the secretability of these proteins was demonstrated (and the avirulence activity of these DC3000 homologs is unknown), the proteins were renamed as HopPtoC (AvrPpiC2 homolog), HopPtoD1 and HopPtoD2 (AvrPphD homologs), and HopPtoJ (AvrXv3 homolog).

Example 3

In vitro Translocation of Effectors

Arabidopsis thaliana accession Columbia (Col-0) and rps2–201 mutant plants were grown in a growth chamber with 12 hr of light at 24° C. (22° C. at night) and 70% relative humidity. For HopPtoK expression, the hopPtoK gene was cloned using forward primer (gcgaattcatcggtttaatcacgcaaggc, SEQ ID No: 34) containing a EcoRI site and reverse primer (ttggtacctcagcagtagagcgtgt, SEQ ID No: 35) containing an KpnI site. The hopPtoK gene was cloned into plasmid vector phopPtoK. In addition, a hopPtoK-'avrRpt2 fusion was prepared using SEQ ID No: 34 (above) as forward primer and reverse primer (aaggatccgcagagcgtgtcgcgacc, SEQ ID No: 36) containing an BamHI site to

4∩

clone the hopPtoK gene. The partial avrRpt2 gene with the N terminal 40 codons deleted was amplified using standard PCR procedures and cloned into pMOD (Madison, Wis.). After confirmation by sequence analysis, it was cloned into the KpnI and SalI sites of the broad-host-plasmid pLK, 5 resulting in p Δ avrRpt2. DNA fragments spanning 200 bp upstream of the Hrp boxes and the complete ORFs for hopPtoK was cloned into p Δ avrRpt2 to produce phopPtoK- Δ avrRpt2. Additionally, the full-length hopPtoK was cloned using PCR into pLK to generate phopPtoK. Each construct 10 was introduced in *P. s. phaseolicola* 3121 by electroporation. Bacterial strains in 10 mM MgCl₂ at a cell density of 10⁸ cfu/ml were infiltrated into *A. thaliana* Col-0 plants with a needleless syringe. Plant responses were documented 18 hours postinoculation. 15

The AvrRpt2 translocation assay was used to test whether the DC3000 ORF that is similar to AvrRps4 (Hinsch & Staskawicz, Mol. Plant-Microbe Interact. 9:55-61 (1996), which is hereby incorporated by reference in its entirety) was translocated into Arabidopsis plant cells (Mudgett et al., 20 Proc. Natl. Acad. Sci. USA 97:13324-13329 (2000);Guttman & Greenberg, Mol. Plant-Microbe Interact. 14:145-155) (2001), each of which is hereby incorporated by reference in its entirety). P. s. phaseolicola carrying a broad-host-range plasmid expressing the AvrRps4 homolog 25 fused to the Avr domain of AvrRpt2 (but lacking the secretion signals of AvrRpt2) elicited an RPS2-dependent HR on A. thaliana Col-0 (FIG. 2B), indicating that the amino terminus of the AvrRps4 homolog supplied sufficient information to direct translocation of the fusion protein into plant 30 cells. Consequently, the AvrRps4 homolog was renamed HopPtoK. P. s. phaseolicola expressing HopPtoK did not elicit an HR, indicating that although translocated into host cells, HopPtoK is probably not recognized by the RPS4 protein present in A. thaliana Col-0, in contrast to its P. s. 35 pisi 151 homolog (Hinsch & Staskawicz, Mol. Plant-Microbe Interact. 9:55-61 (1996), which is hereby incorporated by reference in its entirety).

Example 4

Determining Cytotoxicity of Effector in Yeast

Effector proteins of the present invention will be cloned into pFLAG-CTC (Kodak) to generate an in-frame fusion 45 with the FLAG epitope, which will permit monitoring of protein production with anti-FLAG monoclonal antibodies. The FLAG-tagged genes will then be cloned under the control of the GAL1 promoter in the yeast shuttle vector p415GAL1 (Mumberg et al., 1994). These regulatable pro- 50 moters of Saccharomyces cerevisiae will allow comparison of transcriptional activity and heterologous expression. The recombinant plasmids will be transformed into uracil auxotrophic yeast strains FY833/4, then selected for growth on SC-Ura (synthetic complete medium lacking uracil) based 55 on the presence of the URA3 gene on the plasmid. The transformants will then be streaked onto SC-Ura medium plates containing either 2% galactose (which will induce expression of the effector proteins) or 2% glucose. The presence or absence of growth on the plates supplemented 60 with 2% galactose will be observed. If no growth is observed on 2% galactose (but growth is observed in the 2% glucose control), this result will suggest that the effector protein is having a cytotoxic effect on the transformed yeast. Empty vector controls will also be used. FLAG-tagged nontoxic 65 Avr proteins will be used to confirm that the recombinant effector genes were differentially expressed, as expected, on

plates containing galactose. To further confirm the results, albeit at lower expression levels, the recombinant effector gene will be recloned into p416GALS, which expresses foreign genes at a substantially lower level than p415GAL1.

Example 5

Determining Cytotoxicity of Effector in Plants

To determine whether effector proteins induce cell death on tobacco leaves, a transformation system that delivers the effector gene on T-DNA of Agrobacterium tumefaciens will be used (Rossi et al., Plant Mol. Biol. Reporter 11:220-229 (1993); van den Ackerveken et al., Cell 87:1307-1316 (1996), each of which is hereby incorporated by reference in its entirety). This delivery system works better than biolistics for transiently transforming whole plant leaves. For these experiments, vector pTA7002, kindly provided by Nam-Hai Chua and his colleagues at Rockefeller University, will be used. The unique property of this vector is that it contains an inducible expression system that uses the regulatory mechanism of the glucocorticoid receptor (Picard et al., Cell 54:1073-1080 (1988); Aoyama and Chua, Plant J. 11(3):605-612 (1997); McNellis et al., Plant J. 14(2): 247-257 (1998), each of which is hereby incorporated by reference in its entirety). pTA7002 encodes a chimeric transcription factor consisting of the DNA-binding domain of GAL4, the transactivating domain of the herpes viral protein VP16, and the receptor domain of the rat glucocorticoid receptor. Also contained on this vector is a promoter containing GAL4 upstream activating sequences (UAS) upstream of a multiple cloning site. Thus, any gene cloned downstream of the promoter containing the GAL4-UAS can be induced by glucocorticoids, of which a synthetic glucocorticoid, dexamethasone (DEX), is available commercially. Effector proteins of the present invention will be PCRcloned downstream of the GAL4-UAS. Thereafter, plant leaves from several different test plants will be infiltrated with Argrobacterium carrying recombinant pTA7002 carrying the effector ORF and after 48 hours these plants will be sprayed with DEX to induce expression of the effectors.

Tobacco (Nicotiana tabacum) and tomato (Lycopersicon esculentum) will be grown under greenhouse conditions and then maintained at 25° C. with daylight and supplemental halide illumination for HR and virulence assays. Bacteria will be grown overnight on King's medium B agar supplemented with appropriate antibiotics, suspended in 5 mM MES pH 5.6, and then infiltrated with a needleless syringe into the leaves of test plants at 108 cfu/ml for HR assays and 10^4 cfu/ml for pathogenicity assays (Charkowski et al., J. Bacteriol. 180:5211-5217 (1998), which is hereby incorporated by reference in its entirety). All assays will be repeated at least four times on leaves from different plants. Bacterial growth in tomato leaves will be assayed by excising disks from infiltrated areas with a cork borer, comminuting the tissue in 0.5 ml of 5 mM MES, pH 5.6, with an appropriate pestle, and then dilution plating the homogenate on King's medium B agar with 50 µg/ml rifampicin and 2 µg/ml cycloheximide to determine bacterial populations. The mean and SD from three leaf samples will be determined for each time point.

Plant leaves will be examined to determine the response of plant tissue to the expression of the effector proteins. In particular, plant tissues will be examined for tissue necrosis indicative of a hypersensitive response. Although the invention has been described in detail for the purposes of illustration, it is understood that such detail is solely for that purpose, and variations can be made therein by those skilled in the art without departing from the spirit and scope of the invention which is defined by the following claims.

62

```
SEQUENCE LISTING
```

<160> NUMBER OF SEQ ID NOS: 36

- <210> SEQ ID NO 1
- <211> LENGTH: 1155 <212> TYPE: DNA

<213> ORGANISM: Pseudomonas syringae

<400> SEQUENCE: 1

atgaaaatac	ataacgctgg	cctaacccca	cctttgccgg	gcatttcgaa	tggaaacgtt	60
ggaaaggcgg	cgcaatcatc	aataactcaa	ccgcagagcc	agcaaggctc	ttatggcttg	120
ccaccagaaa	gctctgagac	tcgccctgat	agggcgcgtg	cgaactatcc	atattcatca	180
gtacaaacac	ggttgccgcc	cgttgcgtct	gctgggaaac	cgctgcctga	tacaccatct	240
tctttgcccg	gctacttact	gttgcgaagg	ctggaccatc	gccctgtgga	tcaggaaggt	300
accaaaagtc	tgatcccggc	agacaaggct	gtggctgaag	cgcgccgtgc	attgcccttt	360
ggaagaggca	atattgatgt	ggatgcgcaa	ctttccaatc	tggaaagtgg	agcccgcacc	420
cttgcagcaa	ggtgcttgag	aaaagatgcc	gaggccgccg	gtcatgagcc	tatgcctgcg	480
aatgagccga	tgaactggca	tgttcttgtt	gcgatgtcag	gccaggtgtt	cddcdcdddc	540
aactgtggcg	aacatgctcg	tatagcgagc	ttcgcctatg	gagctttggc	ccaggaaaac	600
ggacgatctg	aatatgaaaa	catctacttg	gctgcatcga	ctgaggaaga	tcatgtgtgg	660
gctgaaaccg	acgaatccca	gtctggcacc	tcaacgattg	tcatggatcc	gtggtcaaat	720
ggttcagcca	tatttgcgga	ggacagtagg	tttgcgaaaa	atcgaaatgc	tgtagagcgt	780
acggatacgt	ttaatctttc	aaccgcagcc	gaagcgggca	aaattacgcg	tgagacagcc	840
gagaaggctt	tgacgcaggt	cacaacccga	ttgcagaaac	gcctggcgga	tcagcaggag	900
caagtctcgc	ccatcaaaag	tggtcgctat	cgaccagaaa	aatcggtact	tgatgatgca	960
tttgtccgca	gagtgagcga	caagttgacc	tcccctgatt	tgcggcgtgc	actacaggta	1020
gatattgaag	cggtcggagt	cgcaatgtcg	ctcggcacca	agggcgtcaa	ggacgctact	1080
cgacaagccc	gacctttggt	tgagcttgca	gtgaaggtcg	cctctcctca	aggcttggcg	1140
agacgagatg	tctga					1155
<210> SEQ : <211> LENG <212> TYPE: <213> ORGAN <400> SEQU	ID NO 2 TH: 384 : PRT NISM: Pseudo ENCE: 2	omonas syri	ngae			
Met Lys Ile	e His Asn A	la Gly Leu	Thr Pro Pro	Leu Pro Gly	/ Ile Ser	
1	5	-	10	-	15	
Asn Gly Ası	n Val Gly L 20	ys Ala Ala	Gln Ser Ser 25	Ile Thr Glr 30	n Pro Gln)	
Ser Gln Glı 3	n Gly Ser T	yr Gly Leu 40	Pro Pro Glu	Ser Ser Glu 45	ı Thr Arg	
Pro Asp Are 50	g Ala Arg A	la Asn Tyr 55	Pro Tyr Ser	Ser Val Glr 60	n Thr Arg	
Leu Pro Pro 65	o Val Ala S	er Ala Gly 70	Lys Pro Leu 75	Pro Asp Thr	r Pro Ser 80	

-continued

Ser Leu Pro Gly Tyr Leu Leu Leu Arg Arg Leu Asp His Arg Pro Val Asp Gln Glu Gly Thr Lys Ser Leu Ile Pro Ala Asp Lys Ala Val Ala Glu Ala Arg Arg Ala Leu Pro Phe Gly Arg Gly Asn Ile Asp Val Asp Ala Gln Leu Ser Asn Leu Glu Ser Gly Ala Arg Thr Leu Ala Ala Arg Cys Leu Arg Lys Asp Ala Glu Ala Ala Gly His Glu Pro Met Pro Ala Asn Glu Pro Met Asn Trp His Val Leu Val Ala Met Ser Gly Gln Val Phe Gly Ala Gly Asn Cys Gly Glu His Ala Arg Ile Ala Ser Phe Ala Tyr Gly Ala Leu Ala Gln Glu Asn Gly Arg Ser Glu Tyr Glu Asn Ile Tyr Leu Ala Ala Ser Thr Glu Glu Asp His Val Trp Ala Glu Thr Asp Glu Ser Gln Ser Gly Thr Ser Thr Ile Val Met Asp Pro Trp Ser Asn Gly Ser Ala Ile Phe Ala Glu Asp Ser Arg Phe Ala Lys Asn Arg Asn Ala Val Glu Arg Thr Asp Thr Phe Asn Leu Ser Thr Ala Ala Glu Ala Gly Lys Ile Thr Arg Glu Thr Ala Glu Lys Ala Leu Thr Gln Val Thr Thr Arg Leu Gln Lys Arg Leu Ala Asp Gln Gln Glu Gln Val Ser Pro Ile Lys Ser Gly Arg Tyr Arg Pro Glu Lys Ser Val Leu Asp Asp Ala Phe Val Arg Arg Val Ser Asp Lys Leu Thr Ser Pro Asp Leu Arg Arg Ala Leu Gln Val Asp Ile Glu Ala Val Gly Val Ala Met Ser Leu Gly Thr Lys Gly Val Lys Asp Ala Thr Arg Gln Ala Arg Pro Leu Val Glu Leu Ala Val Lys Val Ala Ser Pro Gln Gly Leu Ala Arg Arg Asp Val <210> SEQ ID NO 3 <211> LENGTH: 1017 <212> TYPE: DNA <213> ORGANISM: Pseudomonas syringae <400> SEOUENCE: 3 atgaatcgca tttcaaccag ctcagtaaat tccagcttca attacacggc ccctacggag gaagegcaaa accgettege etcagegeee gacaatteee etctagttgt caccacaaca tctatcgccc aagcgtcgga agggctacaa aggccggggg caacgctaag catgcaggcc cagcgactgc gccaattgat ggggagcccg tctgagcagt gccggaggga cacaatgtta gctaaagctt ttgatgctca acgcctaaac attaacactc aagcaggctc ttccaacagc ccacacttga acgeteteaa cacgeteeaa caacgacact teaaacetge ggetggtggg ctagaaatcc cagttacatc caactcctta ttgggcggtg gcaggcaagt ctatcaaatt

-continued

ggc	tcato	cgt d	cacgo	cgag	ct aa	agcca	accga	a cco	ggtca	aatg	atca	agga	ccg	cgcgo	ccette	480
agg	geget	tg a	agego	gctg	ca co	geega	agtto	g tt	agag	ggtg	ggco	gati	tga	gttt	gtgcct	540
aga	ggcao	gca a	acgto	gttg	gc ct	tcaaa	acgto	g ago	ggato	gtcg	acat	tggad	cga	gttco	gatgtc	600
atca	aacto	cta a	aagao	cddc.	tg co	caago	gcatt	t ggo	cacca	actg	gcct	tggga	acc	ctgca	attgca	660
gtg	tgtgo	caa q	gaggo	catgo	ga ta	agaga	aaggo	g cti	cccg	gtgc	tgg	gtgto	cta ·	tcaco	cacagt	720
ggta	atogo	gct d	cacca	agago	ga ta	accat	cggct	t act	cctto	gatc	aago	cgato	gcg	cgata	aaaggt	780
gcti	tgca	aaa †	tcaaa	atac	tc co	ctggi	aggo	c ggo	catga	atca	tgco	ctaaa	aga	ggaaq	gaggct	840
ggca	agcta	atg a	acga	cgag	ca aa	agcti	ttt	g gca	attga	aaag	gca	gtta	ttc	aatco	gaaggg	900
gcg	cgcti	-gc a	atgta	atcc	ga ag	ggcga	aagaq	g gao	cgtgo	cata	ccg	gegag	gga -	caaca	agtgtc	960
aat	gttci	∶gc †	tgate	gaat	ga co	cgcgi	tcto	g tao	cggto	cdcd	acad	cgcto	cta	ctgc	tga	1017
<210 <211 <211 <211)> SE L> LE 2> TY 3> OF	EQ II ENGTH PE: RGANI	D NO H: 33 PRT ISM:	4 38 Psei	ıdomo	onas	syri	Ingae	9							
<400)> SE	QUEN	ICE :	4												
Met 1	Asn	Arg	Ile	Ser 5	Thr	Ser	Ser	Val	Asn 10	Ser	Ser	Phe	Asn	Ty r 15	Thr	
Ala	Pro	Thr	Glu 20	Glu	Ala	Gln	Asn	Arg 25	Phe	Ala	Ser	Ala	Pro 30	Asp	Asn	
Ser	Pro	Leu 35	Val	Val	Thr	Thr	Thr 40	Ser	Ile	Ala	Gln	Ala 45	Ser	Glu	Gly	
Leu	Gln 50	Arg	Pro	Gly	Ala	Thr 55	Leu	Ser	Met	Gln	Ala 60	Gln	Arg	Leu	Arg	
Gln 65	Leu	Met	Gly	Ser	Pro 70	Ser	Glu	Gln	Сув	Arg 75	Arg	Asp	Thr	Met	Leu 80	
Ala	Lys	Ala	Phe	Asp 85	Ala	Gln	Arg	Leu	Asn 90	Ile	Asn	Thr	Gln	Ala 95	Gly	
Ser	Ser	Asn	Ser 100	Pro	His	Leu	Asn	Ala 105	Leu	Asn	Thr	Leu	Gln 110	Gln	Arg	
His	Phe	L y s 115	Pro	Ala	Ala	Gly	Gl y 120	Leu	Glu	Ile	Pro	Val 125	Thr	Ser	Asn	
Ser	Leu 130	Leu	Gly	Gly	Gly	Arg 135	Gln	Val	Tyr	Gln	Ile 140	Gly	Ser	Ser	Ser	
Arg 145	Glu	Leu	Ser	His	Arg 150	Pro	Val	Asn	Asp	Gln 155	Asp	Arg	Ala	Pro	Phe 160	
Arg	Ala	Leu	Glu	Arg 165	Leu	His	Ala	Glu	Leu 170	Phe	Arg	Gly	Gly	Pro 175	Ile	
Glu	Phe	Val	Pro 180	Arg	Gly	Ser	Asn	Val 185	Leu	Ala	Ser	Asn	Val 190	Arg	Asp	
Val	Asp	Met 195	Asp	Glu	Phe	Asp	Val 200	Ile	Asn	Ser	Lys	Asp 205	Gly	Сув	Gln	
Gly	Ile 210	Gly	Thr	Thr	Gly	Leu 215	Gly	Pro	Сув	Ile	Ala 220	Val	Cys	Ala	Arg	
Gly 225	Met	Asp	Arg	Glu	Gly 230	Leu	Pro	Val	Leu	Gly 235	Val	Tyr	His	His	Ser 240	
Gly	Ile	Gly	Ser	Pro 245	Glu	Asp	Thr	Met	Ala 250	Thr	Leu	Asp	Gln	Ala 255	Met	
Arg	Asp	Lys	Gly 260	Ala	Leu	Gln	Ile	L y s 265	Tyr	Ser	Leu	Val	Gly 270	Gly	Met	

-continued

Ile Met Pro Lys Glu Glu Glu Ala Gly Ser Tyr Asp Asp Glu Gln Ser 275 280 285 Phe Leu Ala Leu Lys Gly Ser Tyr Ser Ile Glu Gly Ala Arg Leu His 295 290 300 Val Ser Glu Gly Glu Glu Asp Val His Thr Gly Glu Asp Asn Ser Val 305 310 315 320 Asn Val Leu Leu Met Pro Asp Arg Val Leu Tyr Gly Arg Asp Thr Leu 325 330 335 Tyr Cys <210> SEQ ID NO 5 <211> LENGTH: 396 <212> TYPE: DNA <213> ORGANISM: Pseudomonas syringae <400> SEQUENCE: 5 atgaaaaacg catttgacct gcttgtggaa gggctggcta aggactacaa catgccgccc ttgcctgaca agaaacatat cgatgaagtc tattgctttg agtttcaaag tggtatgaac 120 gtaaaagtat accaagacga atttcgctgg gtatatttca ccgctgacgt tgggacattt 180 caagatagca gtattgacac attaaactac gcgctccagc tgaacaactt tagccttaga 240 aaacctttcc tgaccttcgg aatgacgaag gagaaaaatg gtgtattgca tacacgcacc 300 cccttgattg aggtagacaa cgtgcaaatg cgcaggatat ttgaggagct tataggcgtg 360 gcaggtgaaa tcagaaaaac actaaaactc aaatag 396 <210> SEQ ID NO 6 <211> LENGTH: 131 <212> TYPE: PRT <213> ORGANISM: Pseudomonas syringae <400> SEQUENCE: 6 Met Lys Asn Ala Phe Asp Leu Leu Val Glu Gly Leu Ala Lys Asp Tyr 1 5 10 15 Asn Met Pro Pro Leu Pro Asp Lys Lys His Ile Asp Glu Val Tyr Cys 20 25 30 Phe Glu Phe Gln Ser Gly Met Asn Val Lys Val Tyr Gln Asp Glu Phe 40 35 45 Arg Trp Val Tyr Phe Thr Ala Asp Val Gly Thr Phe Gln Asp Ser Ser 50 55 60 Ile Asp Thr Leu Asn Tyr Ala Leu Gln Leu Asn Asn Phe Ser Leu Arg 65 70 75 80 Lys Pro Phe Leu Thr Phe Gly Met Thr Lys Glu Lys Asn Gly Val Leu 85 90 95 His Thr Arg Thr Pro Leu Ile Glu Val Asp Asn Val Gln Met Arg Arg 100 105 110 Ile Phe Glu Glu Leu Ile Gly Val Ala Gly Glu Ile Arg Lys Thr Leu 115 120 125 Lys Leu Lys 130 <210> SEQ ID NO 7 <211> LENGTH: 579 <212> TYPE: DNA <213> ORGANISM: Pseudomonas syringae

<400> SEQUENCE: 7

-continued

gtgt	tataq	gcc -	catco	ccat	ac ac	caac	gaata	act	tcaç	gctc	ccto	ctaca	atc	cacto	atgtt	60
ggto	ggaga	ata	cacto	gaca	tc ca	attea	atcag	r ctt	tcgo	ata	gtca	agaga	aga	gcagt	ttctg	120
aaca	atgca	atg	atcca	aatga	ag ag	gtaa	tggga	ctt	cgaco	atg	atad	ccgao	gct	tttca	agaacg	180
acgo	gataq	gtc	gctat	tata	aa aa	aacga	ataaa	cto	cdcdd	jgca	atco	cacaa	atc	catgo	gcgagt	240
atco	tta	-gc	atgaa	agaa	ct go	cgcco	ccaat	. cgt	tttç	jcca	gcca	ataca	agg	tgcco	caacca	300
caco	gaago	caa	gggcg	gtac	gt to	ccga	aaaga	ata	aaaaq	gcca	ccga	atcta	agg	agtto	ccatca	360
ctga	aacgi	caa ·	tgact	tggc	tc go	ctago	cgcga	gad	eggaa	atta	gago	cttai	tga	tcaca	atgagt	420
gata	aatca	agg	tctct	tgtca	aa aa	atge	gactg	gga	agatt	ttc	tcga	aaago	1 d d	tggca	aaggtc	480
tato	geega	acg	cttco	gtct	gt aq	gctga	acgat	ggg	ggaaa	acat	caca	agci	tct	gatto	gtcaca	540
ttgo	cccaa	aag	gacaç	gaaa	gt go	ccdd	tcgaa	ago	ggtct	:ga						579
<210 <211 <212 <213)> SE L> LE 2> TY 3> OF	EQ II ENGTI PE: RGAN:	D NO H: 19 PRT ISM:	8 92 Psei	ıdomo	onas	syri	ngae	e							
<400)> SE	QUEI	NCE:	8												
Val 1	Tyr	Ser	Pro	Ser 5	His	Thr	Gln	Arg	Ile 10	Thr	Ser	Ala	Pro	Ser 15	Thr	
Ser	Thr	His	Val 20	Gly	Gly	Asp	Thr	Leu 25	Thr	Ser	Ile	His	Gln 30	Leu	Ser	
His	Ser	Gln 35	Arg	Glu	Gln	Phe	Leu 40	Asn	Met	His	Asp	Pro 45	Met	Arg	Val	
Met	Gly 50	Leu	Asp	His	Asp	Thr 55	Glu	Leu	Phe	Arg	Thr 60	Thr	Asp	Ser	Arg	
Ty r 65	Ile	Lys	Asn	Asp	Lys 70	Leu	Ala	Gly	Asn	Pro 75	Gln	Ser	Met	Ala	Ser 80	
Ile	Leu	Met	His	Glu 85	Glu	Leu	Arg	Pro	Asn 90	Arg	Phe	Ala	Ser	His 95	Thr	
Gly	Ala	Gln	Pro 100	His	Glu	Ala	Arg	Ala 105	Tyr	Val	Pro	Lys	Arg 110	Ile	Lys	
Ala	Thr	A sp 115	Leu	Gly	Val	Pro	Ser 120	Leu	Asn	Val	Met	Thr 125	Gly	Ser	Leu	
Ala	Arg 130	Asp	Gly	Ile	Arg	Ala 135	Tyr	Asp	His	Met	Ser 140	Asp	Asn	Gln	Val	
Ser 145	Val	Lys	Met	Arg	Leu 150	Gly	Asp	Phe	Leu	Glu 155	Arg	Gly	Gly	Lys	Val 160	
Tyr	Ala	Asp	Ala	Ser 165	Ser	Val	Ala	Asp	Asp 170	Gly	Glu	Thr	Ser	Gln 175	Ala	
Leu	Ile	Val	Thr 180	Leu	Pro	Lys	Gly	Gln 185	Lys	Val	Pro	Val	Glu 190	Arg	Val	
<210 <211 <212 <213)> SF L> LF 2> TY 3> OF	EQ II ENGTI PE: RGAN:	D NO H: 21 DNA ISM:	9 118 Psei	ıdomo	onas	syri	ngae	e							
<400	J> SE	QUEI	NCE :	9												
atga	aatco	ctc ·	tacga	atcta	at to	caaca	acaac	att	rgcaa	actc	ccco	caato	cag	tggco	ggtcag	60
ccat	ttaga	acg	cggto	gggc	cc to	caggo	cccag	caa	atcco	catc	ctaa	aaago	gat	ttcad	cttct	120
caat	ttgag	gcc -	aaago	gct	ca co	caggo	ctcta	gaa	acgco	ttt	cago	ctaat	tgc	cgaad	caccaa	180

-continued

cgccttgcat	cactggtacg	caacgctctg	caggatggca	catttcaatt	tcaatccagt	240
aaccacacgc	aagtaaccta	taaagcgtca	atctgtctgc	cagctgacac	cgataccgtg	300
agaaccgacc	acttgattaa	taacgagctg	acggttcagg	cccgattaaa	tgatcaatcg	360
gagtacgaca	tcgtcagcgc	acatttgcat	ggctcttcga	aagccatatc	cttcgacgta	420
cccagccccc	cgcccgcaca	tggttcagca	tcttctgtct	tgagtgaacg	gacccatcta	480
ggtatgagtc	gcgttctctc	acaagatgca	gtagacagca	gtagcctgga	aactccgtta	540
ctgagctcgc	cagaccattc	tcgtccgcca	tcacagccaa	agcccgtgca	tatcgggtcg	600
gtccgcaggg	actctggtag	ccttgtttcc	gataacccgg	tagtgcaggc	cctgctatcg	660
tttgcgcagg	ccgaccaggc	atttccacca	caggccgcga	gcattgccgg	ggtccagctg	720
gaaatgcggc	cacgtcggga	tattgagaaa	gcacttgagg	aattcaaagg	cgccttcacg	780
gtggtgaagg	cgcaactgat	gtccggtgcc	aactcgtcgg	agcgtgtaga	tgaggatgtc	840
aacgcagaca	tccatatccc	cttattgctc	aaggccatcg	agcgggggggc	tgcggcattt	900
ggtccaaacg	catcaatcgg	ccagaatagc	gcgaaagcgt	ttctcgcctc	atgtgctccc	960
aagatcacgt	ccaatgacga	tgtcctctcc	gagttcatca	accagaaact	caaggggggac	1020
gacgatcttc	aggttcgcct	gggcgcacag	gaattgttgc	atgtagccac	caagaaggaa	1080
ttccagctcg	gcggtctagc	cggcagcatc	ggggtcagca	gcatactcgg	ctcggcatgg	1140
gagcttggcg	cttctgagct	gttgaaaaat	gccatcttcg	gcaaaaattt	ctcaccgagc	1200
caatatgccc	tgcaattggc	tggaatcgat	tcagtgcctc	ctttgattat	cgagtccatg	1260
gacaccatgt	gcgtacttgc	catcatcaag	ggcatgaagg	gtgaggagtg	gtccatgagc	1320
gatctacttc	ccaaggcgtt	gaaggccggt	gctatttcct	cggtggtgtc	attccccaat	1380
aatgttttgc	agtatgcagg	tttcaaatcc	agagtcggcg	atcttgcggc	aaactcagtg	1440
acaactgaag	cggccatctt	tggcgccgcc	tccggtattc	cacccgaggt	caaggaaagt	1500
gaagagctga	tgcgtgctgg	cttattccag	agcatgaagg	acggcgtgat	ggctcattca	1560
ggcgaggggg	tggacaccaa	aaaaacgatt	gagcggatga	cgcgccatgc	gctggatatc	1620
gctccgggcg	aaagcaccgc	tgtcaagtcc	atggggctgg	catcgattgt	cgggatgatt	1680
ccactgattg	ccagcaacaa	ggcaaccggg	ctgctgtcgg	aacaggtact	gcgtattttc	1740
cggagcgccg	tcttcaatcc	aatcgaagcc	atcgctctga	acgcgttggc	gcttggcggg	1800
cgtgtcaacg	ttcccgggct	atttgattcc	gacaatgcca	agcatgcacg	cgtggtacaa	1860
accatccttg	cgcgggccag	ccagcacatg	gaagctggag	accgtgacat	ttccgcagag	1920
gagctacatc	aaatgctggc	tccccggagc	gagttcctgc	gccatgtggg	atctgcgatt	1980
gtcaacggca	tgaatgccag	ctttgaggca	attcccgccc	tggttcggaa	gcttggatat	2040
ggtgaggctc	cattggccga	acgtattccg	tatcaagacc	tggctgtgcc	cgacacgtcg	2100
cggcagcccg	caccctga					2118
<210> SEQ 1 <211> LENGT <212> TYPE: <213> ORGAN	ID NO 10 TH: 705 : PRT NISM: Pseudo	omonas syrir	ıgae			
<400> SEQUE	ENCE: 10					
Met Asn Pro 1	b Leu Arg Se 5	er Ile Gln H	His Asn Ile 10	Ala Thr Pro	o Pro Ile 15	
Ser Gly Gly	y Gln Pro Le 20	eu Asp Ala V	/al Gly Pro 25	Gln Ala Gln 30	n Gln Ser)	

His	Pro	Lys 35	Arg	Ile	Ser	Pro	Ser 40	Gln	Leu	Ser	Gln	Ser 45	Ala	His	Gln
Ala	Leu 50	Glu	Arg	Leu	Ser	Ala 55	Asn	Ala	Glu	His	Gln 60	Arg	Leu	Ala	Ser
Leu 65	Val	Arg	Asn	Ala	Leu 70	Gln	Asp	Gly	Thr	Phe 75	Gln	Phe	Gln	Ser	Ser 80
Asn	His	Thr	Gln	Val 85	Thr	Tyr	Lys	Ala	Ser 90	Ile	Cys	Leu	Pro	Ala 95	Asp
Thr	Asp	Thr	Val 100	Arg	Thr	Asp	His	Leu 105	Ile	Asn	Asn	Glu	Leu 110	Thr	Val
Gln	Ala	Arg 115	Leu	Asn	Asp	Gln	Ser 120	Glu	Tyr	Asp	Ile	Val 125	Ser	Ala	His
Leu	His 130	Gly	Ser	Ser	Lys	Ala 135	Ile	Ser	Phe	Asp	Val 140	Pro	Ser	Pro	Pro
Pro 145	Ala	His	Gly	Ser	Ala 150	Ser	Ser	Val	Leu	Ser 155	Glu	Arg	Thr	His	Leu 160
Gly	Met	Ser	Arg	Val 165	Leu	Ser	Gln	Asp	Ala 170	Val	Asp	Ser	Ser	Ser 175	Leu
Glu	Thr	Pro	Leu 180	Leu	Ser	Ser	Pro	Asp 185	His	Ser	Arg	Pro	Pro 190	Ser	Gln
Pro	Lys	Pro 195	Val	His	Ile	Gly	Ser 200	Val	Arg	Arg	Asp	Ser 205	Gly	Ser	Leu
Val	Ser 210	Asp	Asn	Pro	Val	Val 215	Gln	Ala	Leu	Leu	Ser 220	Phe	Ala	Gln	Ala
Asp 225	Gln	Ala	Phe	Pro	Pro 230	Gln	Ala	Ala	Ser	Ile 235	Ala	Gly	Val	Gln	Leu 240
Glu	Met	Arg	Pro	Arg 245	Arg	Asp	Ile	Glu	L y s 250	Ala	Leu	Glu	Glu	Phe 255	Lys
Gly	Ala	Phe	Thr 260	Val	Val	Lys	Ala	Gln 265	Leu	Met	Ser	Gly	Ala 270	Asn	Ser
Ser	Glu	Arg 275	Val	Asp	Glu	Asp	Val 280	Asn	Ala	Asp	Ile	His 285	Ile	Pro	Leu
Leu	Leu 290	Lys	Ala	Ile	Glu	Arg 295	Gly	Ala	Ala	Ala	Phe 300	Gly	Pro	Asn	Ala
Ser 305	Ile	Gly	Gln	Asn	Ser 310	Ala	Lys	Ala	Phe	Leu 315	Ala	Ser	Cys	Ala	Pro 320
Lys	Ile	Thr	Ser	Asn 325	Asp	Asp	Val	Leu	Ser 330	Glu	Phe	Ile	Asn	Gln 335	Lys
Leu	Lys	Gly	Asp 340	Asp	Asp	Leu	Gln	Val 345	Arg	Leu	Gly	Ala	Gln 350	Glu	Leu
Leu	His	Val 355	Ala	Thr	Lys	Lys	Glu 360	Phe	Gln	Leu	Gly	Gly 365	Leu	Ala	Gly
Ser	Ile 370	Gly	Val	Ser	Ser	Ile 375	Leu	Gly	Ser	Ala	Trp 380	Glu	Leu	Gly	Ala
Ser 385	Glu	Leu	Leu	Lys	Asn 390	Ala	Ile	Phe	Gly	L y s 395	Asn	Phe	Ser	Pro	Ser 400
Gln	Tyr	Ala	Leu	Gln 405	Leu	Ala	Gly	Ile	Asp 410	Ser	Val	Pro	Pro	Leu 415	Ile
Ile	Glu	Ser	Met 420	Asp	Thr	Met	Cys	Val 425	Leu	Ala	Ile	Ile	Lys 430	Gly	Met
Lys	Gly	Glu 435	Glu	Trp	Ser	Met	Ser 440	Asp	Leu	Leu	Pro	L y s 445	Ala	Leu	Lys

-continued

Ala Gly Ala Ile Ser Ser Val Val Ser Phe Pro Asn Asn Val Leu Gl 450 455 460	n
Tyr Ala Gly Phe Lys Ser Arg Val Gly Asp Leu Ala Ala Asn Ser Val465470475486	1 D
Thr Thr Glu Ala Ala Ile Phe Gly Ala Ala Ser Gly Ile Pro Pro Glu 485 490 495	L
Val Lys Glu Ser Glu Glu Leu Met Arg Ala Gly Leu Phe Gln Ser Met 500 505 510	t
Lys Asp Gly Val Met Ala His Ser Gly Glu Gly Val Asp Thr Lys Ly 515 520 525	5
Thr Ile Glu Arg Met Thr Arg His Ala Leu Asp Ile Ala Pro Gly Glu 530 535 540	L
Ser Thr Ala Val LysSer Met Gly Leu Ala Ser Ile Val Gly Met Ile545550555560	e)
Pro Leu Ile Ala Ser Asn Lys Ala Thr Gly Leu Leu Ser Glu Gln Va 565 570 575	1
Leu Arg Ile Phe Arg Ser Ala Val Phe Asn Pro Ile Glu Ala Ile Ala 580 585 590	a
Leu Asn Ala Leu Ala Leu Gly Gly Arg Val Asn Val Pro Gly Leu Pho 595 600 605	9
Asp Ser Asp Asn Ala Lys His Ala Arg Val Val Gln Thr Ile Leu Ala 610 615 620	a
Arg Ala Ser Gln His Met Glu Ala Gly Asp Arg Asp Ile Ser Ala Glu625630635640	ц С
Glu Leu His Gln Met Leu Ala Pro Arg Ser Glu Phe Leu Arg His Va 645 650 655	1
Gly Ser Ala Ile Val Asn Gly Met Asn Ala Ser Phe Glu Ala Ile Pro 660 665 670	C
Ala Leu Val Arg Lys Leu Gly Tyr Gly Glu Ala Pro Leu Ala Glu Arg 675 680 685	а
Ile Pro Tyr Gln Asp Leu Ala Val Pro Asp Thr Ser Arg Gln Pro Ala 690 695 700	a
Pro 705	
<210> SEQ ID NO 11 <211> LENGTH: 1407 <212> TYPE: DNA <213> ORGANISM: Pseudomonas syringae	
<400> SEQUENCE: 11	
atgaatcccc tgcaacctat tcagcacagc attacaaatt cccaaatgag tggtggt	cag
caattagagg cggagggctc tcaggcccac aattcctatt cccatcctga caggatt	tcg
ctttcccaat tgagccaaag cgctcaccta gctctagatc acctttcaac tcagccta	aat
accgatcacc aacgcgttgc atcactggta cgcaacgctg tgcaggacgg taagttc	caa
cttcaatcca gtaacgacac gcaagtaacc tataaaactt cagtctgtcc gccagct	aac
gccgacacca tgggggccgc ccacttaatt aataacgagc tgacggttca ggcccga	tta
aatgatcaac ttgagtacga catcgtcagc gctcatttgt atggcccttc ggaagcc	ata
tccatcgatg catccagtcc tccctcggcc aacgatctag cgtcctctgg cttgagc	gaa
cgtacgcatc taggtatgaa tcgtgtcctc ttacgctacg cggtgccccc tcgggaa	acc
gaagaccaat gtgttatggt gatcgacaaa atgccccccc ccaaacacgg caaaatg	tct

-continued

ttcttccgta	ccactaatga	cttgagcaaa	a ctgcctttgg	gaatggagac gggcgggtt	g 660
tccgacctga	aattggctgg	ttgtgaacgt	atttcttccg	tcgagcaggt gaagagtat	c 720
cgcgcagcgc	ttggaggcgg	gccgctcacc	gtactagatc	tgcgcgaaga atctcatgc	g 780
attgtcaacg	gtttgcctat	caccttacgt	ggcccgatgg	attgggccaa cgccggcct	a 840
tcccaggttg	acggagcggc	acgtgaaagt	gccatgatta	cagaactgaa gcgcactaa	ig 900
tctttaacgt	tggtcgatgc	caattatgta	a aaaggtaaaa	aaagtaatcc tcaaacgac	a 960
gaactgaaaa	atttgaatgt	ccggagcgag	g cgagaagtcg	ttacagaggc cggcgcgac	c 1020
tatcgccgcg	tggccattac	cgaccataac	aggcctagtc	cggaagcgac cgacgagct	a 1080
gtagacatca	tgcgccactg	cctgcaggca	a aatgagtcgc	tagttgtgca ctgtaacgg	rc 1140
ggtcggggcc	gtactaccac	ggctatgata	a atggtcgaca	tgcttaagaa cgctcgtaa	ic 1200
cattccgcag	aaaccctcat	cacgcgtate	g gccaagctaa	gctatgacta caacatgac	g 1260
gatctaggca	gcatttctgc	actcaagcgg	g ccattcctag	aggacagact aaaatttct	g 1320
caggcctttc	acgactatgc	ccgcaacaac	ccaagcggat	tatctcttaa ttggacaca	ig 1380
tggcgcgcaa	aaatagcgtt	agaatga			1407
<210> SEQ 3 <211> LENG <212> TYPE <213> ORGAN <400> SEQU:	ID NO 12 TH: 468 : PRT NISM: Pseud ENCE: 12	omonas syri	ngae		
Met Asn Pr 1	o Leu Gln P 5	ro Ile Gln	His Ser Ile 10	Thr Asn Ser Gln Met 15	
Ser Gly Gl	y Gln Gln L 20	eu Glu Ala	Glu Gl y Ser 25	Gln Ala His Asn Ser 30	
Tyr Ser Hi 3	s Pro Asp A 5	rg Ile Ser 40	Leu Ser Gln	Leu Ser Gln Ser Ala 45	
His Leu Al 50	a Leu Asp H	is Leu Ser 55	Thr Gln Pro	Asn Thr Asp His Gln 60	
Arg Val Al 65	a Ser Leu V	al Arg Asn 70	Ala Val Gln 75	Asp Gly Lys Phe Gln 80	
Leu Gln Se	r Ser Asn A 85	sp Thr Gln	Val Thr Tyr 90	Lys Thr Ser Val Cys 95	
Pro Pro Al	a Asn Ala A 100	sp Thr Met	Gly Ala Ala 105	His Leu Ile Asn Asn 110	
Glu Leu Th 11	r Val Gln A 5	la Arg Leu 120	Asn Asp Gln	Leu Glu Tyr Asp Ile 125	
Val Ser Al 130	a His Leu T	yr Gly Pro 135	Ser Glu Ala	Ile Ser Ile Asp Ala 140	
Ser Ser Pr 145	o Pro Ser A 1	la Asn Asp 50	Leu Ala Ser 155	Ser Gly Leu Ser Glu 160	
Arg Thr Hi	s Leu Gly M 165	et Asn Arg	Val Leu Leu 170	Arg Tyr Ala Val Pro 175	
Pro Arg Gl	u Thr Glu A 180	sp Gln Cys	Val Met Val 185	Ile Asp Lys Met Pro 190	
Pro Pro Ly 19	s His Gl y L 5	ys Met Ser 200	Phe Phe Arg	Thr Thr Asn Asp Leu 205	
Ser Lys Le 210	u Pro Leu G	ly Met Glu 215	Thr Gly Gly	Leu Ser Asp Leu Lys 220	
Leu Ala Gl	y Cys Glu A	rg Ile Ser	Ser Val Glu	Gln Val Lys Ser Ile	

-continued

225	230			235			240
Arg Ala Ala Le	eu Gly Gly 245	Gly Pro	Leu Thr 250	Val L	.eu Asp	Leu Arg 255	Glu
Glu Ser His Al 20	la Ile Val 50	Asn Gly	Leu Pro 265	Ile T	hr Leu!	Arg Gly 270	Pro
Met Asp Trp Al 275	la Asn Ala	Gly Leu 280	Ser Gln	Val A	Asp Gly 285	Ala Ala	Arg
Glu Ser Ala Me 290	et Ile Thr	Glu Leu 295	L y s Arg	Thr L 3	ys Ser	Leu Thr	Leu
Val Asp Ala As 305	sn Ty r Val 310	Lys Gly	Lys Lys	Ser A 315	Asn Pro	Gln Thr	Thr 320
Glu Leu Lys As	sn Leu Asn 325	Val Arg	Ser Glu 330	Arg G	lu Val	Val Thr 335	Glu
Ala Gly Ala Th 34	nr Ty r Arg 40	Arg Val	Ala Ile 345	Thr A	Asp His	Asn Arg 350	Pro
Ser Pro Glu Al 355	la Thr Asp	Glu Leu 360	Val Asp	Ile M	let Arg 365	His Cys	Leu
Gln Ala Asn Gl 370	lu Ser Leu	Val Val 375	His Cys	Asn G 3	Gly Gly	Arg Gly	Arg
Thr Thr Thr Al 385	la Met Ile 390	Met Val	Asp Met	Leu L 395	ys Asn	Ala Arg	Asn 400
His Ser Ala G	lu Thr Leu 405	Ile Thr	Arg Met 410	Ala L	ys Leu	Ser Tyr 415	Asp
Tyr Asn Met Th 42	nr Asp Leu 20	Gly Ser	Ile Ser 425	Ala L	leu Lys	Arg Pro 430	Phe
Leu Glu Asp An 435	rg Leu Lys	Phe Leu 440	Gln Ala	Phe H	lis Asp 445	Tyr Ala	Arg
Asn Asn Pro Se	er Gly Leu	Ser Leu	Asn Trp	Thr G	ln Trp	Arg Ala	Lys
450 Ile Ala Leu Gl 465	lu	455		4	160		
<210> SEQ ID N <211> LENGTH: <212> TYPE: DN <213> ORGANISM	10 13 810 JA 1: Pseudomo	onas syri	ingae				
<400> SEQUENCE	E: 13						
atgacaatcg tgt	tctggaca c	atcggaaaa	a caccca	agcc t	aaccact	gt tcaa	gctggg 60
tottoggott ogg	gtcgagaa t	caaatgcc	t gatcct	gcac a	igttcagt	ga tgga	cggtgg 120
aaaaagcttc cga	acccaatt g	tcgtcaat	t acattg	gcga g	jattogat	ca ggat	atttgc 180
acgaataatc ato	ggcatcag t	cagegtge	a atgtgc	tttg g	geetttea	itt gagc	tggatt 240
aacatgattc ato	gccgggaa a	gatcatgt	t acgccc	tatg c	atcggca	iga aaga	atgagg 300
tttctgggtt cct	tttgaagg g	gtggtgca	t gctcgt	actg t	tcataac	tt ctat	cggact 360
gagcacaaat tto	ctgatgga g	caagcttco	c gcaaac	cccg g	gagtatca	ag tggc	gcgatg 420
gctggcacag aaa	agtttatt g	caagctgc	t gagttg	aagg g	gttaaag	ct tcaa	cctgtt 480
ctagaggaca agt	tcgaactc a	ggcctacc	c ttccta	attg c	gtgtaag	ica gtca	gggcgg 540
caggtgagca cag	gatgaagc t	gcgctaag	c tcctta	tgtg a	itgcaatt	gt agaa	aataag 600
agaggggtaa tgo	gtgatata c	agccaaga	a attgcc	cacg c	tttgggc	tt ttct	gtatca 660
tcagatggca aaa	agagcgac c	ttatttga	t cccaat	ctcg g	gagagttt	ca taca	cactcg 720
aaagcgttgg cto	gatactat c	gaaaacata	a tcatcg	gcag a	tgggctg	cc ttta	atcggc 780

gttcaagtat tcgcttcaaa aatacactga													
<210> SEQ ID NO 14 <211> LENGTH: 269 <212> TYPE: PRT <213> ORGANISM: Pseudomonas syringae													
<400> SE	QUENCE :	14											
Met Thr 1	Ile Va	L Ser 5	Gly H	His	Ile	Gly	Lys 10	His	Pro	Ser	Leu	Thr 15	Thr
Val Gln	Ala Gl 20	y Ser)	Ser A	Ala	Ser	Val 25	Glu	Asn	Gln	Met	Pro 30	Asp	Pro
Ala Gln	Phe Sei 35	r Asp	Gly A	Arg	Trp 40	Lys	Lys	Leu	Pro	Thr 45	Gln	Leu	Ser
Ser Ile 50	Thr Let	ı Ala	Arg I	Phe 55	Asp	Gln	Asp	Ile	Суз 60	Thr	Asn	Asn	His
Gly Ile 65	Ser Glı	n Arg	Ala M 70	Met	Cys	Phe	Gly	Leu 75	Ser	Leu	Ser	Trp	Ile 80
Asn Met	Ile His	s Ala 85	Gly I	Lys	Asp	His	Val 90	Thr	Pro	Tyr	Ala	Ser 95	Ala
Glu Arg	Met Are 100	g Phe)	Leu (Gly	Ser	Phe 105	Glu	Gly	Val	Val	His 110	Ala	Arg
Thr Val	His Ası 115	n Phe	Tyr A	Arg	Thr 120	Glu	His	Lys	Phe	Leu 125	Met	Glu	Gln
Ala Ser 130	Ala Ası	n Pro	Gly V	Val 135	Ser	Ser	Gly	Ala	Met 140	Ala	Gly	Thr	Glu
Ser Leu 145	Leu Gli	n Ala	Ala (150	Glu	Leu	Lys	Gly	Leu 155	Lys	Leu	Gln	Pro	Val 160
Leu Glu	Asp Ly:	s Ser 165	Asn S	Ser	Gly	Leu	Pro 170	Phe	Leu	Ile	Ala	Cys 175	Lys
Gln Ser	Gly Are 180	g Gln)	Val S	Ser	Thr	A sp 185	Glu	Ala	Ala	Leu	Ser 190	Ser	Leu
Cys Asp	Ala Ile 195	e Val	Glu A	Asn	L y s 200	Arg	Gly	Val	Met	Val 205	Ile	Tyr	Ser
Gln Glu 210	Ile Ala	a His	Ala I 2	Leu 215	Gly	Phe	Ser	Val	Ser 220	Ser	Asp	Gly	Lys
Arg Ala 225	Thr Let	ı Phe	Asp 1 230	Pro	Asn	Leu	Gly	Glu 235	Phe	His	Thr	His	Ser 240
Lys Ala	Leu Ala	a Asp 245	Thr 1	Ile	Glu	Asn	Ile 250	Ser	Ser	Ala	Asp	Gly 255	Leu
Pro Leu	Ile Gly 260	y Val)	Gln V	Val	Phe	Ala 265	Ser	Lys	Ile	His			
<210> SE <211> LE <212> TY <213> OF	Q ID NO NGTH: 8 PE: DNA RGANISM:) 15 331 A Pseu	ıdomor	ıas	syri	.ngae	1						
<400> SE	QUENCE :	15											
atgcacgo	caa atco	cttta	ag cto	cttt	caad	: aga	igcto	caac	atg	gcaat	tat g	gacta	aatgta
gaggccag	gcc aag	taaa	tc ggo	cago	jaaco	tct	tcca	acca	ctaa	atata	aga d	cagta	aaaac
attgaaga	aac atg	tgca	ga cag	gact	cagt	: gat	ttag	ggca	gaco	ctga	tgg t	ggat	tggttt
ttcgagaa	agt cact	tggc	ac ctt	tgaa	aaat	tta	aato	cttg	agca	agtta	agc d	cggaa	atccat
gatgtact	taa aati	caaca	ga tgo	gcgt	aaaq	g aac	atto	gtct	ctt	tgga	agc t	cggg	gaagga

-continued

ggctto	cgagt	tggc	aatgo	ca gi	tttc	gtcat	t gai	ttat	caca	gato	ctcaa	aca H	taag	gatgaa	L	360
aactco	gccgc	acga	tgccq	gc aa	actca	atta	t cti	gate	gcaa	tca	geete	gca a	atcaa	acaaa	L	420
tttaca	aaaac	ttga	aaaa	ct ad	caaca	atgta	a gat	gtat	tta	aaat	tgcaa	aaa d	cccgi	tttgg	r	480
gatgto	cgggt	acaa	aaaco	gg aa	attgo	cgcad	c gca	aaaa	aaaa	tgg	catto	ett (cataa	acgcca	L	540
gagtg	gctgg	gttc	tgati	tt ci	tgtaa	aacaq	g gaa	attco	cagt	ggci	ttago	cga a	aacaa	aaaac	:	600
aaaga	cataa	aatc	tgcat	tt to	gtgai	tctt	t aaa	agato	gtag	acti	taaaa	aag d	caaaa	aatatg	r	660
acaag	tatct	tcaa	tttt	ge ag	gacti	tccat	t aaa	atcad	cgcg	tcat	tgato	ggc a	aagca	acacct	:	720
cccgaa	atcgg	gatte	gaata	aa to	gtaaa	aaato	c gaa	aaata	agcg	ttga	accto	gaa t	tttca	aagagg	r	780
ttatta	aactg	accg	tgagi	tc af	tggga	aacta	a aat	caati	tcc	tage	gega	cta a	a			831
<210> SEQ ID NO 16 <211> LENGTH: 276 <212> TYPE: PRT <213> ORGANISM: Pseudomonas syringae																
Met H	is Ala	Asn	Pro	Leu	Ser	Ser	Phe	Asn	Ara	Ala	Gln	His	Glv	Asn		
1	IS AIU	ABII	5	цец	Der	Der	FIIG	10	лгу	лıu	GIII	111.0	15	ABII		
Leu Th	hr Asn	Val 20	Glu	Ala	Ser	Gln	Val 25	Lys	Ser	Ala	Gly	Thr 30	Ser	Ser		
Thr Th	hr Asn 35	Ile	Asp	Ser	Lys	Asn 40	Ile	Glu	Glu	His	Val 45	Ala	Asp	Arg		
Leu Se	er Asp 50	Leu	Gly	Arg	Pro 55	Asp	Gly	Gly	Trp	Phe 60	Phe	Glu	Lys	Ser		
Leu G. 65	ly Thr	Leu	Lys	Asn 70	Leu	Asn	Leu	Glu	Gln 75	Leu	Ala	Gly	Ile	His 80		
Asp Va	al Leu	Lys	Leu 85	Thr	Asp	Gly	Val	Lys 90	Asn	Ile	Val	Ser	Phe 95	Gly		
Ala A	rg Glu	Gly 100	Gly	Phe	Glu	Leu	Ala 105	Met	Gln	Phe	Arg	His 110	Asp	Leu		
Tyr A	rg Ser 115	Gln	His	Pro	Asp	Glu 120	Asn	Ser	Pro	His	Asp 125	Ala	Ala	Thr		
His Ty 13	yr Leu 30	Asp	Ala	Ile	Ser 135	Leu	Gln	Ser	Asn	L y s 140	Phe	Thr	Lys	Leu		
Glu Ly 145	ys Leu	Gln	His	Val 150	Asp	Val	Phe	Lys	Met 155	Gln	Asn	Pro	Phe	Trp 160		
Asp Va	al Gly	Tyr	L y s 165	Asn	Gly	Ile	Ala	His 170	Ala	Lys	Lys	Met	Ala 175	Phe		
Phe I	le Thr	Pro 180	Glu	Trp	Leu	Gly	Ser 185	Asp	Phe	Суз	Lys	Gln 190	Glu	Phe		
Gln T	rp Leu 195	Ser	Glu	Thr	Lys	Asn 200	Lys	Asp	Ile	Lys	Ser 205	Ala	Phe	Val		
Ile Pl 23	he Lys 10	Asp	Val	Asp	Leu 215	Lys	Ser	Lys	Asn	Met 220	Thr	Ser	Ile	Phe		
Asn Pl 225	he Ala	Asp	Phe	His 230	Lys	Ser	Arg	Val	Met 235	Met	Ala	Ser	Thr	Pro 240		
Pro G	lu Ser	Gly	Leu 245	Asn	Asn	Val	Lys	Ile 250	Glu	Asn	Ser	Val	Asp 255	Leu		
Asn Pl	he L y s	Arg 260	Leu	Leu	Thr	Asp	Arg 265	Glu	Ser	Trp	Glu	Leu 270	Asn	Asn		

-continued

275

<210> SEQ ID NO 17 <211> LENGTH: 855 <212> TYPE: DNA <213> ORGANISM: Pseudomonas syringae <400> SEOUENCE: 17 atggggctat gtatttcaaa acactctggt agcagttaca gctacagtga tagcgaccgc 60 tggcaagtgc ctgcatgccc tccaaacgcc aggtctgtat ccagtcatca aacagcatct 120 gcgagtgaca tcgcatcagg cgatgtggat gaacgtcctg caacgttttc tcattttcaa 180 cttgcgcggt gcggtggaga gtacacgctt agcatggttt ctgcagcggc ttatcaagca 240 gaaagacggc atcgcggtaa tttaataaaa gatcgtagtc aatccatact cccatgggtc 300 caggtatatc attctaaaaa aggtttggat tacagcttcc agatcgacag aactacgact 360 gttaaagtgg ctggattcaa ctgctctatc cccaataaca gagggactcg gcatttatac 420 agcgctggta cgagtcagac aaacatgcct gtcatcgcag acaacatgag cgcatgcatt 480 gctgtcgcgt gtgcggcgga aaacgtggat gctggcacgg gtgaacgtag gccggggggg 540 aaagttcgcg tattccatct actccctttt cgacgcgaag accttgtgcc agaagaagtt 600 ttagcttctg tgcgcgatta tctgcgaacg accaaagaac aggggctaac aatgcgcgta 660 gctatgcatg gagggaatac agagggtgat ttctcagtca gcactgcgca ggcattgaaa 720 780 ggcctgtttg ctaatgaagg gatcccgctt gaatttgacg agacctgtgc aaaccgaacg 840 tctqaaacac tqcttqqtqc cqttatctta qatqacaact cqactcattt cataaaacat 855 ctggtcgcac aataa <210> SEO ID NO 18 <211> LENGTH: 284 <212> TYPE: PRT <213> ORGANISM: Pseudomonas svringae <400> SEOUENCE: 18 Met Gly Leu Cys Ile Ser Lys His Ser Gly Ser Ser Tyr Ser Tyr Ser 5 10 1 Asp Ser Asp Arg Trp Gln Val Pro Ala Cys Pro Pro Asn Ala Arg Ser 20 25 30 Val Ser Ser His Gln Thr Ala Ser Ala Ser Asp Ile Ala Ser Gly Asp 35 40 45 Val Asp Glu Arg Pro Ala Thr Phe Ser His Phe Gln Leu Ala Arg Cys 55 50 60 Gly Gly Glu Tyr Thr Leu Ser Met Val Ser Ala Ala Ala Tyr Gln Ala 70 75 80 Glu Arg Arg His Arg Gly Asn Leu Ile Lys Asp Arg Ser Gln Ser Ile 85 90 95 Leu Pro Trp Val Gln Val Tyr His Ser Lys Lys Gly Leu Asp Tyr Ser 105 100 110 Phe Gln Ile Asp Arg Thr Thr Thr Val Lys Val Ala Gly Phe Asn Cys 115 120 125 Ser Ile Pro Asn Asn Arg Gly Thr Arg His Leu Tyr Ser Ala Gly Thr 130 135 Ser Gln Thr Asn Met Pro Val Ile Ala Asp Asn Met Ser Ala Cys Ile 145 150 155 160 Ala Val Ala Cys Ala Ala Glu Asn Val Asp Ala Gly Thr Gly Glu Arg

-continued

165 170 175	
Arg Pro Gly Ala Lys Val Arg Val Phe His Leu Leu Pro Phe Arg Arg 180 185 190	
Glu Asp Leu Val Pro Glu Glu Val Leu Ala Ser Val Arg Asp Tyr Leu 195 200 205	
Arg Thr Thr Lys Glu Gln Gly Leu Thr Met Arg Val Ala Met His Gly 210 215 220	
Gly Asn Thr Glu Gly Asp Phe Ser Val Ser Thr Ala Gln Ala Leu Lys 225 230 235 240	
Gly Leu Phe Ala Asn Glu Gly Ile Pro Leu Glu Phe Asp Glu Thr Cys	
Ala Asn Arg Thr Ser Glu Thr Leu Leu Gly Ala Val Ile Leu Asp Asp	
Asn Ser Thr His Phe Ile Lys His Leu Val Ala Gln 275 280	
<210> SEQ ID NO 19 <211> LENGTH: 291 <212> TYPE: DNA <213> ORGANISM: Pseudomonas syringae	
<400> SEQUENCE: 19	
atgatcatcg acaatacgtt cgcgctgaca ctgtcatgcg attacgcgcg tgagcgcctg	60
ctgttgatcg gcttgcttga gccgcacaag gacatacctc agcagtgcct tttggctggc	120
gctctcaatc cgctcctcaa tgcaggccca ggccttggcc tggatgagaa aagcggcctg	180
tatcacgcgt atcaaagcat ccctcgagaa aaactcagcg tgccgacgct caaacgcgaa	240
atggcaggtc tgctggagtg gatgaggggc tggcgcgaag caagccaata g	291
<210> SEQ ID NO 20 <211> LENGTH: 96 <212> TYPE: PRT <213> ORGANISM: Pseudomonas syringae	
<400> SEQUENCE: 20	
Met Ile Ile Asp Asn Thr Phe Ala Leu Thr Leu Ser Cys Asp Tyr Ala 1 5 10 15	
Arg Glu Arg Leu Leu Leu Ile Gly Leu Leu Glu Pro His Lys Asp Ile 20 25 30	
Pro Gln Gln Cys Leu Leu Ala Gly Ala Leu Asn Pro Leu Leu Asn Ala 35 40 45	
Gly Pro Gly Leu Gly Leu Asp Glu Lys Ser Gly Leu Tyr His Ala Tyr 50 55 60	
Gln Ser Ile Pro Arg Glu Lys Leu Ser Val Pro Thr Leu Lys Arg Glu 65 70 75 80	
Met Ala Gly Leu Leu Glu Trp Met Arg Gly Trp Arg Glu Ala Ser Gln 85 90 95	
<210> SEQ ID NO 21 <211> LENGTH: 1143 <212> TYPE: DNA <213> ORGANISM: Pseudomonas syringae	
<400> SEQUENCE: 21	
atgaacccca ttcagtcacg cttctccagt gtgcaagagc tcagacgatc caacgttgat	60
attccggcgc tcaaagccaa tggccaactg gaggtcgacg gcaagaggta cgagattcgt	120

-continued

	t tteggteett	cgaccggagc	aacaatccaa	agcgaaaagt 180
tttttcaagg gcgcttccca	a gttgataggt	ggcagcagcc	agcgcgcgca	gattgcccag 240
gcgctcaacg agaaggtcg	c atcggcacgc	actgtcttgc	accagagege	tatgacgggc 300
ggacgcttgg acacccttga	a gcgggggggaa	agcagctcag	ccacaacagc	catcaaaccc 360
actgccaaac aggctgcgca	a aagtactttt	aacagctttc	atgagtgggc	caaacaggca 420
gaggcgatgc gaaacccgt	c tcgaatggat	atctacaaga	tctataaaca	agatgcacct 480
cactcacacc ccatgageg	a cgagcagcaa	gaagagttcc	tgcacacgct	aaaggcattg 540
aatggcaaaa acggcattg	a ggtgcgcact	caggaccacg	acagcgtcag	aaataaaaa 600
gaccgcaacc tggacaagta	a catcgcagag	agcccggatg	caaagaggtt	tttctatcga 660
attatcccca aacatgagc	g ccgagaagat	aagaatcaag	ggcgattgac	cattggcgtg 720
caaccccaat atgcaacaca	a gttgacccgc	gccatggcaa	ccctgatagg	gaaggaaagt 780
gcaatcacgc atggcaaag	t aataggcccc	gcctgccacg	gccaaatgac	cgattcggca 840
gttttgtata tcaacggtga	a tgttgcaaag	gcagaaaagc	tgggcgagaa	actgaaacag 900
atgagcggca ttcctctgg	a tgcgttcgtt	gagcacaccc	ctttgagcat	gcaatccctg 960
agtaaaggtc tgtcctatg	c agaaagcatc	ctgggcgaca	ccagaggcca	tgggatgtcg 1020
cgagcggaag tgatcagcga	a tgccttgagg	atggacggga	tgccatttct	ggccagattg 1080
aagctatcac tgtctgccaa	a tggctatgac	ccggacaacc	cggcccttcg	aaacacgaaa 1140
tga				1143
<210> SEQ 1D NO 22 <211> LENGTH: 380				
<212> TYPE: PRT <213> ORGANISM: Pseud <400> SEQUENCE: 22	lomonas syri:	ngae		
<212> TYPE: PRT <213> ORGANISM: Pseud <400> SEQUENCE: 22 Met Asn Pro Ile Gln : 1 5	domonas syri: Ser Arg Phe	ngae Ser Ser Val 10	Gln Glu Leu	Arg Arg 15
<212> TYPE: PRT <213> ORGANISM: Pseud <400> SEQUENCE: 22 Met Asn Pro Ile Gln 3 1 5 Ser Asn Val Asp Ile 1 20	lomonas syri: Ser Arg Phe Pro Ala Leu	ngae Ser Ser Val 10 Lys Ala Asn 25	Gln Glu Leu Gly Gln Leu 30	Arg Arg 15 Glu Val
<212> TYPE: PRT <213> ORGANISM: Pseud <400> SEQUENCE: 22 Met Asn Pro Ile Gln a 1 5 Ser Asn Val Asp Ile 1 20 Asp Gly Lys Arg Tyr 0 35	lomonas syri: Ser Arg Phe Pro Ala Leu Glu Ile Arg 40	ngae Ser Ser Val 10 Lys Ala Asn 25 Ala Ala Asp	Gln Glu Leu Gly Gln Leu 30 Asp Gly Thr 45	Arg Arg 15 Glu Val Ile Ser
<212> TYPE: PRT <213> ORGANISM: Pseud <400> SEQUENCE: 22 Met Asn Pro Ile Gln 3 1 5 Ser Asn Val Asp Ile 1 20 Asp Gly Lys Arg Tyr 0 35 Val Leu Arg Pro Glu 0 50	lomonas syri: Ser Arg Phe Pro Ala Leu Glu Ile Arg 40 Gln Gln Ser 55	ngae Ser Ser Val 10 Lys Ala Asn 25 Ala Ala Asp Lys Ala Lys	Gln Glu Leu Gly Gln Leu 30 Asp Gly Thr 45 Ser Phe Phe 60	Arg Arg 15 Glu Val Ile Ser Lys Gly
<pre><212> TYPE: PRT <213> ORGANISM: Pseud <400> SEQUENCE: 22 Met Asn Pro Ile Gln 3 1 5 Ser Asn Val Asp Ile 1 20 Asp Gly Lys Arg Tyr 0 35 Val Leu Arg Pro Glu 0 50 Ala Ser Gln Leu Ile 0 65</pre>	domonas syri: Ser Arg Phe Pro Ala Leu Slu Ile Arg 40 Sln Gln Ser 55 Sly Gly Ser 70	ngae Ser Ser Val 10 Lys Ala Asn 25 Ala Ala Asp Lys Ala Lys Ser Gln Arg 75	Gln Glu Leu Gly Gln Leu 30 Asp Gly Thr 45 Ser Phe Phe 60 Ala Gln Ile	Arg Arg 15 Glu Val Ile Ser Lys Gly Ala Gln 80
<pre><212> TYPE: PRT <213> ORGANISM: Pseud <400> SEQUENCE: 22 Met Asn Pro Ile Gln a 1 5 Ser Asn Val Asp Ile 1 20 Asp Gly Lys Arg Tyr 0 35 Val Leu Arg Pro Glu 0 Ala Ser Gln Leu Ile 0 65 Ala Leu Asn Glu Lys 85</pre>	lomonas syri: Ser Arg Phe Pro Ala Leu Glu Ile Arg 40 Gln Gln Ser 55 Sly Gly Ser 70 Val Ala Ser	ngae Ser Ser Val 10 Lys Ala Asn Ala Ala Asp Lys Ala Lys Ser Gln Arg 75 Ala Arg Thr 90	Gln Glu Leu Gly Gln Leu 30 Asp Gly Thr 45 Ser Phe Phe 60 Ala Gln Ile Val Leu His	Arg Arg 15 Glu Val Ile Ser Lys Gly Ala Gln 80 Gln Ser 95
<pre><212> TYPE: PRT <213> ORGANISM: Pseud <400> SEQUENCE: 22 Met Asn Pro Ile Gln a 1 5 Ser Asn Val Asp Ile I 20 Asp Gly Lys Arg Tyr 0 Asp Gly Lys Arg Tyr 0 Ala Ser Gln Leu Ile 0 Ala Ser Gln Leu Ile 0 Ala Leu Asn Glu Lys 8 S Ala Met Thr Gly Gly 2 </pre>	domonas syri: Ser Arg Phe Pro Ala Leu Glu Ile Arg 40 Gln Gln Ser 55 Gly Gly Ser 70 Val Ala Ser Arg Leu Asp	ngae Ser Ser Val 10 Lys Ala Asn 25 Ala Ala Asp Lys Ala Lys Ser Gln Arg 75 Ala Arg Thr 90 Thr Leu Glu	Gln Glu Leu Gly Gln Leu 30 Asp Gly Thr 45 Ser Phe Phe 60 Ala Gln Ile Val Leu His Arg Gly Glu 110	Arg Arg 15 Glu Val Ile Ser Lys Gly Ala Gln 80 Gln Ser 95 Ser Ser
<pre><212> TYPE: PRT <213> ORGANISM: Pseud <400> SEQUENCE: 22 Met Asn Pro Ile Gln 3 1 5 Ser Asn Val Asp Ile 1 20 Asp Gly Lys Arg Tyr 0 35 Val Leu Arg Pro Glu 0 Ala Ser Gln Leu Ile 0 65 Ala Leu Asn Glu Lys 85 Ala Met Thr Gly Gly 2 Ser Ala Thr Thr Ala 3 115 </pre>	Adomonas syri: Ser Arg Phe Pro Ala Leu Glu Ile Arg 40 Gln Gln Ser 55 Gly Gly Ser 70 Val Ala Ser Arg Leu Asp Ile Lys Pro 120	ngae Ser Ser Val 10 Lys Ala Asn Ala Ala Asp Lys Ala Lys Ser Gln Arg 75 Ala Arg Thr 90 Thr Leu Glu 105 Lys	Gln Glu Leu Gly Gln Leu 30 Asp Gly Thr 45 Ser Phe Phe 60 Ala Gln Ile Val Leu His Arg Gly Glu 110 Gln Ala Ala	Arg Arg Glu Val Ile Ser Lys Gly Ala Gln 80 Gln Ser Ser Ser Gln Ser
<pre><212> TYPE: PRT <213> ORGANISM: Pseud <400> SEQUENCE: 22 Met Asn Pro Ile Gln a 1 5 Ser Asn Val Asp Ile 1 20 Asp Gly Lys Arg Tyr 0 Asp Gly Lys Arg Tyr 0 Val Leu Arg Pro Glu 0 Ala Ser Gln Leu Ile 0 Ala Leu Asn Glu Lys 3 Ala Met Thr Gly Gly 2 Ser Ala Thr Thr Ala 3 Thr Phe Asn Ser Phe 1 130</pre>	Adomonas syri: Ser Arg Phe Pro Ala Leu Glu Ile Arg 40 Gln Gln Ser 55 Gly Gly Ser 70 Val Ala Ser Arg Leu Asp Ile Lys Pro 120 His Glu Trp 135	ngae Ser Ser Val 10 Lys Ala Asn 25 Ala Ala Asp Lys Ala Lys Ser Gln Arg 75 Ala Arg Thr 105 Leu Glu Thr Ala Lys Ala Lys Gln	Gln Glu Leu Gly Gln Leu 30 Asp Gly Thr 45 Ser Phe Phe 60 Phe Ala Gln Ile Val Leu His Arg Gly Glu 110 Gln Ala Ala 125	Arg Arg 15 Glu Val Ile Ser Lys Gly Ala Gln 80 Gln Ser Ser Ser Gln Ser Met Arg
<pre><212> TYPE: PRT <213> ORGANISM: Pseud <400> SEQUENCE: 22 Met Asn Pro Ile Gln a 1 5 Ser Asn Val Asp Ile I 20 Asp Gly Lys Arg Tyr 0 Asp Gly Lys Arg Tyr 0 Ala Ser Gln Leu Ile 0 Ala Ser Gln Leu Ile 0 Ala Leu Asn Glu Lys 8 5 Ala Met Thr Gly Gly 2 Ser Ala Thr Thr Ala 3 Thr Phe Asn Ser Phe I 130 Asn Pro Ser Arg Met 3 145</pre>	Alomonas syri: Ser Arg Phe Pro Ala Leu Glu Ile Arg 40 Gln Gln Ser 55 Gly Gly Ser 70 Val Ala Ser Arg Leu Asp Ile Lys Pro 120 His Glu Trp 135	ngae Ser Ser Val 10 Lys Ala Asn 25 Ala Ala Asp Lys Ala Lys Ser Gln Arg 75 Ala Arg Thr 90 Thr Leu Glu 105 Thr Ala Lys Ala Lys Gln Lys Ile Tyr	Gln Glu Leu Gly Gln Leu 30 Asp Gly Thr 45 Phe Phe 60 Phe Phe Ala Gln Ile Val Leu His Arg Gly Glu 110 Gln Ala Ala 140 Glu Ala	Arg Arg 15 Glu Val Ile Ser Lys Gly Ala Gln 80 Gln Ser 95 Ser Ser Gln Ser Met Arg Ala Pro 160
<pre><212> TYPE: PRT <213> ORGANISM: Pseud <400> SEQUENCE: 22 Met Asn Pro Ile Gln a 1 5 Ser Asn Val Asp Ile 1 20 Asp Gly Lys Arg Tyr 0 35 Val Leu Arg Pro Glu 0 50 Ala Ser Gln Leu Ile 0 65 Ala Leu Asn Glu Lys 8 50 Ala Met Thr Gly Gly 2 50 Ser Ala Thr Thr Ala 3 115 Thr Phe Asn Ser Phe 1 130 Asn Pro Ser Arg Met 2 145</pre>	IdomonassyrinSerArgPheProAlaLeuSluIleArg 40GluIleArg 55SerGlyGlySer70GlySer70GlySer71AlaSerArgLeuAspIleLysPro 120HisGluTrp 135AspIleTyrSerAspGlu	ngae Ser Ser Val 10 Lys Ala Asn Ala Ala Asp Lys Ala Lys Ser Gln Arg 75 Ala Arg Thr 90 Thr Leu Glu Thr Ala Lys Ala Lys Gln Lys Ile Tyr 155 Gln Gln Glu	Gln Glu Leu Gly Gln Leu 30 Asp Gly Thr 5er Phe Phe 60 Phe Phe Val Leu His Arg Gly Glu 110 Gln Ala Ala 140 Glu Ala Lys Gln Asp Glu Phe Leu	Arg 15ArgGluValIleSerLysGlyAlaGln 80GlnSerSerSerGlnSerMetArgAlaPro 160HisThr

His Asp Ser Val Arg Asn Lys Lys Asp Arg Asn Leu Asp Lys Tyr Ile 200 195 Ala Glu Ser Pro Asp Ala Lys Arg Phe Phe Tyr Arg Ile Ile Pro Lys 215 210 220 His Glu Arg Arg Glu Asp Lys Asn Gln Gly Arg Leu Thr Ile Gly Val 225 230 235 240 Gln Pro Gln Tyr Ala Thr Gln Leu Thr Arg Ala Met Ala Thr Leu Ile 245 250 255 Gly Lys Glu Ser Ala Ile Thr His Gly Lys Val Ile Gly Pro Ala Cys 260 265 270 His Gly Gln Met Thr Asp Ser Ala Val Leu Tyr Ile Asn Gly Asp Val 275 280 285 Ala Lys Ala Glu Lys Leu Gly Glu Lys Leu Lys Gln Met Ser Gly Ile 290 295 300 Pro Leu Asp Ala Phe Val Glu His Thr Pro Leu Ser Met Gln Ser Leu 310 305 315 320 Ser Lys Gly Leu Ser Tyr Ala Glu Ser Ile Leu Gly Asp Thr Arg Gly 325 330 335 His Gly Met Ser Arg Ala Glu Val Ile Ser Asp Ala Leu Arg Met Asp 340 345 Gly Met Pro Phe Leu Ala Arg Leu Lys Leu Ser Leu Ser Ala Asn Gly 355 360 Tyr Asp Pro Asp Asn Pro Ala Leu Arg Asn Thr Lys 370 375 380 <210> SEQ ID NO 23 <211> LENGTH: 2598 <212> TYPE: DNA <213> ORGANISM: Pseudomonas syringae <400> SEOUENCE: 23 gtgccgcgta tcgtcgccgg ccatgcagaa ggcgtgtgcg tggtcaacgg ccggcactat gtcgagctgt ccggtagaac ctttcaagtc cattacgaca cacatctgcg cggctggcag attgtcgatc cagaaaaccc gttcgccttt tttggccagc agccggtgcg cctagatgaa caggggcaat ggcagcttgt cgcccgtcga cgtctgcgtg gcggtggcgt aggtgactcc agccatgccc acctgcccga agaaacaccg ggctccagca caggctcgat tccgagcgac tacgaaatgc cggccgccat gcaggcaggc cttgatgtcg tgttgagcaa caagccctac gacccgaccg ggattggcat ggagtcttac tttgagagct atttcgtgga tctgcgtcag agttttgtgg cgcgcaggga aaagctttat gaggatgccc ggacattttt cgccggtttt tctccgccgc caaagccgca attgcctccg ctggcgccac ctgttgccat cgacaccctg attgaacacg tcttcgcgca gggtaacggc ctggttttga gtgaagcacc gaagtcggtc gccagcaaac ggctgctgtt actcaacatg ccgctgctgg ccgaacagcg tgtcaagatt ctgtatatcg agcacctgct gaccgacaag cacctgtcta aactggccag gtatcgtcaa ctgggcaaaa agagccgctc aggctcgcac gaactcaagc attacctgca cgatctcaac cgcgggacgc tgaacaattc cagcaccgac tacgactatt accacctcat caaggcagcg catcgctatg gtatcgaggt gcgaccgttc agctcgtcga tcagctaccc gtttctggac catccggtat tgagcgcagc caacgacacg actgcagtac aaaaaatgag caattttttc ggccatacgc tcatcagcag cgatgtcgca tccgcgccga caaaacgctg ggttgccttg 1020

60

120

180

240

300

360

420

480

540

600 660

720

780

840

900

-continued

ctcgaccaga	agctggccac	gacccacgac	ggggtattag	gcattgccga aatgcagggc	1080
gtggtcagtg	tgcatgtccg	cgacatcccg	gcaggccggc	cgacgcgcat cactaaaggc	1140
acaggcgaac	tgccacgcga	gggcacgcag	gcccgctgcg	acttcacgat tgcgttttcc	1200
gatccgacgc	tgattgtgcc	ccaggcgcct	cacccgcacg	gtaccaaact ggacgacatg	1260
ctgctcagag	aactgagggg	ccaatctgcc	ggtgccgggg	gcgaacgctg ggccggccag	1320
tacggattca	tccgtgacga	ggacggtgcc	tggcggtgga	tcgcgcctga ggactggccc	1380
gcagacagcc	cgatgacggc	aatccagcaa	tccctgaccg	accctgtcta tgagatgcca	1440
ctggacactc	gaacaacgct	tcatacgctg	gcgaacttcg	aaagaagggg gctcgacatg	1500
gagtatttct	ttgaagaaag	ccagtacgaa	actgttcgca	acgtattcgc cctgcaccgc	1560
aaaaagctgc	aacaggatgc	ggccttgatc	agcgctgtac	agttgccgcc tcgtccgacg	1620
atgccggccg	tcaaccctcg	gacgaccacg	gcgcagctgt	ttgaaacgct gtaccagcac	1680
accgatggca	tcgtgatcgg	cgagtcgcat	ttttcggtcg	ccagcaagaa aatgatcatc	1740
gacaacctgc	cgttgctgtc	gcagcaaaac	gtacgaacgc	tgtacatgga gcacttgctc	1800
accgacttgc	atcaggcgga	tctggatcgc	ttttcgaaa	cagggcaaat gagcaaaacc	1860
ctgcttcacg	acctgaaagt	gctggatcgg	ggccatcgca	ccgacccgga caaggtttac	1920
acctttgagc	aactggtcat	caaggcgcag	cagcacggca	tggaagtccg cgccatcgac	1980
tgcgcagcca	gctaccacct	tagtggcctt	gacaacgatg	gttcaatcac ccgtcagcaa	2040
atgatgaact	actttgcgtc	gcgcaccctg	cgcaggcatc	aggacgtcat gggctcacac	2100
aagtggatcg	cgctggtcgg	caacagccat	tccaatgtct	atcaaggcgt cgtgcctggt	2160
atcgccgagc	tggaaggcgg	catcggcctg	cgggttatcg	acgtggcacc ggggcagtcg	2220
aagggtgtca	tgcacgacct	ggggggagctg	gtctcggcag	acatctcgag aaccaaagta	2280
cacatcaaag	gcgattatcg	agtggagata	gaaataccgc	gtgcgaagga tgccattcgg	2340
ccaccccagc	ctgttaccct	cgaacagcga	ctggccagac	cgggattgtt tctggtggaa	2400
gagagtgagg	gcaatctgct	gaccattgtc	caccgcgctc	gcgacacctg gattcaccgc	2460
acgccggtgc	tggtcaatgc	cgagggcaag	ctgtacctgg	agcgcgtgcg ctggccgcgc	2520
atccacctca	aaccctttga	tgacatggac	gcgctggtag	cggcgctgga ggagatgaac	2580
ctgacgcggg	taggctga				2598
210 000	D NO 04				
<210> SEQ	CH: 865				
<212> TYPE: <213> ORGAN	NISM: Pseudo	omonas s y ri	ngae		
<400> SEQUI	ENCE: 24				
Val Pro Aro 1	g Ile Val A 5	la Gly His .	Ala Glu Gly 10	Val Cys Val Val Asn 15	
Gly Arg Hi	s Tyr Val G 20	lu Leu Ser	Gly Arg Thr 25	Phe Gln Val His Ty r 30	
Asp Thr His 3	s Leu Arg G 5	ly Trp Gln 40	Ile Val Asp	Pro Glu Asn Pro Phe 45	
Ala Phe Pho 50	e Gly Gln G	ln Pro Val . 55	Arg Leu Asp	Glu Gln Gly Gln Trp 60	
Gln Leu Va 65	l Ala Arg A	rg Arg Leu . 70	Arg Gly Gly 75	Gly Val Gly Asp Ser 80	
Ser His Al	a His Leu P 85	ro Glu Glu	Thr Pro Gly 90	Ser Ser Thr Gly Ser 95	

-continued

Ile	Pro	Ser	Asp 100	Tyr	Glu	Met	Pro	Ala 105	Ala	Met	Gln	Ala	Gly 110	Leu	Asp
Val	Val	Leu 115	Ser	Asn	Lys	Pro	Ty r 120	Asp	Pro	Thr	Gly	Ile 125	Gly	Met	Glu
Ser	Ty r 130	Phe	Glu	Ser	Tyr	Phe 135	Val	Asp	Leu	Arg	Gln 140	Ser	Phe	Val	Ala
Arg 145	Arg	Glu	Lys	Leu	Ty r 150	Glu	Asp	Ala	Arg	Thr 155	Phe	Phe	Ala	Gly	Phe 160
Ser	Pro	Pro	Pro	Lys 165	Pro	Gln	Leu	Pro	Pro 170	Leu	Ala	Pro	Pro	Val 175	Ala
Ile	Asp	Thr	Leu 180	Ile	Glu	His	Val	Phe 185	Ala	Gln	Gly	Asn	Gly 190	Leu	Val
Leu	Ser	Glu 195	Ala	Pro	Lys	Ser	Val 200	Ala	Ser	Lys	Arg	Leu 205	Leu	Leu	Leu
Asn	Met 210	Pro	Leu	Leu	Ala	Glu 215	Gln	Arg	Val	Lys	Ile 220	Leu	Tyr	Ile	Glu
His 225	Leu	Leu	Thr	Asp	L y s 230	His	Leu	Ser	Lys	Leu 235	Ala	Arg	Tyr	Arg	Gln 240
Leu	Gly	Lys	Lys	Ser 245	Arg	Ser	Gly	Ser	His 250	Glu	Leu	Lys	His	Ty r 255	Leu
His	Asp	Leu	Asn 260	Arg	Gly	Thr	Leu	Asn 265	Asn	Ser	Ser	Thr	Asp 270	Tyr	Asp
Tyr	Tyr	His 275	Leu	Ile	Lys	Ala	Ala 280	His	Arg	Tyr	Gly	Ile 285	Glu	Val	Arg
Pro	Phe 290	Ser	Ser	Ser	Ile	Ser 295	Tyr	Pro	Phe	Leu	Asp 300	His	Pro	Val	Leu
Ser 305	Ala	Ala	Asn	Asp	Thr 310	Thr	Ala	Val	Gln	L y s 315	Met	Ser	Asn	Phe	Phe 320
Gly	His	Thr	Leu	Ile 325	Ser	Ser	Asp	Val	Ala 330	Ser	Ala	Pro	Thr	L y s 335	Arg
Trp	Val	Ala	Leu 340	Leu	Asp	Gln	Lys	Leu 345	Ala	Thr	Thr	His	Asp 350	Gly	Val
Leu	Gly	Ile 355	Ala	Glu	Met	Gln	Gl y 360	Val	Val	Ser	Val	His 365	Val	Arg	Asp
Ile	Pro 370	Ala	Gly	Arg	Pro	Thr 375	Arg	Ile	Thr	Lys	Gly 380	Thr	Gly	Glu	Leu
Pro 385	Arg	Glu	Gly	Thr	Gln 390	Ala	Arg	Cys	Asp	Phe 395	Thr	Ile	Ala	Phe	Ser 400
Asp	Pro	Thr	Leu	Ile 405	Val	Pro	Gln	Ala	Pro 410	His	Pro	His	Gly	Thr 415	Lys
Leu	Asp	Asp	Met 420	Leu	Leu	Arg	Glu	Leu 425	Arg	Gly	Gln	Ser	Ala 430	Gly	Ala
Gly	Gly	Glu 435	Arg	Trp	Ala	Gly	Gln 440	Tyr	Gly	Phe	Ile	Arg 445	Asp	Glu	Asp
Gly	Ala 450	Trp	Arg	Trp	Ile	Ala 455	Pro	Glu	Asp	Trp	Pro 460	Ala	Asp	Ser	Pro
Met 465	Thr	Ala	Ile	Gln	Gln 470	Ser	Leu	Thr	Asp	Pro 475	Val	Tyr	Glu	Met	Pro 480
Leu	Asp	Thr	Arg	Thr 485	Thr	Leu	His	Thr	Leu 490	Ala	Asn	Phe	Glu	Arg 495	Arg
Gly	Leu	Asp	Met 500	Glu	Tyr	Phe	Phe	Glu 505	Glu	Ser	Gln	Tyr	Glu 510	Thr	Val

-continued

Arg	Asn	Val 515	Phe	Ala	Leu	His	Arg 520	Lys	Lys	Leu	Gln	Gln 525	Asp	Ala	Ala
Leu	Ile 530	Ser	Ala	Val	Gln	Leu 535	Pro	Pro	Arg	Pro	Thr 540	Met	Pro	Ala	Val
Asn 545	Pro	Arg	Thr	Thr	Thr 550	Ala	Gln	Leu	Phe	Glu 555	Thr	Leu	Tyr	Gln	His 560
Thr	Asp	Gly	Ile	Val 565	Ile	Gly	Glu	Ser	His 570	Phe	Ser	Val	Ala	Ser 575	Lys
Lys	Met	Ile	Ile 580	Asp	Asn	Leu	Pro	Leu 585	Leu	Ser	Gln	Gln	Asn 590	Val	Arg
Thr	Leu	Ty r 595	Met	Glu	His	Leu	Leu 600	Thr	Азр	Leu	His	Gln 605	Ala	Asp	Leu
Asp	Arg 610	Phe	Phe	Glu	Thr	Gly 615	Gln	Met	Ser	Lys	Thr 620	Leu	Leu	His	Asp
Leu 625	Lys	Val	Leu	Asp	Arg 630	Gly	His	Arg	Thr	Asp 635	Pro	Asp	Lys	Val	Ty r 640
Thr	Phe	Glu	Gln	Leu 645	Val	Ile	Lys	Ala	Gln 650	Gln	His	Gly	Met	Glu 655	Val
Arg	Ala	Ile	Asp 660	Cys	Ala	Ala	Ser	Ty r 665	His	Leu	Ser	Gly	Leu 670	Asp	Asn
Asp	Gly	Ser 675	Ile	Thr	Arg	Gln	Gln 680	Met	Met	Asn	Tyr	Phe 685	Ala	Ser	Arg
Thr	Leu 690	Arg	Arg	His	Gln	Asp 695	Val	Met	Gly	Ser	His 700	Lys	Trp	Ile	Ala
Leu 705	Val	Gly	Asn	Ser	His 710	Ser	Asn	Val	Tyr	Gln 715	Gly	Val	Val	Pro	Gl y 720
Ile	Ala	Glu	Leu	Glu 725	Gly	Gly	Ile	Gly	Leu 730	Arg	Val	Ile	Asp	Val 735	Ala
Pro	Gly	Gln	Ser 740	Lys	Gly	Val	Met	His 745	Asp	Leu	Gly	Glu	Leu 750	Val	Ser
Ala	Asp	Ile 755	Ser	Arg	Thr	Lys	Val 760	His	Ile	Lys	Gly	Asp 765	Tyr	Arg	Val
Glu	Ile 770	Glu	Ile	Pro	Arg	Ala 775	Lys	Asp	Ala	Ile	Arg 780	Pro	Pro	Gln	Pro
Val 785	Thr	Leu	Glu	Gln	Arg 790	Leu	Ala	Arg	Pro	Gly 795	Leu	Phe	Leu	Val	Glu 800
Glu	Ser	Glu	Gly	Asn 805	Leu	Leu	Thr	Ile	Val 810	His	Arg	Ala	Arg	A sp 815	Thr
Trp	Ile	His	Arg 820	Thr	Pro	Val	Leu	Val 825	Asn	Ala	Glu	Gly	L y s 830	Leu	Tyr
Leu	Glu	Arg 835	Val	Arg	Trp	Pro	Arg 840	Ile	His	Leu	Lys	Pro 845	Phe	Asp	Asp
Met	Asp 850	Ala	Leu	Val	Ala	Ala 855	Leu	Glu	Glu	Met	Asn 860	Leu	Thr	Arg	Val
Gl y 865															
<210)> SE L> T.F	Q II NGTH	NO	25											
<212	2> TY	PE:	PRT	.	£	<u> </u>									
<213	<213> ORGANISM: Artificial Sequence <220> FEATURE:														

<223> OTHER INFORMATION: Description of Artificial Sequence: human immunodeficiency virus, TAT protein transduction domain

-continued

100

<400> SEQUENCE: 25 Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg 5 10 1 <210> SEQ ID NO 26 <211> LENGTH: 42 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: hopPtoC primer <400> SEQUENCE: 26 agtcggatcc gaatagggcg ctgaaaatat gacaatcgtg tc 42 <210> SEQ ID NO 27 <211> LENGTH: 55 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: hopPtoC primer <400> SEQUENCE: 27 agtcctcgag tcacttgtca tcgtcgtcct tgtagtcgtg tatttttgaa gcgaa 55 <210> SEQ ID NO 28 <211> LENGTH: 45 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: hopPtoD1 primer <400> SEQUENCE: 28 ccacacattg gatccgatta cttcatccgg gacagctgat agcgc 45 <210> SEQ ID NO 29 <211> LENGTH: 55 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: hopPtoD1 primer <400> SEQUENCE: 29 attctcgagt catttatcat catcatcttt ataatcgggt gcgggctgcc gcgac 55 <210> SEQ ID NO 30 <211> LENGTH: 28 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: hopPtoD2 primer <400> SEQUENCE: 30 atgcaagett atccaatgcc tttcgtca 28 <210> SEQ ID NO 31 <211> LENGTH: 58 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: hopPtoD2 primer

-continued

101

<400> SEQUENCE: 31 atgcctcgag tcaagcgtaa tctggaacat cgtatgggta ttctaacgct attttgc 58 <210> SEQ ID NO 32 <211> LENGTH: 28 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: hopPtoJ primer <400> SEQUENCE: 32 agtaaagctt gagctgcacg catgcgag 28 <210> SEQ ID NO 33 <211> LENGTH: 55 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: hopPtoJ primer <400> SEQUENCE: 33 55 agtatctaga tcacttgtca tcgtcgtcct tgtagtcttg tgcgaccaga tgttt <210> SEQ ID NO 34 <211> LENGTH: 29 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: hopPtoK primer <400> SEQUENCE: 34 29 gcgaattcat cggtttaatc acgcaaggc <210> SEQ ID NO 35 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: hopPtoK primer <400> SEQUENCE: 35 ttggtacctc agcagtagag cgtgt 25 <210> SEQ ID NO 36 <211> LENGTH: 26 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: hopPtoK primer <400> SEQUENCE: 36 aaggateege agagegtgte gegaee 26 What is claimed:

1. An isolated nucleic acid molecule comprising a nucleotide sequence which

encodes a protein or polypeptide comprising SEQ ID No: 12.

2. The nucleic acid molecule according to claim **1**, wherein the nucleic acid molecule comprises the nucleotide sequence according to SEQ ID No: 11.

3. The nucleic acid molecule according to claim 1, $_{10}$ wherein the nucleic acid molecule is DNA.

4. An expression system comprising a vector into which is inserted the nucleic acid molecule according to claim 3.

5. The expression system according to claim 4, wherein the nucleic acid molecule is inserted in sense orientation relative to a promoter.

6. A host cell comprising the nucleic acid molecule according to claim 3.

7. The host cell according to claim 6, wherein the host cell is a bacterial cell or a plant cell.

8. The host cell according to claim **7**, wherein the bacterial cell is *Agrobacterium*.

9. A transgenic plant comprising the nucleic acid molecule according to claim 3. **10**. A method of making a transgenic plant cell comprising:

providing nucleic acid molecule according to claim **3**, and transforming a plant cell with the nucleic acid molecule, whereby the nucleic acid molecule is expressed by the transformed plant cell.

11. A method of making a transgenic plant comprising:

transforming a plant cell with the nucleic acid molecule according to claim **3**, whereby the nucleic acid molecule is expressed by the transformed plant cell, and

regenerating a transgenic plant from the transformed plant cell.

12. A method of making a plant hypersusceptible to colonization by nonpathogenic bacteria, said method com-15 prising:

transforming a plant cell with the nucleic acid molecule of claim **3**, and

regenerating a transgenic plant from the transformed plant cell,

wherein a transgenic plant expresses a protein or polopeptide encoded by a nucleic acid molecule, thereby rendering the transgenic plant hypersusceptible to colonization by nonpathogenic bacteria.

* * * * *